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Abstract 
It is well known that antiretroviral (ARV) drug resistant variants of HIV-1 can be sexually 
transmitted. Several studies have shown that in resource-rich geographical locations as many as 
15-20% of individuals are newly infected with HIV-1 containing at least one drug resistant 
mutation. In contract, resource limited geographical locations, such as Sub-Saharan Africa, have 
shown prevalences in the range of 5 to 10%. Since the ART rollout in these resource-limited 
locations are generally not well monitored with virological genotyping, the transmission of drug 
resistant HIV-1 is likely to increase, with significant clinical and public health consequences.  
HIV-1 transmission is characterised by the transmission of a single founder virus, or narrow 
spectrum of founder viruses, that develop into the viral quasispecie. It is unlikely that drug resistant 
virus will coexist with wild type (wt) virus, in the case of non-drug resistance transmission. 
However, initiating in ARV treatment, drug non-adherence may select of ARV drug resistance 
mutations and may subsequent lead to treatment failure. Drug resistant virus may be transmitted 
to a new host, as drug resistant mutations do not appear to hamper transmission efficiency of the 
mutated virus. Several studies have shown that transmitted drug resistance mutations (TDRMs) 
persist either as the dominant species or as minority variants, or revert to wild type over time, in 
the absence of drug pressure. It is generally acknowledged that many drug resistance mutations 
decrease the replicative capacity of HIV-1, and thus reversion confers a potential survival 
advantage. 
Because of the emergence of wild type variants from TDRM quasispecies requires evolution and 
back-mutation, the rate at which individual TDRMs become undetectable may vary substantially. 
Contradictory findings of persistence versus reversion of TDRMs have been reported, and may be 
attributed to the fact that minority variants are difficult to detect by conventional population based 
Sanger sequencing, and patient numbers studied are small. Consequently, individuals infected with 
HIV-1 harbouring TDRM have a higher chance of failing their first-line therapy. Understanding 
the population dynamics of transmitted drug resistant HIV-1 in the absence of drug pressure is 
essential for clinical management and public health strategies.  
The individuals identified with TDRMs from the IAVI-Early Infections Cohort (Protocol C) 
provides a unique research opportunity to address the aforementioned issue. This study describes 
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the evolutionary mechanisms of ARV drug resistant HIV-1 after transmission to a new host to 
provide insight into persistence and/or rates of reversion to wild type. 
TDRMs initially identified by Price et al. (2011) in the IAVI-Early Infections Cohort (Protocol C) 
using population-based Sanger sequencing (the current diagnostic gold standard), were confirmed 
in this study by newer ultra-deep next generation sequencing (NGS) technology on the Illumina 
Miseq platform. Longitudinal samples were made available for individuals in which transmitted 
drug resistance were identified, and we also sequenced using NGS on the Illumina Miseq platform. 
Additional minority variants (present at <20% of the sequenced viral population) were identified 
by NGS. This study found a large percentage of TDRMs to persist for a significant amount of time 
after transmission to a new, drug naïve host, in the longitudinal samples. The level of persistence, 
or rate of reversion of TDRMs, appear to be subject to the type of resistance (NRTI, NNRTI or 
PI), level of resistance the mutation confers, as well as the combination of mutations that are co-
transmitted. Findings of this study highlight the importance of drug resistance screening prior to 
ART initiation, as well as the importance of the drug resistance screening assay sensitivity. As 
rates of transmitted drug resistance are increasing in developing countries of which the IAVI-Early 
Infections Cohort (Protocol C) are composed of, understanding the population dynamics of 
transmitted drug resistant HIV-1 in the absence of drug pressure is essential for clinical 
management, public health strategies and informing future vaccine design.  
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CHAPTER 1: Introduction 
Infection with Human Immunodeficiency Virus (HIV) is one of the most significant, confounding 
and demanding medical challenges the world is currently facing. The virus is classified under the 
lentivirus genus, and is part of the retrovirus family (Fauci, 1988). Two types of HIV have been 
classified; HIV type 1 (HIV-1) and HIV type 2 (HIV-2), the former being the most prominent 
global circulating type with the highest prevalence, infectivity and virulence of the two virus types. 
The United Nations Programme on HIV/AIDS (UNAIDS) statistics, published at the end of 2015, 
reveal that a total of 36.7 million people are globally infected with HIV-1, with 2.1 million new 
infections and 1.1 million acquired immune deficiency syndrome (AIDS) related deaths in 2015 
(UNAIDS, 2016b). The majority of global HIV-1 infections are located in sub-Saharan Africa, 
accounting for over 69.5% (25.5 million individuals) of global HIV-1 infection (UNAIDS, 2016b). 
Statistics provided by Statistics South Africa shows that the estimated HIV-1 prevalence rate in 
South Africa is 12.7%, amongst the highest in the world. The total number of individuals that are 
currently infected with HIV-1 in South Africa is 7.03 million individuals (Statistics-SA, 2014). 
Since the start of the HIV-1 epidemic, over 78 million individuals have been infected by the virus, 
and more than 39 million individuals have died in AIDS related deaths (UNAIDS, 2016b). 
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1.1 HIV Life Cycle 
 The HIV viral life cycle goes through several distinct stages, producing infectious HIV virions 
shown in Figure 1.1.  
 
Figure 1.1: A schematic representation of the replicative life cycle of HIV-1, highlighting the 
main stages of the life cycle. The various stages of the HIV-1 life cycle (A to G) correspond to 
descriptions in the text below (Copied from Laskey & Siliciano, 2014). 
 
The primary and preferential target cell of HIV-1 is the CD4+ T-cell. The CD4+ T-cell plays a 
crucial role in the immune protection, by regulating several vital immune functions. They regulate 
functions such as activating B cells to produce antibodies, inducing macrophage cells to develop 
and enhanced microbicidal activity. Furthermore CD4+ T-cells recruit a range of cells such as 
neutrophils, eosinophils, and basophils to sites of infection and inflammation. CD4+ T-cells 
additionally mediate the production of cytokines and chemokines (Mosmann, Cherwinski, Bond, 
Giedlin, & Coffman, 1986).  
The viral surface protein gp120 binds to a glycoprotein called Cluster of Differentiation 4 (CD4) 
that is located on the of surface of the target CD4+ T-cells (shown as A in Figure 1.1). CD4 
functions in conjunction with the T cell receptor (TCR) as a co-receptor, and furthermore assists 
B
 
A 
C
 
D
 
E
 
G
 
F
 
A
 
B
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TCR to communicate with antigen-presenting cells. CD4 and TCR are constituent parts of the T 
cell receptor complex. The main natural target of CD4 is a distinct region of the antigen-presenting 
MHCII molecule. An extracellular domain of CD4, D1, binds to a region termed β2 on MHCII 
molecules. CD4 is close in proximity both intra- and extracellularly to TCR, which allows for the 
activation of motifs located in the cytoplasmic regions of the complex to be phosphorylated. Once 
phosphorylated, it allows the cytoplasmic motifs to amplify signals that are generated by the TCR 
complex. Depending on the antigen the TCR complex interacts with, different signals may be 
produced and thus amplified, which in turn may signal specific signal dependent T helper cells. 
Once the HIV-1 gp120 interacts and binds with CD4, a conformational change in the gp120-CD4 
complex is induced, which in turn allows for the gp120 viral protein to successfully make contact 
and interact with the co-receptor CCR5 (S. Miller, 2002). An additional conformational change in 
which leads to hydrophobic portions of gp41 to be exposed is caused by the gp120-CCR5 
interaction. A six-helix bundle is additionally subsequently formed. The conformational changes 
described above brings the target cell and the viral surfaces closer to one another, and ultimately 
leads to fusion (shown as B in Figure 1.1) of HIV-1 with the target cell (S. Miller, 2002). Once 
fusion has taken place, gp120 is shed into the peripheral blood of the infected individual, which 
then acts as an immune decoy (Costin, 2007).  
Following fusion, the core of the virus enclosed by p24 viral proteins, is released into the host cell 
cytoplasm where uncoating occurs. The uncoating event leads to the release of the HIV-1 RNA 
genome, viral proteins reverse transcriptase (RT) and integrase (IN) and several additional 
regulatory proteins. Shortly after uncoating, reverse transcription by RT occurs in the host cell’s 
cytoplasm where the RNA viral genome is transcribed into viral complementary DNA (cDNA) 
(shown as C in Figure 1.1). A pre-integration complex is formed after reverse transcription, which 
is composed of the viral cDNA and a range of viral proteins (including Vpr and IN) and host 
proteins. The HIV-1 pre-integration complex is transported  into the host cell nucleus by the viral 
assessor protein Vpr (Costin, 2007). Once in the nucleus, the complex is permanently integrated 
into the host cell’s genome by the HIV-1 viral protein IN (shown as D in Figure 1.1). The Vpr 
protein first binds to the long terminal repeat (LTR) regions of the reverse transcribed viral DNA, 
whereby it then catalyses the reaction in which the 3’ terminal of the viral DNA is cleaved and 
subsequently transferred via strand transfer into the host cell genome (Hazuda, 2009). 
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As the infected host cell assumes normal function and progresses through its cell growth cycle, the 
integrated proviral genome is actively transcribed (S. Miller, 2002). Products of proviral 
transcription, messenger RNA (mRNA), is spliced into several variants, after which the variants 
are transported and translated in the host cell cytoplasm (shown as E in Figure 1.1). An important 
viral enzyme that is transcribed and translated at this point is protease (PR). PR has a critically 
important function in the process in the maturation of new HIV-1 virions. PR additionally 
influences all constituent viral components that have been transcribed and translated to assemble, 
and to furthermore interact to the host cell plasma membrane. Shortly after assembly, budding of 
immature HIV-1 virions occur (shown as F in Figure 1.1), which leads to the release of newly 
assembled HIV-1 virions. The PR enzyme continues the maturation of the HIV-1 virions post 
budding (shown as G in Figure 1.1) to ensure that the newly produced viruses will have the full 
capacity to infect additional target cells (Costin, 2007; S. Miller, 2002). 
1.2 Natural Disease Progression of HIV-1 Infection 
HIV-1 primarily and preferentially infects cells that express the cell surface glycoprotein CD4, 
such as CD4+ T cells. CD4+ T cells are a crucial component of an individual’s immune system, 
and make up parts of both the innate and adaptive immunity (Douek et al., 2002; Zhu & Paul, 
2008). HIV-1 infection causes target cell death and thus leads to the decline in the levels of CD4+ 
T-cells (Fink & Cookson, 2005). This results in the immune system being unable to effectively 
contain pathogenic infections (Perelson, Kirschner, & De Boer, 1993). Advanced stages of HIV-1 
infection leads to the progressive weakening of the immune system, primarily due to the low levels 
of CD4+ T-cells, with the infected individual ultimately advancing to a state of immunodeficiency, 
as graphically represented below in Figure 1.2. 
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Figure 1.2: Changes in plasma viral load (RNA copies/ml) and CD4+ T cells (cells/mm3) post 
HIV-1 transmission. An initial spike in viral load and sudden decline in CD4+ T cells is observed 
during the first several weeks of acute HIV-1 infection. During the asymptomatic clinical latency 
phase, a slow decline of CD4+ T cells occurs as HIV-1 viral load gradually increases. Without 
treatment, a state of immunodeficiency is achieved (Adapted from Fauci & Pantaleo, 1996). 
The initial spike in viral load and decline of CD4+ T cells observed within the first weeks of 
infection is followed by a partial recovery of CD4+ T cells as the infected individual’s immune 
system produces anti-HIV-1 cellular responses to partly contain the infection. Cellular responses 
involve activity of CD4+ and CD8+ T (otherwise known as cytotoxic T lymphocytes) cells. The  
CD8+ T cells act against HIV-1 during acute HIV-1 infection by eliminating HIV-1 infected cells 
and producing anti-HIV-1 chemokines (Walker, Moody, Stites, & Levy, 1986). The humoral 
response to HIV-1 infection involves the production of anti-HIV-1 antibodies 4 to 8 weeks post 
infection, defined as seroconversion, when an individual is acutely infected.  
Viral diversification however allows for the selection of viruses that have the capacity to evade 
and escape responses produced by the infected individual’s immune system. During the HIV-1 life 
cycle viral RNA is reverse transcribed to DNA prior to host genome integration, by an error prone 
RT that lacks a proof-reading capability and has a mutation rate of ~3 x 10-5 per nucleotide per 
replication cycle (Steinhauer, Domingo, & Holland, 1992). The errors introduced by the RT leads 
to the vast and rapid diversification of HIV-1, and hence the selection of viruses to which the both 
humoral and cellular immune responses are ineffective. Over time the selection of viruses which 
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escape immune responses perpetuate, which leads to viral load increases and CD4+ T cell levels 
to decrease.   
The advanced stage of HIV-1 infection, in which the immune system does not function properly 
and is unable to contain pathogenic infection, regardless of CD4+ T cell count, is defined as AIDS 
(Blattner, Gallo, & Temin, 1988). AIDS is characterised by the appearance/emergence of 
secondary opportunistic infections due to the impaired function of the immune system, which 
ultimately leads to the death of the infected individual (Blattner et al., 1988). 
1.3 HIV-1 Treatment 
The primary treatment strategy that is implemented to treat HIV-1 infection is the use of 
antiretroviral (ARV) drugs. Several different ARV drugs are administered in combination in order 
to target multiple stages/sites of the HIV-1 life cycle, and are referred to as antiretroviral therapy 
(ART) or highly active antiretroviral therapy (HAART). This is currently the standard treatment 
for advanced HIV-1 infection (Hamers et al., 2011). This treatment aims to suppress and contain 
viral replication in preventing HIV-1 disease progression to AIDS. The advantage of implementing 
a potent HAART regimen is that the total burden of HIV-1 with regards to viral load is reduced in 
an individual, as well as disease progression to AIDS is suppressed (Oyugi et al., 2004). An 
individual’s eligibility to receive ART/HAART is dependent on age, viral load and CD4+ T cell 
count.  The World Health Organization’s (WHO) 2013 guidelines recommended that individuals 
were eligible for treatment when having a CD+ T cell count of < 500 cells/mm2. Furthermore, the 
now outdated guidelines encouraged that individuals with CD4+ T cell counts of less than 350 
cells/mm2 should have been treated as a priority with ART (World Health Organization, 2013) . In 
July 2014, the guidelines were updated to a strong recommendation that ART should be initiated 
regardless of CD4+ T cell count (World Health Organization, 2014). The most recent consolidated 
guidelines  recommend that as a priority that ART should be administered to all individuals over 
19 years of age that are HIV positive regardless of WHO clinical stage or CD4+ T cell count 
(World Health Organization, 2016b). It is additionally recommended that infants and children that 
are HIV-1 positive should initiate ART without delay (World Health Organization, 2016b). 
The WHO additionally recommends that ART should be initiated in individuals regardless of CD4 
count should the individual be co-infected with active Tuberculosis (TB) disease; and/or co-
infected with Hepatitis B virus (HBV) with severe chronic liver disease (World Health 
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Organization, 2016b). Pregnant and breastfeeding women infected with HIV-1, and HIV 
serodiscordant couples are immediately eligible for ART by WHO recommendations in order to 
reduce HIV-1 transmission (World Health Organization, 2016a). Children less than five years old 
are immediately eligible for ART. Children in the range of 5 to 10 years of age however may 
initiate treatment when their CD4 ≤ 500 cells/µl, or when they present symptomatic characteristics 
irrespective of CD4 count (Department of Health, 2015a). ART for adolescents aged 10 to 15 may 
be initiated when CD4 count ≤500 cells/µl (Department of Health, 2015a). In South Africa, HIV-
1 infected individuals with a CD4 count of < 500 cells/mm2 qualify for ART. 
ARV drugs may, in addition, be utilised as a successful prevention strategy to protect individuals 
with a high risk of infection. Examples of this risk group include men who have sex with men 
(MSM) and sex workers. Current pre-exposure prophylaxis (PrEP) is a combination of two ARV 
drugs (tenofovir and emtricitabine) (Centers for Disease Control and Prevention, 2016). PrEP is 
thus a preventative intervention, significantly reducing infection among high risk individuals 
within the last decade (S. E. Cohen et al., 2015). In 2014, the WHO recommended that high risk 
individuals, should consider consuming preventative ARV drugs such PrEP to significantly reduce 
their risk of contracting HIV-1 (Grant et al., 2010). 
1.4 Antiretroviral drug therapy (ART) 
The availability of ART has increased significantly in developed countries over the past decade, 
and is rapidly increasing in developing sub-Saharan African countries (Abdool Karim, 2015). The 
use of combination HAART has the potential to significantly reduce the morbidity and mortality 
among patients infected with HIV-1, as well as manage HIV-1 as a chronic condition and attempt 
to prevent HIV-1 infection progressing and developing to AIDS (Palella Jr et al., 2006). Several 
ARV drugs are available to treat HIV-1 treatment by effectively supressing viral replication and 
cause viremia remission. ARVs target different sites and stages of the HIV-1 life cycle. The 
different classes of ARVs are presented below in Table 1.1, and discussed below. 
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Table 1.1: Five classes of United States Food and Drug Administration approved Antiretroviral 
drugs 
Fusion and Entry 
inhibitors 
NRTIs NNRTI Integrase inhibitors PIs 
Enfuvirtide (ENF) Tenofovir (TDF) Delavirdine (DLV) Dolutegravir (DTG) Amprenavir (APV) 
Maraviroc (MVC) Emtricitabine (FTC) Efavirenz (EFV) Elvitegravir (EVG) Atazanavir (ATV) 
 Abacavir (ABC) Etravirine (ETR) Raltegravir (RAL) Darunavir (DRV) 
 Didanosine (DDI) Nevirapine (NVP)  Fosamprenavir (APV) 
 Lamivudine (3TC) Rilpivirine (RVP)  Indinavir (IDV) 
 Stavudine (d4T)   Lopinavir (LPV) 
 Zidovudine (AZT/ZDV)   Nelfinavir (NFV) 
 Zalcitabine (ddC)   Ritonavir (RTV) 
    Saquinavir (SQV) 
    Tipranavir (TPV) 
 
 
Figure 1.3: A schematic representation of the HIV-1 lifecycle and the target sites of ARVs. 
Steps A to D correspond to stages of the HIV-1 life cycle that are targeted by ARV drugs, and 
are described below. 
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1.4.1 Entry Inhibitors 
The first stage of the HIV life cycle is the binding of the viral envelope glycoprotein (gp120) on 
the surface of HIV with the CD4 glycoprotein expressed on the surface of target cells, followed 
by subsequent fusion of the virus to the target cell. Entry inhibitors (shown A in Figure 1.3) are 
also termed fusion inhibitors and thus impede the virus from acquiring entry to the host cell 
cytoplasm. Entry inhibitors work mechanistically in one of two possible processes. The drug will 
interfere with either the gp120 envelope glycoprotein or CD4 complex and/or subsequent 
downstream conformational changes of the complex, or interfere with the CCR5/CXCR4 co-
receptor binding and the gp120 envelope glycoprotein. The two drugs currently approved as 
ARV’s by U.S. Food and Drug administration include Enfuvirtide and Maraviroc 
1.4.2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs)/ Nucleotide Reverse Transcriptase 
Inhibitors (NtRTIs).  
As HIV-1 is an RNA virus, possessing a genome comprised entirely of single stranded positive 
sense RNA, the viral genome must therefore first be converted into double stranded DNA before 
it can be successfully integrated into the target host cell genome. The subsequent viral gene 
replication and expression may then occur (Little et al., 2002; S. Miller, 2002). Therefore, a vital 
step in the HIV-1 lifecycle, post-fusion and cell entry, is the un-coating of the virus and the reverse 
transcription of the single stranded positive sense viral RNA to cDNA. This process is completed 
by a virally encoded RT enzyme that is transported along with the virus particle and released upon 
viral un-coating. It is important to note that this reverse transcription is critically important for the 
downstream success of viral replication and the production of new virions; to inhibit this 
imperative step in the HIV-1 life cycle would result in overall stagnation of new virus production 
(Cann & Karn, 1989). This class of ARV’s specifically inhibit the viral reverse transcription stage.  
The NRTIs/ NtRTIs (shown B in Figure 1.3) are nucleotide analogues, which mean that they are 
similar to nucleosides, but differ structurally in the fact that they lack a 3’ hydroxyl (OH) group to 
which a succeeding nucleotide must bind, as seen in Figure 1.4.  
The difference between NRTIs and NtRTIs arise in that NRTIs lack a phosphate group on the 5’ 
end of the molecule, which is replaced with an OH group. It is important to note that NRTIs and 
NtRTIs block replication by the same mechanism – a lack of an OH group on the 3’ end of the 
molecule, which leads to chain termination during DNA replication. NRTIs are first 
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phosphorylated by host cell kinases; NtRTIs avoid the initial phosphorylation step. NtRTIs are 
essentially  “pre-activated” and subsequently require less metabolic processing to an active state 
whereby the compounds may be utilized in DNA polymerization (Jochmans, 2008). 
 
 
 
 
 
 
 
Figure 1.4: The molecule structures of the nucleotide adenine shown on the left, and its 
nucleotide analogue Stavudine shown on the right. Black arrows indicate where the hydroxyl 
group is removed for NRTIs, and that result in DNA polymerization termination. Red arrows 
indicate where the phosphate group is replaced with an OH group for nucleoside reverse 
transcriptase inhibitors (NRTIs). 
 
“NRTIs are essentially non-extendable nucleoside analogue monophosphate which attach to the 
3’ end of the growing pro-viral DNA chain” (Clavel & Hance, 2004). This prevents the subsequent 
nucleotide to be incorporated by RT, as the crucial hydrogen bond between the defective and 
successive nucleotide cannot be formed. This results in an incomplete and non-functional sequence 
of polynucleotides that cannot be integrated into the host genome. Thus NRTIs inhibit the reverse 
transcription process by causing chain termination of the cDNA polymerisation (Gu et al., 1999). 
Several NRTIs are available and used to suppress the viral replication of HIV-1, and are commonly 
used in combination as first line drug therapies for HIV-1 infected individuals. 
1.4.3 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 
Non-Nucleoside reverse transcriptase inhibitors (NNRTIs) (shown B in Figure 1.3), likewise also 
inhibit reverse transcription, but are mechanistically different from NRTIs. NNRTIs are chemical 
compounds that bind to an allosteric site of the HIV-1 RT enzyme, which results in a non-
          Adenine                                Stavudine 
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functional enzyme and thus inhibiting the reverse transcription process and blocking DNA 
polymerization (Frentz, Boucher, & Van De Vijver, 2012). The hydrophobic pocket that NNRTIs 
bind to is not part of the active site of the enzyme, but is located close to it (Clavel & Hance, 2004). 
The pocket to which NNRTIs bind to is however not present in the absence of NNRTIs. Once 
NNRTIs have bound, they associate with amino acids and create a pocket, which in turn results in 
a sterically blocking movement, preventing the appropriate function of the enzyme.  HIV-2 
replication cannot, however, be suppressed with NNRTI’s, as it exhibits natural resistance against 
NNRTIs (Geretti, 2006). 
In South Africa, an NRTI combination of tenofovir (TDF) and emtricitabine (FTC) with the 
NNRTI of efavirenz (EFV) is used as a fixed dose combination first line therapy (Department of 
Health, 2015b).    
1.4.4 Integrase Inhibitors 
The fourth type of ARV drug that is used to suppress HIV-1 viral replication, aims to inhibit the 
crucial integration step into the target host cell’s genome. Integrase inhibitors (INIs) (shown as C 
in Figure 1.3), alternatively known as integrase strand transfer inhibitors (INSTIs) targets the HIV-
1 integrase enzyme which is responsible for integrating the HIV-1 cDNA (the pre-integration 
complex) into the host genome. Integration is achieved through a several DNA cutting and joining 
reactions.  The first reaction is termed 3’-end processing. Two nucleotides are removed from each 
3’-end of the viral DNA which to be integrated (Temesgen & Siraj, 2008). The second step is 
termed DNA strand transfer. In this step, the processed viral DNA ends are inserted and joined 
into the host cell’s DNA. The first two steps are catalysed by the viral IN enzyme. In the third and 
final step, host cellular enzymes repair the single gaps in the host DNA by the removal of the two 
unpaired nucleotides at the 5’ ends of the viral DNA (Temesgen & Siraj, 2008).  
INIs contain potent moieties that specifically inhibit the second strand transfer step that 
subsequently results in an incomplete integration process. The production of a provirus is can thus 
not occur and HIV-1 viral replication is suppressed as no new HIV-1 viral genomic material may 
be produced and subsequent products thereof (Pommier, Johnson, & Marchand, 2005; Temesgen 
& Siraj, 2008). 
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1.4.5 Protease Inhibitors (PIs) 
The final ARV drug class that is utilised in order to contain and suppress HIV-1 replication is 
protease inhibitors (PIs) (shown as D) in Figure 1.3. During or directly after the budding of new 
HIV-1 viral particles, the HIV-1 protease enzyme cleaves the gag and gag-pol polypeptide 
precursors into functional peptides. HIV-1 protease cleaves viral polypeptides at several different 
cleavage sites to yield the HIV-1 structural proteins and viral enzymes such as RT and IN (Clavel 
& Hance, 2004). PIs aim to arrest maturation, and effectively block the infectivity of nascent HIV-
1 virions (Clavel & Hance, 2004). PIs bind to the active site of the viral protease enzyme and 
actively inhibit the function of the enzyme. This is accomplished due to the fact that PIs mimic the 
natural polypeptides substrates that the enzyme aims to cleave.  
1.4.6 HIV-1 Viral Diversity and Quasispecies 
HIV-1 is transmitted through viral exposure to mucosal surfaces, or transmitted by means of 
percutaneous or intravenous inoculations (M. S. Cohen, 1998).  In the majority of HIV-1 
transmission, a single (founder virus) (represented as a black dot in Figure 1.5) or limited number 
of viral variants establish infection in a new host, resulting in a uniform initial viral population 
(Keele et al., 2008; Poss et al., 1995).   
Shortly after infection, swift diversification of the founder virus occurs, and the initial quasispecies 
is established. HIV-1 has an exceptionally high evolutionary potential in the human host. The rapid 
diversification is due to the high replication rate of HIV-1, in conjunction with error prone RT 
which has a mutation rate of ~3 x 10-5 per nucleotide per replication cycle. This results in a viral 
turnover of 108 to 109 virions per day. This diversification occurs via the acquisition of mutations 
throughout the viral genome (Mansky & Temin, 1995; Menéndez-Arias, 2011; Steinhauer et al., 
1992). The high level of recombination of different viral strains and immune pressure additionally 
drives the virus to diversify (Department of Health, 2015a; Steinhauer et al., 1992). It is important 
to note that it is most likely that the majority of mutations may have a negative effect on the virus, 
and would be eliminated by negative selection (Coffin, 1995). The continued diversification of the 
initial founder virus leads to an expanding range of mutant swarms that are genetically linked to 
the founder virus. HIV-1 has a remarkably plastic genome, with a very small number of nucleotide 
positions conserved across the entire genome (Coffin, 1995; Deacon et al., 1995; Maldarelli et al., 
2013). The combination of complex HIV-1 mutant swarms may thus exist together as a 
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quasispecies (Coffin, 1995; Deacon et al., 1995). In the case of more than one founder virus, it is 
possible for one or more quasispecies to emerge that are each genetically linked to their respective 
founder virus (Lauring & Andino, 2010).  
Figure 1.5: A schematic representation of HIV-1 quasispecies that are each genetically linked 
to the initial founder virus sequence. The black dot represents the founder virus, which soon 
diversifies to establish an initial quasispecies, followed by further diversification and growth of 
the quasispecies. Each branch in the figure represents two variants connected by a point mutation, 
and the concentric circles each represent a replication cycle (copied from Lauring and Andino, 
2010). 
 
The highly diverse viral quasispecies that emerges following long term infection is highly 
susceptible to selective pressures that facilitate resistance to ARV drugs and immune escape 
(Maldarelli et al., 2013). Certain populations contained within the viral quasispecies may contain 
sufficient mutations in key drug target sites, which will allow replication despite the drug being 
present. Susceptible viral populations will be suppressed, and resistant populations will continue 
to replicate and have the capacity to be transmitted to a new host. 
 
1.5 HIV-1 Drug Resistance 
HIV-1 drug resistance means that the virus has the ability to continue replicating itself despite the 
presence of ARV drugs. Drug resistance is caused by mutations in viral genes that encode for 
proteins used in viral replication. These proteins are drug targets, and if mutated are not fully 
affected by the drug. 
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Mutations in the viral genome are denoted by the original amino acid, the position according to 
the start of the viral protein, and the resulting amino acid change. An example of the 
aforementioned is G190A; in which a glycine mutates to an alanine at position 190 in the RT gene 
of the HIV-1 genome. HIV-1 drug susceptibility is detected by observing the viral genome on a 
nucleotide level by utilising sequencing techniques. 
1.5.1 Mechanisms of Drug Resistance 
The most common cause for treatment failure and subsequent virological failure in HIV-1 infected 
individuals is due to ARV drug resistance. There are several types of ARV drug resistance, that 
differ mechanistically from one another respective to the drugs selecting the resistance. 
1.5.1.1 Resistance to Nucleoside Reverse Transcriptase Inhibitors (NRTIs) 
There are two types of resistance to NRTIs (Clavel & Hance, 2004). The first type involves 
mutations that lead to an increased drug discrimination at the drug target site. As mentioned before, 
NRITs are nucleotide analogues which bind the HIV-1 genome and effectively inhibits the reverse 
transcription reaction to cDNA by a blocking action. Mutations in the RT gene of HIV-1, results 
in an increased drug selection capacity. This essentially means that with this type of NRTI 
mutation/s and resistance, the HIV-1 RT enzyme will preferentially bind analogous natural 
deoxynucleoside triphosphate (dNTPs) and avoid binding of NRTIs (Clavel & Hance, 2004; 
Marcelin, 2006). 
The second type of NRTI resistance is enhancing the phosphorolytic removal of the chain 
terminating NRTI from the 3’ end of the primer, post incorporation into the viral DNA. This is 
often referred to as primer unblocking. After the NTRI has been incorporated, it is effectively 
removed by a process referred to as pyrophosphorolysis. Key mutations significantly enhance 
pyrophosphorolysis, such as mutations selected for by Zidovudine and Stavudine. The mutations 
that lead to the manifestation of this type of resistance are referred to as thymidine analogue 
mutations (TAMS) (Clavel & Hance, 2004; Marcelin, 2006). 
1.5.1.2 Resistance to Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 
NNRTIs are designed to bind to amino acids that the HIV-1 RT enzyme is composed of (Clavel & 
Hance, 2004). Drug binding to a target sequence of amino acids subsequently lead to the formation 
of a hydrophobic pocket within the RT enzyme (the pocket is not present in the absence of the 
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drug, and thus induced by the NNRTI drug) (Clavel & Hance, 2004). The formation of the pocket 
causes conformational change of the RT enzyme, and sterically hinders various areas of the 
enzyme. Conformational change and steric hindrance thus restricts the movement of the enzyme 
and thus is unable to complete its intended function of transcribing viral RNA to DNA. It is 
important to note however that the drug target site and the subsequent hydrophobic pocket do not 
comprise part of the active site of the enzyme (Clavel & Hance, 2004). Mutations such as L100I, 
Y181C, G190A and M230L are amino acids that prevent the formation of the pocket, and thus 
results in a functional RT enzyme (Clavel & Hance, 2004; Jingshan Ren & Stammers, 2008). A 
common NNRTI mutation, K103N, has a different resistance mechanism. Position 103 of RT is 
not contained within the hydrophobic binding pocket, but is close to the entrance of the pocket 
(Clavel & Hance, 2004; Jingshan Ren & Stammers, 2008). The mutation in which the lysine at 
position 103 is altered to an asparagine creates a hydrogen bond in the un-ligated enzyme near the 
entrance to the hydrophobic pocket (Clavel & Hance, 2004; Jingshan Ren & Stammers, 2008). 
The hydrogen bond effectively blocks the NNRTI drugs from accessing the amino acids which 
create the pocket upon binding, thus resulting in a functional enzyme that can transcribe viral RNA 
to DNA. 
1.5.1.3 Resistance to Integrase Inhibitors 
The HIV-1 integrase enzyme is responsible for and mediates the irreversible integration of viral 
DNA to genomic host DNA (Chiu & Davies, 2004; Craigie, 2001). Efficient expression of viral 
proteins for generation of new viruses are a crucial step of the HIV-1 life cycle; integration via 
integrase allows for the maintenance of viral DNA in the host genome and thus expression of viral 
proteins (Hazuda, 2009).  
Integrase inhibitors target strand transfer, the last step of the integration reaction (A. A. Johnson, 
Marchand, & Pommier, 2004; Pommier et al., 2005; Young, 2001), and thus are referred to as 
integrase strand transfer inhibitors (INSTIs) (see 1.2.4). Thus, integrase inhibitors bind only to the 
integrase-viral DNA complex, prior to strand transfer. The INSTI drugs contain a metal binding 
pharmacophore, and a hydrophobic group. The pharmacophore interacts with two essential 
magnesium metal ion co-factors that are located in the active site of the integrase enzyme (Espeseth 
et al., 2000). Upon binding, the drug sequesters the magnesium ions completely inhibiting the 
function of the enzyme. The hydrophobic group that constitutes part of the drug does not interact 
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with the magnesium ions, but however significantly increases the affinity for integrase to bind the 
drug (Hazuda, 2009). 
Resistance occurs when amino acids residues that are localised within the active site of integrase, 
in proximity to residues that are required for coordinating the magnesium ion co-factors, are 
altered. This essentially results in a reduced susceptibility of INSTI drug, depending on the residue 
change (Hazuda, 2009). 
1.5.1.4 Resistance to Protease Inhibitors (PIs) 
The HIV-1 protease enzyme is a homodimer, which means that it is a complex of two identical 
proteins (Clavel & Hance, 2004). The active site of the enzyme is located within a pocket at the 
centre of the two parts of the dimer. The main function of HIV-1 protease is to process gag-pol 
(p160) and gag (p55) poly-protein products into viral enzymes that may be utilised by the virus for 
subsequent downstream steps. The process of viral maturation may occur instantaneously during 
or directly after viral budding/viral release (see Figure 1.1). In this process, HIV-1 protease 
cleaves the aforementioned poly-proteins at 9 distinct cleavage sites, resulting in the viral enzymes 
RT, integrase and protease. Other proteins that are yielded by the cleavage are p17, p24, p7 and 
p6 (Brik & Wong, 2003; Clavel & Hance, 2004). 
The FDA approved PIs that are currently in use as part of ART are peptide sequences that bind to 
the active site located in a pocket, in the centre of the homodimer (Clavel & Hance, 2004). The 
PIs contain a synthetic analogue of the phenylalanine-proline amino acids at 167 and 168 of the 
gag-pol poly-protein, which when bound, inhibits the activity of the enzyme. This results in 
incomplete cleavage of the poly-protein precursors, and thus arresting maturation and barring the 
infectivity capacity of emerging virions (Brik & Wong, 2003; Clavel & Hance, 2004). 
Many mutations that are selected to allow for the functioning of HIV-1 protease in the presence of 
PIs, are not located near the active site of the enzyme. These various mutations all mechanistically 
act in a similar fashion, causing slight conformational changes to the protease that leads to a 
subsequent widening of the active site pocket in the middle of the homodimer (Appadurai & 
Senapati, 2016; Clavel & Hance, 2004). The widened active site cavity results in the ineffective 
binding of PIs, and thus ineffective inhibition of enzymatic activity, which varies by mutation and 
respective PI. Additionally, the expanded cavity of the active site does not completely inhibit the 
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viral enzyme from binding its natural poly-protein substrates. The affinity for the natural substrates 
are altered and lost to some extent, affecting the viral fitness of the mutant strains. However, the 
loss of affinity is significantly more profound for the protease inhibitors drugs (Clavel & Hance, 
2004). This results in a protease that has a slightly less fit, but ultimately may still perform its 
intended function. 
1.5.2 Types of Drug Resistance  
The mutations that lead to HIV-1 drug resistance may be acquired before or during treatment. 
Acquired drug resistance (ADR) occurs by diversification of the virus, and the selection of resistant 
variants by a selection pressure such as ART. This type of resistance occurs during treatment. 
Transmitted drug resistance (TDR) differs to ADR in that it occurs before treatment initiation. It 
occurs when drug resistant variant population of HIV-1 is transmitted to a new host. The two types 
of drug resistance will be further described below. 
1.5.2.1 Acquired Antiretroviral Drug Resistance (ADR)/Secondary Drug Resistance  
During the early stages of infection, latent reservoirs of memory CD4+ T cells with integrated 
provirus are established (Chun et al., 1997). A latent reservoir is defined as “a cell type or 
anatomical site in association with which a replication-competent form of the virus accumulates 
and persists with more stable kinetic properties than in the main pool of actively replicating virus” 
(Arion, Sluis-Cremer, & Parniak, 2000). In these reservoirs, viral strains may be harboured that 
contain mutations which may allow for a small survival advantage in the presence of an ARV; or 
several mutations in key sites which permits viral replication regardless of the presence of certain 
ARV drug classes. Additionally, the wild type (WT) predominantly circulating HIV-1 strains may 
be harboured in the reservoirs. 
At the point where an individual would either be eligible for ART or be diagnosed with HIV 
infection and be placed on an ART regimen, the virus has diversified a considerable amount. Two 
major causes for selection of acquired drug resistance is i) incorrect and suboptimal drug treatment, 
and ii) patient medication non-adherence. 
When treatment is initiated, a drug pressure is introduced, which results in the main circulating 
productively replicating wild-type virus replication to be supressed. Certain viral strains may have 
diversified to the extent in which the strains may harbour several sufficient key mutations, or 
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resistance-associated mutations (RAMs), which would allow the stains to replicate in the presence 
of certain ARV drug classes. If viral genotyping is not performed (to access drug susceptibility 
and resistance) and thus RAMs are not detected, the said resistant viral strains may emerge as 
dominant circulating strains. With the continued use of incorrect ART/HAART, susceptible virus 
replication will be hindered. However, viruses that harbour RAMs in key drug target locations 
would thus replicate unhindered, and would subsequently result in an increase in viral load. 
Alternatively, in the case of drug non-adherence, given sufficient time post the initial date of 
infection for the establishing wild time virus to diversify, small sub-populations mutated may 
emerge. The said sub-populations may contain key mutations which would allow a small survival 
advantage in the presence of an ART/HAART drug pressure. Upon drug non-adherence, in which 
the drug pressure is reduced, the small population of viral strains with the survival advantage may 
re-emerge and replicate at an adequate level, which will allow the acquisition of additional key 
mutations, RAMs, and thus permit a greater survival advantage than before. If this process is 
permitted to perpetuate, with continued drug on and off ART use, a strain/s will inevitably emerge 
that may replicate in the presence of the drug pressure. Strains that can replicate, regardless of the 
specific drug classes used initially to suppress it, are said to be drug resistant to those specific 
drugs. Viruses that are not suppressed and replicate under drug pressure are at risk of developing 
additional RAMs that will lead to the development of multi-drug resistance and resistance to 
several drug classes (Barber et al., 2012). Drug non-adherence leads to virologic failure, and 
significantly reduces ART’s long term clinical success. A significant minority of individuals 
receiving treatment do not achieve optimal adherence, and the average treatment adherence is 
estimated to be greater than ~70%, reported in an extensive review de Kok et al. (2018). Adherence 
is generally measured by adherence self-reporting and pharmacy dispensation records. The general 
recommendation is that long term viral suppression requires near perfect drug adherence to prevent 
the emergence of drug resistance and virologic failure (De Kok, Widdicombe, Pilnick, & Laurier, 
2018; Pingen, Sarrami-Forooshani, et al., 2014; Rhee, Liu, Ravela, Gonzales, & Shafer, 2004). 
Literature reports however have shown that exceptionally high levels of adherence will not prevent 
population levels of drug resistance, and drug resistance will inevitably develop in certain 
individuals (Bangsberg et al., 2003; Rocheleau, Brumme, Shoveller, Lima, & Harrigan, 2017; 
Tabb et al., 2018).   
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Additionally, there is evidence that indicates on-going viral replication in patients receiving 
HAART/ART, even when viruses are suppressed to levels that are undetectable (Meyer, Matsuura, 
So, & Scott, 1998; V. Miller et al., 2000). Latent reservoirs of CD4+ T-cells with integrated 
provirus are believed to perpetuate this on-going viral replication (Chun et al., 1997; Condra et al., 
1996). Some of the integrated provirus in these reservoirs may harbour drug resistance mutations, 
acquired in the early stages of diversification when the viral reservoirs were established; whereas 
other integrated provirus may be a form of the predominantly circulating “WT”. The integrated 
provirus is competent to replicate, if and when the CD4+ T-cells undergo antigen-driven 
activation, and thus will drive viral replication in the presence of HAART/ART (Chun et al., 1997; 
Little et al., 2002). Drug resistant viral strains that are archived will emerge rapidly when activated, 
as the drug pressure is unable to suppress the viral replication. 
1.5.2.2 Transmitted Antiretroviral Drug resistance (TDR)/ Primary Drug Resistance  
An HIV-1 infected individual that harbours viral strains containing sufficient mutations in key 
locations, permitting viral replication in the presence of certain drug types, are considered to be 
drug resistant to the said drug types. TDR is defined as the transmission of virus that contains one 
or more RAM (Blower, Aschenbach, Gershengorn, & Kahn, 2001). Drug resistant strains may be 
transmitted from individuals that are drug naïve and unaware of their infection status, or from 
individuals that are treatment experienced that have acquired drug resistance and subsequent 
virologic failure (Baxter et al., 2015). It is generally acknowledged that ~80% of heterosexual 
transmission events results in the transmission of a single transmitted/founder virus (T/F virus) 
(Abrahams et al., 2009; Derdeyn et al., 2004; Haaland et al., 2009; Keele et al., 2008; Wolinsky & 
Wike, 1992). Because of this genetic bottleneck which allows for the transmission of a single or 
otherwise narrow spectrum of quasispecies that goes on to establish infection, WT virus is unlikely 
to coexist with drug resistant variants. Thus, due to this genetic bottleneck, it is likely that in a case 
of transmitted drug resistance, a single drug resistant quasispecies establishes infection. 
TDR occurs from infection with an HIV-1 strain that contains one or more RAMs (Perelson et al., 
1993). The transmission of HIV-1 containing at least one or more RAM is typically in the range 
from 5-15% in resource rich geographical areas such as USA and Europe (Steinhauer et al., 1992; 
Walker et al., 1986). Transmission of drug resistant HIV-1 in Africa is lower at, ranging from 5 - 
10% (Hamers et al., 2011; Ssemwanga et al., 2014), however this percentage is expected to rise 
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significantly in the next decade. Increased availability and rollout of ART/HAART in Sub-Saharan 
Africa, in conjunction with limited virological monitoring techniques will drive the percentage of 
TDR (Hamers et al., 2011; Oyugi et al., 2004). With very limited laboratory monitoring available 
in Africa, there is a severe increase in the potential risk for the rise of drug resistant HIV-1 stains 
and transmission thereof; given that the prolonged time between virological failure and inevitable 
clinical consequences (Perelson et al., 1993). 
Most common transmitted drug resistant mutations (TDRMs) that have been detected are first 
generation NRTIs and NNRTIs, with PIs having a lower prevalence (Perelson et al., 1993). NRTI 
mutations that are most common are M184V/I, K65R, K70E, L74V/I and Y115F (Stanford 
University, 2017). The M184V/I mutation, a high prevalence mutation, is selected by Lamivudine 
(3TC) and FTC and reduces the susceptibility to these drugs more than a 100 fold (Grant et al., 
2010). The M184V/I mutation additionally reduces the transmission and replication capacity of 
the viral strain (Abdool Karim, 2015). NRTI mutations additionally include Thymidine Analog 
Mutations (TAMs) discussed in section 1.1.3.1. TAMs are mutations that are non-polymorphic 
selected by thymidine analogues Azidothymidine (AZT) and Stavudine (d4T). These TAMs lead 
to the reduction in NRTI susceptibility by facilitating primer unblocking and thus permitting 
polymerisation, and subsequent viral genome replication (Centers for Disease Control and 
Prevention, 2016; S. E. Cohen et al., 2015; World Health Organization, 2016a). The most common 
TAMs are M41L, D67N, K70R, L210W, T215Y/F and K219Q/E (World Health Organization, 
2016b). Mutations M41L and T215Y, frequent TAMs, are commonly found in combination, and 
confers a high level of drug resistance to AZT and d4T. T215Y is known to have a significant 
impact on viral fitness, and is replaced with intermediate variants at a rapid rate (Perelson et al., 
1993). The K70R mutation is additionally known to have a significantly higher fitness cost when 
present in combination with other mutations (Perelson et al., 1993). Commonly detected major 
NNRTIs mutations are L100I, K101E/P, K103N/S, V106A/M, E138A/G/K/Q, Y181C/I/V, 
Y188L/C/H, G190A/G/E and M230L. K101E/P and K103N/S are frequently detected NNRTIs, 
with K101E/P occurring in combinations with other NNRTI mutations and selected by Nevirapine 
(NVP) which reduces susceptibility 3 to 10 fold. K103N/S is similarly selected by NVP and EFV, 
and reduces the susceptibility of these drugs by 50 and 20 fold, respectively (Palella Jr et al., 2006). 
The less frequent, but still prominent, major PI mutations are D30N, V32I, L33F, M46I/L, I47V/A, 
G48V/M, I50L/V, I54V/T/A/L/M, L76V, V82A/F/T/S, I84V, N88D/S and L90M. The most 
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commonly detected PI mutation is M46I/L, and is selected for by Indinavir (IDV), Nelfinavir 
(NFV), Fosamprenavir (FPV), Atazanavir (ATV) and Lopinavir (LPV) (Cann & Karn, 1989; Little 
et al., 2002). M46I/L is commonly detected in combination with several other mutations such as 
I54V and V82A, and increases the protease catalytic efficiency of the HIV-1 protease (Henderson 
et al., 2012; Schock, Garsky, & Kuo, 1996). 
1.5.3 Persistence and/or reversion of drug resistant mutations 
The persistence and/or reversion of drug resistance mutations in both transmitted and acquired 
drug resistant HIV-1 strains is multifactorial and differ from one another. 
Reversion of drug resistance mutations have often been observed in individuals with ADR. ART 
regimens that span for limited, short periods are often used to reduce the risk of transmission from 
HIV-1 infected pregnant mothers to their unborn children. Transmission of HIV-1 from an infected 
mother to an unborn child is referred to as HIV-1 mother-to-child transmission (MTCT). In 
resource limited settings, the strategy of utilising short-term ART to reduce MTCT is commonly 
used. The NNRTI Nevirapine (NVP) (see section 1.2.3), is administered in a single dose (also 
known as single dose nevirapine (SD-NVP)) to pregnant mothers. Infants are often additionally 
administered SD-NVP shortly after birth with the intention to prevent HIV-1 transmission from an 
HIV-1 positive mother (Guay et al., 1999). This method of prevention is simple, safe, inexpensive 
and effective in the context of HIV-1 MTCT prevention (Flys et al., 2005; Guay et al., 1999). The 
disadvantage of utilising this regimen to prevent transmission is the emergence of NVP drug 
resistance. In the HIV-1 NET 012 study, NVP drug resistance was detected in 25% of women and 
in 46% of infants 6 – 8 weeks after the single dose delivery (Eshleman et al., 2004; Eshleman et 
al., 2001). Another study investigating the prevalence of NVP drug resistance in infants found that 
in their study cohort of HIV-1 infected infants that were previously exposed to SD-NVP at birth, 
62% of infants harboured NVP drug resistance mutations below the age of 6 months (Hunt et al., 
2011). Interestingly they also found that the prevalence of NVP drug resistance would decrease as 
the children got older. NVR drug resistance mutations were detected in 39% of children between 
the ages of 6 – 12 months, in 22% aged 12 – 18 months, and 16% aged 18 – 24 months (Hunt et 
al., 2011). 
Further investigation into the HIV-1 NET 012 participants detected NVP drug resistance in the 
form of the K103N mutation in 8 of 9 women and 4 of 5 infants 6 – 8 weeks after SD NVP 
  
30 
exposure. Drug resistance mutations were detected with the more sensitive LigAmp mutation 
detection method; a method which is more sensitive than population-based sequencing methods as 
it utilises mutation-specific ligation of 2 oligonucleotides to a DNA template, followed by 
detection of the ligated product by real-time polymerase chain reaction (PCR). The LigAmp 
method thus had a K103N mutation detection cut-off of 0.1%. The study detected NVP drug 
resistance mutation K103N in 3 of 9 women and in 1 of 5 infants 24 months after SD NVP. The 
less sensitive detection method, such as population-based sequencing did not detect any mutations. 
The results of the study highlight that the NVP drug resistance mutation K103N reverted to below 
0.1% of the viral population within 24 months (Flys et al., 2005).  
Overall, in the context of ADR, there is sufficient evidence that suggests that reversion of drug 
resistance mutations (DRMs) occurs in the absence of a selecting pressure such as ARVs. A broad 
range of viral strains are present prior to ART in ADR individuals. When ART is initiated, viral 
replication of drug susceptible virus is supressed, and conversely, strains that harbour mutations 
that allow for replication in the presence of treatment continues to replicate. Studies have however 
shown that persistent replication of drug susceptible virus occurs at levels below detectable limits 
(<50 RNA copies/ml) when an individual that is considered to be on fully suppressive therapy 
(Dinoso et al., 2009; Fletcher et al., 2014). The same low-level replication of drug susceptible virus 
also occurs in individual that harbour drug resistant virus. Subsequently, when the selective 
pressure of ART is stopped, fitter, WT virus replication is no longer suppressed and allowed to 
compete with drug resistant virus. Inevitably, the fitter WT re-emerges and out-competes the drug 
resistant virus and leads to the observed reversion of viral strains in ADR individuals.  
The reversion of TDRMs however differ from ADR mutations. Due to the narrow genetic bottle 
neck that ensues upon HIV-1 transmission (Wolfs, Zwart, Bakker, & Goudsmit, 1992; Wolinsky 
& Wike, 1992), it is highly unlikely that a WT viral strain may be transmitted and co-exist with a 
drug resistant strain (Castro et al., 2013). Thus, when ART is initiated in an individual that harbours 
TDRMs, the transmitted strain will continue to replicate. In the cessation of treatment, there is no 
fitter susceptible virus present at low level in reservoir or in lymphatic tissues and thus reversion 
is not observed.  
Reversion of TDRMs however may occur in the absence of treatment. The reversion of some drug 
resistant mutations to WT has been observed and reported in studies that have investigated TDR 
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(Barbour et al., 2004; Brenner et al., 2002; Gandhi et al., 2003; Little et al., 2008; Pao et al., 2004). 
Viral diversification from the TDR viral strain which established infection occurs due to HIV-1’s 
error prone RT. Viral progeny that emerge as fitter viral strains, with improved viral replicative 
capacity that have subsequently back mutated to WT sequences or sequences more similar to WT, 
may continue to diversify and thus outcompete the less fit transmitted mutated virus. The rates at 
which TDRMs become undetectable are dependent on multiple factors, such as the number of 
required back mutations, the fitness of the mutated virus relative to the WT, the rate at which the 
mutated virus replicated and thus viral turnover, and the presence of possible compensatory 
mutations (Castro et al., 2013). The rate at which TDRMs may be lost varies significantly, and 
thus there is a paucity of data on viral diversity and evolution of TDR HIV-1. 
It has been reported that the most significant factor in the reversion rate of TDRMs is the associated 
fitness cost; the higher the fitness cost of the mutation, the faster the reversion of the mutation 
(Perelson et al., 1993). Recent studies have quantified the rate at which TDRMs are lost, and have 
discovered that NNRTI and PI mutations revert more rapidly, and at a similar rate (Perelson et al., 
1993). NRTIs and more specifically TAMs are lost at a slower rate, relative to PIs and NNRTIs 
(Perelson et al., 1993). 
 
1.6 HIV-1 Viral Genotyping and Drug Resistance Detection 
HIV-1 drug susceptibility is determined by observing the viral genome on a nucleotide level by 
utilising sequencing techniques, and determining whether nucleic acid changes will lead to 
functional amino acid alterations. Initially a blood sample is collected from an HIV-1 infected 
individual. Cell free HIV-1 virus is isolated from the plasma layer of blood (Katzenstein et al., 
1992). Viral RNA is obtained by initial viral particle lysis and subsequent viral RNA isolation. 
Viral RNA genes encoding drug target regions are reverse transcribed to cDNA and subsequently 
amplified. The amplified cDNA amplicons are then sequenced using an appropriate sequencing 
technology. Conventional Sanger sequencing is the current gold standard for HIV-1 viral 
genotyping, allowing up to 20% sequenced viral population to be detected (Palmer et al., 2005).  
Newer technologies such as next generation sequencing (NGS) have the capacity to detect DRMs 
well below 1% of the sequenced viral population. Identifying the DRMs at high confidence in the 
analysis steps however presents a challenge. Thus, taking into consideration the error profiles of 
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NGS platforms, the accepted cut-off for high confidence DRM identification using NGS is set at 
1% of the sequenced viral population (Fonager et al., 2015; Zhou, Jones, Mieczkowski, & 
Swanstrom, 2015). It is important to note however that the prevalence cut-off may differ, 
depending on the error correction models used in respective downstream bioinformatic tools. The 
general process of obtaining clinically relevant results from HIV-1 sequencing is illustrated in 
Figure 1.6, and described below. 
Figure 1.6: An illustration of the process followed from instrument to a clinical result that reveals 
the drug susceptibility or resistance of virus sequenced from an HIV-1 infected individual.  
 
For conventional Sanger sequencing, the raw sequencing reads are assembled, aligning and a 
consensus sequence generated. Various software tools are available (RECall (pssm.cfenet.ubc.ca), 
QualTrace III (www.nucleics.com), ClinQC (www.sourceforge.net/projects/clinqc), and several 
others) to assemble and align reads, and furthermore may automatically perform analysis. The 
software will apply quality control measures in which indeterminate basecalls in the chromatogram 
will be processed in the software’s internal algorithms, to assign the most probable correct 
basecall.  
Once a consensus sequence is generated, it is used as an input for analysis by the Stanford 
University HIV drug resistance database (https://hivdb.stanford.ed). The Stanford algorithm aligns 
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the consensus sequence to the HIV-1 reference genome and identifies variants relative to the 
reference. The Stanford algorithm uses the subtype B consensus sequence that is derived from an 
alignment of subtype B sequences maintained at the Los Alamos HIV Sequence Database 
(hiv.lanl.gov).  Once variants are identified, the algorithm furthermore interprets the significance 
of the variant in terms of drug resistance. A drug resistant variant is then scored on the level of 
resistance the mutation confers.  
For NGS, reads produced by are short sequences that range in nucleotide length. The short reads 
are produced without any position information relative to the organism’s genome and need to be 
aligned to a reference genome in a process termed mapping. Once a quality control step has 
removed any reads that are not of sufficient quality, the reads are aligned and compared to a 
reference genome (HXB2 in the case of HIV-1). Variants are identified relative to the reference, 
and based on the number of times the variant is identified in the sequencing reads, an overall 
prevalence percentage is assigned. Variants that are present at a defined cut-off of the sequenced 
viral population are identified, analysed and scored by the Stanford University HIV drug resistance 
database tool to determine the level of drug resistance a variant confers. Alternatively, a consensus 
sequence of the mapped reads may be generated, and thereafter analysed by the Stanford 
University HIV Drug Resistance Database tool. Other tools available for HIV drug resistance 
analysis are Agence Nacional de Recherche sur le SIDA (ANRS) 
(http://www.hivfrenchresistance.org/) and Rega Institute (Rega) 
(http://regaweb.med.kuleuven.be/software/rega_algorithm/) algorithms. 
1.6.1 Conventional Sanger Sequencing 
Fred Sanger and Alan R. Coulson developed and published two methodological papers describing 
methods to rapidly determine the sequence of DNA (Fred Sanger & Coulson, 1975; Frederick 
Sanger, Nicklen, & Coulson, 1977). Their chemistry method was based on the incorporation of 
dideoxynucleosides (ddNTPs) by DNA polymerase. The ddNTPs lack a 3’ hydroxyl group that is 
required for the subsequent formation of a phosphodiester bond to a succeeding nucleotide, and 
thus the ddNTPs have chain terminating properties (Fred Sanger & Coulson, 1975; Frederick 
Sanger et al., 1977). The above mentioned ddNTPs may be fluorescently or radioactively labelled 
with a probe such that it may be distinguished by a particular detection system (Fred Sanger & 
Coulson, 1975; Smith et al., 1985). 
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A DNA sample of interest is used in four separate reactions, each using one ddNTP per reaction; 
the ddNTPs may be ddGTP (dideoxyguanine triphosphate), ddATP (dideoxyadenine 
triphosphate), ddCTP (dideoxycytosine triphosphate) or ddTTP (dideoxythymine triphosphate). 
Conventional unmodified deoxynucleosides (dNTPs) (adenine (A), thymine (T), guanine (G) and 
cytosine (C)), primers sequenced that are complementary to the target DNA, and DNA polymerase 
are added to each of the four respective reactions that contain one ddNTP. Unmodified dNTPs are 
added in a 100-fold higher concentration to allow both full sequence transcription and chain 
terminated fragments to be produced. Primers serve as a starting point for DNA transcription 
(Frederick Sanger et al., 1977). The resulting DNA fragments from each of the reactions are then 
heat denatured and size separated via agarose gel electrophoresis. By detecting the signal that is 
produced by the probe linked to the ddNTPs, and utilising the different fragment sizes, a DNA 
sequence may be inferred. 
The principle of Sanger sequencing was refined and optimised in subsequent years, and became 
the gold standard of DNA sequencing. Dye-terminator sequencing allowed the utilisation of all 
four-chain terminating ddNTPs in a single reaction, each emitting their own district wavelengths 
that can be detected. DNA fragment separation was further developed and improved, separating 
fragments using capillary electrophoresis. This resulted in highly automated and relatively high 
throughput instruments that allowed the sequencing of several samples at a time, and outputting 
results as chromatograms for analysis and interpretation. Sanger sequencing however does have 
its limitations. Sanger sequencing has the capacity to provide only a consensus sequence of a mixed 
sample, with a limit of detection for a mutation at ~20%. In the context of HIV-1, the percentage 
at which a mutation can be identified is limited to ~20% of the overall viral population. Below 
20% of the viral population that is sequenced, the mutation would be considered undetectable 
(Church et al., 2006; B. Larder et al., 1993; Palmer et al., 2005). Drug resistant mutations that are 
not detected may have significant clinical implications, if appropriate ARV’s are not selected for 
by the attending clinician. 
Sanger sequencing however has been the gold standard for HIV-1 ARV drug resistance detection 
for well over a decade. Despite its limitations, this method has proved extremely valuable to 
accurately assign a correct ART regimen for an individual that harbours drug resistant HIV-1, and 
subsequently limit the progression to virological failure. 
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1.6.2 Next Generation Sequencing (NGS) 
High throughput sequencing, also known as NGS, is the umbrella term used to describe modern 
high capacity sequencing technologies. Driven by the need to reduce cost per sample and increase 
output, NGS has revolutionised the sequencing field as a whole. Massively parallel sequencing 
methods utilised by NGS technologies have addressed and overcome scalability of conventional 
Sanger sequencing by hybridising DNA molecules to beads or solid surfaces such that millions of 
micro-reactions may occur in parallel (Reis-Filho, 2009). As opposed to utilising longer read 
lengths in Sanger sequencing, NGS generates millions of shorter read lengths which effectively 
allows for mutation detection in a small subpopulation that is amongst a large population of WT 
sequences (Reis-Filho, 2009; Schuster, 2007). This is especially useful in the context of HIV-1 
genotyping. Minority variants that harbour mutations that constitute a very small percentage of the 
total viral population can be accurately detected. 
Overall, there are currently four major platforms each utilising unique chemistry, which may be 
used for the purpose of NGS shown below in Table 1.2: 
Table 1.2: Summary of commonly used next generation sequencing technologies (adapted from 
Gibson et al., 2014) 
  454 (GS Jr.) Illumina (MiSeq) 
Ion Torrent 
(S5) 
PacBio (RS II) 
Amplification method 
Emulsion PCR on 
beads 
Bridge PCR in situ 
Emulsion 
PCR on beads 
Linear 
Principle (chemistry) 
Synthesis 
(pyrosequencing) 
Sequencing by 
Synthesis (SBS) 
(reversible 
termination) 
Synthesis  
(H+ detection) 
Single molecule, real-
time synthesis 
Average read length 
(bp) 
400–700 150 - 300 200 - 400 4,200–8,500 
Primary error (error 
rate) 
Indel ~1 % Substitution ~0.1 % Indel ~1 % Indel ~13 % 
Main advantage(s) 
Long read length, 
maturity 
Easy work flow, 
maturity 
Low cost, fast 
run 
Longest reads 
Main disadvantage(s) 
Homopolymer 
misreads, high cost 
per Mb 
Shortest reads 
Homopolymer 
misreads 
High error rate, 
expensive 
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1.6.2.1 Roche 454 Pyrosequencing  
The Roche 454 was the first NGS sequencing platform made commercially available and utilised 
the chemistry principle termed pyrosequencing. Chemiluminescent signals are produced in the 
event of a complementary nucleotide reaction which allows for the determination of a nucleotide 
sequence (Balzer, Malde, Lanzén, Sharma, & Jonassen, 2010).  
Pyrosequencing on the 454 platform is performed by fragmenting DNA of interest by either 
mechanical or enzymatic methods into fragments of approximately 400 to 600 base pairs (bp) 
(Rothberg & Leamon, 2008). Adapters are ligated to the ends to the fragments, where they are heat 
denatured to single stranded DNA fragments. Resin beads are added to the DNA mixture, which 
are covered by oligonucleotides on the bead surfaces that are complementary to the adapters at the 
ends of the DNA fragments. The DNA fragments bind to the bead surface, ideally one fragment 
per bead (Rothberg & Leamon, 2008). An emulsion oil is added to the bead-DNA solution, which 
forms droplets that separate the beads from one another. An emulsion PCR is then performed, 
whereby each bead surface is covered by amplification to result in identical copies of the single 
DNA fragment that hybridized to the bead initially. Beads are added to a pico-titer plate, such that 
each bead occupies one well of the plate. DNA polymerase and primers are then added to the wells. 
The primers bind to specific primer binding sites on the adapters, and incorporate nucleotides that 
are added to the wells in waves. One of the four nucleotides (adenine, thymine, cytosine and 
guanine) is added per wave. The incorporation of a nucleotides to the template DNA fragment 
leads to the release of a pyrophosphate, which after a chain of subsequent reactions, causes 
chemiluminescent reaction that is detected as light emission by a specialised camera (Rothberg & 
Leamon, 2008). The intensity of the light emission is proportional to the number of nucleotides 
incorporated into a nucleotide sequence; i.e. a stretch of 3 adenines would have three times the 
intensity of a single adenine. Pyrosequencing is however limited by the number of homopolymers 
it can accurately sequence. The light intensities are linked to the nucleotide wave patterns, and the 
sequence of DNA fragments per well are determined by way of computational processing, and 
converted to a DNA sequence file.  
1.6.2.2 llumina Paired End Sequencing & Sequencing by Synthesis  
Paired end sequencing chemistry, or sequencing by synthesis (SBS) describes the sequencing 
chemistry that is utilised on the Illumina platform, and more specifically the Illumina Miseq 
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platform that was utilised in this study. Input DNA is fragmented and uniquely identified, by 
hybridizing a unique combination of adaptors to the 5’ and 3’ ends of the fragments. 
Illumina sequencing by synthesis, consists of three basic steps. The three steps are: (i) 
sample/library preparation (ii) cluster generation and (iii) sequencing.  
Input DNA is randomly fragmented by an enzymatic reaction utilising the Illumina transposome, 
adapters are thereafter attached to the ends of the DNA fragments by means of reduce cycle 
amplification. Indexes that uniquely label each sample are ligated to the adapters, such that pooling 
and multiplexing of samples may occur. A specific size of fragments is selected for, which will be 
used for cluster generation and sequencing (Illumina, 2016b). 
The clustering step is a process in which DNA fragments are passed over the flow cell surface, 
hybridize, and are isothermally amplified. The flow cell is a glass slide that is comprised of several 
lanes, each coated with a lawn of two types of oligonucleotides that are complimentary to the 
oligonucleotide motifs at the end of the generated fragments. A schematic illustration of clustering 
by bridge amplification is shown below in Figure 1.7.  
 
Figure 1.7: A schematic representation of bridge amplification. Bridge amplification is the 
process in which fragments are isothermally amplified multiple times on the surface of the 
sequencing flow cell (Adapted from Illumina).   
Hybridisation is enabled by the first of the two types of oligonucleotides on the surface of the flow 
cell. The 3’ end of the fragment is blocked, and cannot bind to its complementary oligo on the 
surface of the flow cell.  The 5’ end of fragments bind via their complementary oligo motif to the 
flow cell surface (A). Following binding, a polymerase is passed over the surface of the flow cell 
which creates a complement of the hybridised fragments (B). The resulting double stranded 
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molecule is then denatured, and the original fragment is washed away (C). The 3’ ends are now 
unblocked. The remaining fragments on the flow cell surface are then clonally amplified via 
Illumina’s bridge amplification. The stands on the surface of the flow cell to fold over, and the 
oligo motifs on the opposite end of the strand hybridise to the second type of oligo on the surface 
of the flow cell (D). A polymerase again generates a complementary strand which results in a 
double stranded bridge (E). The bridge is denatured, and thus results in two single copies of the 
molecule that is tethered to the flow cell (F). The process is thereafter repeated until a required 
cluster density is obtained (Illumina, 2016b). 
Once approximately thousand cycles of bridge amplification are completed, the reverse strands are 
cleaved and washed away. This ensures that reads are all obtained in the same 5’ to 3’ direction 
for read one. The sequencing reaction begins by the extension of the first sequencing primer, which 
binds to the index on the 3’ end (as seen in Figure 1.8). 
 
 
 
 
 
 
 
Figure 1.8: The 5’ to 3’direction of the first sequencing read. The first read sequencing primer 
binds to the primer binding site, and produces the first read by incorporating nucleotides in the 
sequencing cycles that follow. 
With each cycle, fluorescently tagged nucleotides compete for the addition to the growing chain. 
A single nucleotide is incorporated based on the sequence of the template strand. Once a single 
nucleotide is incorporated, the last incorporated nucleotide with fluorochrome attached is excited 
by a light source, which results in a characteristic florescent single to be emitted and detected, 
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which thus determines the base call. The number of cycles, in which nucleotides are incorporated, 
determines the read length of the reaction. Hundreds of millions of clusters are sequenced 
simultaneously, in a massively parallels process. Upon completion of the first read, the read 
product is denatured and washed away. An index read then follows once the read product is washed 
away. A primer binds to a sequence on the 5’ end of the DNA fragment attached to the flow cell, 
which extends to sequence the index on the 5’ end (termed p5). As the fragment remains in same 
location on the flow cell, the first index sequence is assigned to the read that was produced in the 
previous step, and mapped to the same location on the flow cell. The strands bend over and again 
by hybridizing to the complementary oligonucleotide sequences on the surface of the flow cell, as 
shown in Figure 1.9 (A).  
 
Figure 1.9: The production of the second sequencing read. The second read is produced by 
reading the second index primer first, and then proceeding with the sequencing reaction.  
First the second index read is performed (B). A primer attaches to the binding site on the opposite 
end of the fragment, and extends to sequence the index second index (termed p7) (B).  As the 
strand is still bent over, a polymerase is added to the reaction and proceeds to extend the bent over 
fragment (C). Once the original forward strand is copied and the stands are denatured (D). The 
original forward strand is cleaved and washed away (E). The second read is now performed. As in 
the first read, the number of cycles are repeated until the read length is obtained (F) (Illumina, 
2016b). 
1.6.2.3 Thermo Fisher Ion Torrent Platform 
The Thermo Fisher Ion torrent systems, and more specifically the most recent instrument termed 
the S5, utilises semi-conductor technology. A semi-conductor chip containing millions of wells is 
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used to capture chemical information that is generated during the DNA sequencing process. The 
release of a hydrogen ion upon successful incorporation of a nucleotide is detected and measured, 
and converted into digital information that provides data to determine a base call.  
The amplification method used by this platform is similar to that of Roche 454 pyrosequencing. 
Input DNA is fragmented and denatured, followed by the addition of adapter sequences to end of 
the fragments. The sequence of the adapters allows for the fragments to bind to complementary 
oligonucleotides on the surface of a resin bead, ideally one fragment at a time (Rothberg et al., 
2011). An emulsion oil is added, and results in one oil droplet to contain one bead with one 
fragment. The oil droplet contains all the PCR components that are required to amplify the single 
fragment, to cover the entire surface of the bead. Millions of different beads are thus covered with 
identical copies per bead of millions of different fragments (Rothberg et al., 2011).  
The beads are then passed over the semi-conductor chip, which is pitted with millions of wells. 
One bead is deposited into one well. The chip is thereafter flooded with one of the four different 
DNA nucleotides every 15 seconds. When a nucleotide is incorporated to a complementary 
nucleotide on the single stranded DNA fragments on the surface of the bead, a hydrogen ion is 
released (Rothberg et al., 2011). The release of the hydrogen ion leads to a potential of hydrogen 
(pH) change in the well, which is detected and read directly on the sequencing chip by an ion 
sensitive layer at the bottom of each well. The pH change is converted to voltage and recorded, 
which indicates an incorporation of a nucleotide, and subsequently calling the base (Rothberg et 
al., 2011). If a nucleotide is not incorporated, no ion is released, and no voltage change is detected 
and recorded. When two or more nucleotides are incorporated, a voltage change proportional to 
the number of nucleotides incorporated is recorded (Rothberg et al., 2011). This platform can 
perform a sequencing reaction faster than other light-based sequencing platforms, and is moreover 
vastly scalable. The platform however is not as accurate in base calling as other platforms, with 
increased homopolymer  misreads (Rothberg et al., 2011).  
1.6.2.4 Pacific Biosciences PacBio  
The PacBio platform utilises a DNA sequencing technology termed single molecule real time 
(SMRT) DNA sequencing. This technology utilises the DNA polymerase to incorporate propriety 
phospholinked nucleotides. The polymerase activity is visualised, by using nucleotides that are 
each fluorescently labeled specific to the four different nucleotides. The labeled nucleotides differ 
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from other light-based sequencing platforms in that the PacBio phospholinked nucleotides carry 
their fluorescent labels on the terminal phosphate, rather than the nucleotide base (Fabbri, 2013). 
The fluorescent label is cleaved away once the nucleotide has been incorporated to a 
complementary nucleotide in the template DNA strand. A completely natural DNA strand results 
once the labeled nucleotide has been incorporated and cleaved, thus allowing for the exploitation 
of the inherent properties of DNA polymerase’s activity. These properties allow for high speed of 
sequencing, significantly longer read length and high fidelity (Fabbri, 2013). Although the PacBio 
platform allows for significantly higher read lengths, the technology is more expensive and has a 
significantly higher error rate relative to other light-based sequencing platforms. 
1.6.3 NGS Error Correction 
The process in which genetic material of interest is prepared for sequencing, known as library 
preparation, introduces artificial errors in downstream amplified and processed genetic material. 
The introduction of errors may be problematic especially in the context of NGS, as the technology 
has the capacity to produce deep coverage of target sequences, and thus the detection of low 
frequency variants. The sequencing instruments may additionally read individual base pairs in 
genetic sequences incorrectly. The above is considered and addressed bioinformatically, however 
it is important to note that not all artificially introduced errors, as well as sequencing errors, may 
be corrected with bioinformatic tools. Thus, a cut off of 1% of the sequenced sample is used, as at 
this percentage, base calls at a high confidence may be made. 
1.6.3.1 PCR Amplification Bias and Sequencing Error 
The conversion of viral RNA to cDNA is performed by reverse transcription polymerase chain 
reaction (RT-PCR). Despite using high fidelity RT-PCR enzymes, errors may be introduced in the 
reverse transcription reaction. The amplification of cDNA with conventional PCR in the 
subsequent step that follows RT-PCR, introduces yet another potential step in which artificial 
errors may be introduced. PCR re-sampling may occur in the amplification steps, and involves the 
artificial inflation of the prevalence of one variant. An error may be introduced in the first round 
of PCR, and may be particularly problematic as the erroneous sequence may emerge as the 
dominant sequence.  
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The innate properties of the sequencing chemistry may additionally result in nucleotides being 
read incorrectly by the sequencer, and is termed sequencing error. The innate properties of the SBS 
chemistry has a defined error rate of 0.1%. A specific sequencing reaction may have its own quality 
metric, known as the Q value. The Q30 value is the 0.001% probability that that a nucleotide will 
be called incorrectly. Thus, the higher the percentage of reads at or above Q30, the higher the 
quality of the library. Reads with less than 100% Q30 are simply discarded in the bioinformatic 
pipeline. Alternatively, the bioinformatic pipeline may be altered based on the Q30 scores, 
depending on the sensitivity required.  
It is very difficult to quantify the errors introduced in the final sequenced product by PCR error. 
Sequencing error is easier to identify as the error profiles of instruments are known, and the number 
of reads required to confidently call a mutation can be based on this error profile.  However, due 
to the error prone nature of the amplification steps that precedes the library preparation, and 
sequencing error, a mutation cut-off of 1% is used. Mutations frequencies below 1% should not be 
interpreted with any clinical regard.  
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1.7 Rationale, Aims and Objectives of the study 
The increasing availability of ART in sub-Saharan Africa, in conjunction with WHO 
recommendations for earlier initiation of treatment for HIV-1infected individuals has led to an 
increase in HIV-1 drug resistance. A consequence of increased drug resistance is an increasing 
prevalence of TDR. Individuals identified with baseline drug resistance in the International AIDS 
Vaccine Initiative (IAVI) Early Infections Cohort (Protocol C) provided a unique research 
opportunity to study HIV-1 transmitted drug resistance. Of particular interest is the persistence 
and/or reversion of TDRMs in drug naïve individuals.  
Longitudinal samples with varying periods of follow-up were made available for 23 the individuals 
identified with TDR. Of the 23 individuals, only one initiated ART during the follow up period; 
all other individuals were ART naïve. Ten of the 23 individuals initiated treatment outside of the 
follow-up period of this study. Understanding the population dynamics of TDR HIV-1 in the 
absence of drug pressure is essential for clinical management and public health strategies. 
 
The study aim was to monitor and study the evolution of TDRMs in the individuals identified 
with baseline resistance. 
i. To extract viral RNA from longitudinally collected plasma from the antiretroviral drug-
naïve recently infected participants with documented transmitted HIV-1 drug 
resistance.  
ii. Develop an NGS drug resistance assay on the Illumina Miseq platform to detect 
minority variants that may harbour transmitted drug resistance mutations (TDRMs) 
with a prevalence of 1% utilising NGS on the Illumina Miseq platform in the 
longitudinally collected plasma.  
 
iii. To measure, analyse, and compare the decay (reversion) or persistence of TDRMs in 
the longitudinally collected plasma. 
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CHAPTER 2: Materials and Methods 
2.1 International Aids Vaccine Initiative (IAVI) Protocol C Cohort 
Participant samples from the IAVI protocol C cohort were used in this study, and included acutely 
HIV-1 infected and antiretroviral drug naïve participants from Kenya, Uganda, Rwanda, Zambia 
and South Africa (Price et al., 2011). The Protocol C project was initially launched in 2006, and 
to date 613 participants have been voluntarily enrolled (http://www.iavi.org). Population based 
Sanger sequencing performed in our laboratory identified 29 participants with TDRM. These 
sequences were available for comparative purposes in this study. 
Longitudinal blood plasma samples (n=160) were available from 23 of the 29 individuals in which 
TDRMs mutations were identified. The number of sample available for each of the 23 participants, 
in shown in Table 1 in Appendix D. Samples for 6 of the 29 individuals were not available for use 
in this study. Plasma samples were shipped to Johannesburg and stored at -80C until used. Human 
ethical clearance was obtained from the University of the Witwatersrand for research on human 
subjects  (Clearance number M160691; Appendix A). A 159 of 160 samples were sequenced using 
NGS on the Illumina Miseq platform. 
2.2 Viral RNA Extraction, Reverse Transcription and Nested Polymerase Chain Reaction 
(RT-PCR) Amplification 
2.2.1 Viral RNA Extraction 
Viral RNA was extracted from participant blood plasma samples utilising the NucliSENS® 
easyMAG® total nucleic acid automated extractor (BioMérieux, France). Briefly, 500 µl of plasma 
was added to an 8 well NucliSENS® easyMAG® disposable cartridge (BioMérieux, France). The 
viral on-board lysis program was initiated on the easyMAG® instrument. Once lysis was complete, 
50 µl of NucliSENS® easyMAG® magnetic silica beads (BioMérieux, France) was added to each 
well containing lysed sample and re-suspended. Standard protocol procedures were followed on 
the NucliSENS® easyMAG® instrument and extracted viral RNA was eluted in a final volume of 
25 µl. Viral RNA was immediately stored at -80°C to minimize RNA degradation, until required. 
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2.2.2 Reverse Transcription PCR (RT-PCR) 
The HIV-1 polymerase (pol) gene, encompassing the viral genes protease (pro) and reverse 
transcriptase (RT), was RT-PCR amplified. A one step RT-PCR protocol was followed to reverse 
transcribe viral RNA to cDNA and PCR amplify an approximately 2.38 kilobase (kb) fragment.  
The first-round RT-PCR reaction utilised the SuperScript® III One-Step RT-PCR System with 
Platinum Taq High Fidelity PCR kit (Thermo Fisher Scientific, Massachusetts, USA). The outer 
primers used were IN3 (5’- GCA AGA GTT TTG GCT GAA GCA ATG AG -3’) (Integrated 
DNA Technologies (IDT), USA) as the forward primer and G25REV (5’- TCT ATC CCA TCT 
AAA AAT AGT ACT TTC CT -3’) (Integrated DNA Technologies (IDT), Iowa, USA) as the 
reverse primer. The PCR reaction volumes for a single reaction were 0.5 µl Superscript III 
RT/Platinum Taq Mix, 12.5 µl 2x Reaction Mix, 0.5 µl each of IN3 and G25REV (10 pM stock 
concentration), 1.5 µl of MgSO4 (5 mM stock concentration), 1.5 µl of sterile nuclease free water 
and 8 µl of extracted viral RNA, for a total reaction volume of 25 µl.  
The master mix was then placed in a GeneAmp PCR system 2700 (Applied Biosystems, USA) 
and the following cycling conditions were used: cDNA synthesis for 60 minutes (min) at 50C, 
initiation for 2 min at 94C, followed by 35 cycles of denaturation for 15 seconds (sec) at 94C, 
annealing for 30 sec at 54.5C, and elongation for 2 min 30 sec at 68C. A second elongation was 
initiated after the 35 cycles were completed for 10 min at 68C, followed by a 4C hold. 
 
2.2.3 Nested PCR of RT-PCR Products  
A nested PCR protocol was implemented to improve the amplicon yields. The first round was 
followed by a nested PCR reaction to amplify an approximately 1.8 kb pol fragment. 
The second-round utilised Platinum Taq DNA Polymerase High Fidelity PCR kit (Thermo Fisher 
Scientific, Massachusetts, USA) with primers PolM4 (5’- CTA TTA GCT GCC CCA TCT ACA 
TA -3’) (Integrated DNA Technologies (IDT), USA) as forward primer and AV150 (5’- GTG 
GAA AGG AAG GAC ACC AAA TGA AAG -3’) (Integrated DNA Technologies (IDT), USA) 
as reverse primer. The PCR reaction volumes for a single reaction were 0.2 µl Platinum Taq DNA 
High Fidelity Polymerase, 6 µl 10x high fidelity buffer, 0.5 µl each AV150 and POLM4 (at 20 
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µM stock concentration), 2 µl MgSO4 (50 mM stock concentration), 37.8 µl sterile nuclease free 
water and 3 µl cDNA from first round RT-PCR, for a final reaction volume of 50 µl. 
The second-round DNA-master mix mixtures were then placed in a GeneAmp PCR system 2700 
(Applied Biosystems, USA) and the following cycling conditions were used: initiation for 2 min 
at 95°C, followed by 35 cycles of denaturation for 30 sec at 95°C, annealing for 30 sec at 51°C, 
and elongation for 2 min 30 sec at 68°C. A second elongation was initiated after the 35 cycles were 
completed for 10 min at 68°C, followed by a 4°C hold. 
The resulting PCR products were purified utilising the GeneJet Purification Kit (Thermo Scientific 
Fisher, USA) according to manufacturer’s instruction (Appendix B). The purified PCR products 
were verified by gel electrophoresis on a 1% (w/v) agarose gel (appendix B) and visualised under 
UV trans-illumination (Biorad, USA). The purified PCR products were stored at -20°C until 
required in subsequent steps. 
 
2.3 Next Generation Sequencing on the Illumina Miseq Platform 
The Nextera XT DNA sample preparation kit, Nextera XT Index Kit (all Illumina, California, 
USA) were used to generate a sequencing library as per manufacturer’s instructions, with several 
exceptions as outlined below. The MiSeq Reagent Kit V3 (Illumina, California, USA) was used to 
perform the sequencing reaction. Samples one to 38 were sequenced in run one, 39 to 79 in run 
two, 80 to 125 in run three and 126 to 159 in run four. 
2.3.1 Amplicon Quantification 
Purified PCR amplicons were quantified on the Qubit 2.0 fluorometer using the Qubit dsDNA 
High Sensitivity Assay Kit (Thermo Fisher Scientific, Massachusetts, USA) (Appendix B).  The 
PCR products were thereafter diluted with nuclease-free water (Thermo Fisher Scientific, 
Massachusetts, USA) to a final concentration of 0.2 ng/l. To limit pipetting error, a constant 
volume of 2 µl per sample was added to an appropriate diluting volume of nuclease free water 
(Thermo Fisher Scientific, Massachusetts, USA). 
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2.3.2 Sample/Library preparation 
The Nextera XT DNA sample preparation kit and Nextera XT Index kits were used for 
sample/library preparation following the Nextera XT library preparation guide. The library 
preparation consisted of four main steps, specifically: (i) input DNA fragmentation (tagmentation), 
(ii) sample indexing, (iii) fragment size selection and (iv) library normalisation. 
2.3.2.1 Input DNA Fragmentation (Tagmentation)  
A total of 1 ng (5 l total volume per sample at 0.2 ng/l) of each participant sample was added 
onto a 96 well PCR plate (Biorad, USA), to which 10 l of tagment DNA buffer (TD) and 5 l of 
amplicon tagment mix (ATM) was added to each well. The ATM contains the transposome that 
enzymatically fragments the input DNA, whilst tagging the fragments with a transposon primer at 
the ends of the fragments. The plate was then sealed using a microseal B adhesive seal (Biorad, 
USA), and subjected to centrifugation at 280 x g at 20C for 1 min, and placed in the C1000 Touch 
Thermal Cycler (Bio-Rad, USA). The thermocycler was run at 55C for 5 min, followed by a hold 
at 10C. Once 10C was reached, the plate was removed, and 5 l of neutralize tagment (NT) 
buffer was added to each well to neutralise the transposome activity.  
.  
2.3.2.2 Sample Indexing 
Once the input DNA was fragmented (tagmented), the DNA was amplified in a limited cycle PCR 
that adds indexes and sequences to the end of the fragments that are required for cluster generation. 
Indexing of samples serves as a method to multiplex and identify each sample after pooling and 
post sequencing. Unique combinations of indexes (i7 & i5 – 6- 12 base pairs (bp) sequences; 
provided in the Nextera XT Index kit) were hybridized to the ends of the DNA fragments, to which 
the transposon attached adapter sequences. The index sequences as a whole consist of 3 motifs: (i) 
a sequence that is complementary to oligonucleotide sequences on the flow cell surface (ii) i7/i5 
indexes and (iii) read primer that is complementary to the transposon primer that was added in the 
tagmentation step. The motifs are graphically represented in Figure 2.1. The combination of index 
primers was determined utilising the Illumina Experiment Manager (Version 1.9.1). Indexing of 
samples was performed as per the Nextera XT library preparation guide. 
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Figure 2.1: Schematic representation of Illumina paired end sequencing adapters added to 
both ends of the cDNA fragments. Forward reads are indicated by an orange arrow moving in a 
5’ to 3’ direction. Reverse reads are indicated by a blue arrow moving in a 5’ to 3’on the 
complementary strand (Adapted from http://www.gendx.com). 
 
Fifteen microliters of Nextera PCR master mix (NPM) was added to each well of the plate that 
contained the fragmented DNA. Five microliters of read primer 1 (i7) and 5 µl of read primer 2 
(i5) was added to each well, in a unique combination that was determined by means of the Illumina 
Experiment Manager. The contents of each well were mixed thoroughly by pipetting the solution 
up and down five to seven times, followed by sealing the plate with a Microseal A film (Bio-Rad, 
USA). The plate was subjected to centrifugation at 280 x g at 20ºC for 1 minute, and placed in the 
C1000 Touch Thermal Cycler. The following program was performed on the thermocycler: 72°C 
for 3 min; 95°C for 30 sec; 12 cycles of: 95°C for 10 sec, 55°C for 30 sec and 72°C for 30 sec; 
followed by 72°C for 5 min and a final hold at 10°C. 
Limited cycle PCR 
5’                      3’  
3’                      5’  
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2.3.2.3 Fragment Size Selection 
 After the samples were fragmented and uniquely indexed, they were subjected to a size selection. 
Solid phase reverse immobilisation (SPRI) AMPure XP beads (Beckman Coulter, USA), stored at 
4ºC, were brought to room temperature. A fresh solution of 80% ethanol was prepared by diluting 
ethanol absolute (Merck, USA) with nuclease free water. Forty microliters of the indexed PCR 
products from the previous indexing step was transferred to a new clean 96 well plate. The AMPure 
XP beads were vigorously vortexed to ensure a homogenous bead solution. Bead volumes relative 
to DNA volumes (bead ratios) was determined by using work performed by Connolly et al. (2010). 
The resulting purified fragments obtained by Connolly et al. (2010) were resolved on a 2% (w/v) 
agarose gel. The gel image obtained by Connolly et al. (2010) is shown in Figure 2.2 below: 
 
     
 
 
 
 
 
 
 
 
 
 
Figure 2.2: A range of SPRI bead ratios (0.4 to 2.5 times SPRI bead volume to DNA sample 
volume) were used to purify fragmented DNA samples, and the resulting purified fragments were 
resolved on a 2% agarose gel (Connolly et al., 2010). 
 
SPRI beads were specifically developed by the Whitehead institute (Massachusetts, USA) in 1995 
to eliminate smaller DNA fragments, and thus to isolate and purify amplicons as a post-PCR clean 
up (DeAngelis, Wang, & Hawkins, 1995). Each SPRI bead is composed of a polystyrene core, 
covered by a layer of magnetite. The magnetite is crucial for the function of SPRI beads, as it 
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results in the surface of the bead covered in carboxyl groups (DeAngelis et al., 1995). The 
magnetite additionally gives the beads the property of being paramagnetic, which prevents 
clumping and falling out of solution in the absence of a magnetic field. The carboxyl groups 
reversibly bind to negatively charged DNA in the presence of NaCl and polyethylene glycol 
(PEG), which acts as an aggregation agent. The concentration of PEG and NaCl is proportional to 
the initial amount of DNA immobilised per bead, and thus the volume of beads to DNA is critical.  
DNA size is proportional to the charge of the DNA molecule, i.e. a larger DNA molecule (a larger 
number of base pairs in sequence) will be more negatively charged relative to a smaller molecule. 
Due to this property, larger DNA molecules are more likely to bind to the beads due to electrostatic 
interaction with the beads surface, and thus displace smaller DNA fragments. Thus, the lower the 
volume of beads relative to DNA, the higher the DNA fragment will bind to the bead surface 
(DeAngelis et al., 1995). This ratio can subsequently be manipulated to obtain a spectrum of 
fragment sizes of interest. 
SPRI Size Selection Ratios 
Four Miseq sequencing runs were performed. For each run, a library preparation was performed, 
in which a SPRI size selection step was done. Below are the details for each run as to how the 
SPRI selection was completed and how the selections differed from each run.  
SPRI to DNA Ratio for Run One 
A double size selection method was utilised in the first run. A double size selection is the use of 
SPRI beads to eliminate smaller fragments, and thereafter performing an additional size selection 
to eliminate larger fragments. For the first run an average library fragment size of ~250 basepairs 
(bp) was desired.  
The first SPRI bead ratio to DNA was 1x beads:DNA (50 µl beads to 50 µl DNA). This ratio would 
eliminate all fragments smaller than 200 bp (fragments approximately >200 bp would bind to the 
beads, and fragments approximately <200 bp would remain in the supernatant). A volume of 50 
µl SPRI beads were added to the wells containing sample. The bead-DNA mixture was thoroughly 
but gently mixed by pipetting the solution up and down ten times, followed by placing the plate 
on a micro plate shaker set at 1800 revolutions per minute (RPM) for 2 minutes. The plate was 
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thereafter placed onto a magnetic stand for 2 minutes, and visually inspected to ensure the solution 
had cleared. The supernatant was carefully removed, so as not to disrupt the beads, and discarded. 
Fresh 80% ethanol, 200 µl, was added to each well. The ethanol was allowed to incubate in the 
wells containing the beads for 30 seconds where after it was removed and discarded from each 
well. This ethanol wash step was repeated. Following the second ethanol wash, the plate was 
allowed to air dry in a laminar flow cabinet for 15 minutes. The beads were thereafter suspended 
in 55 µl re-suspension buffer (RBS), and placed back onto the magnetic stand. Once the solution 
had cleared, 50 µl of the supernatant was collected and transferred to a new 96 well plate. 
A second size selection step was performed, in which a 0.5x ratio of AMPure XP beads to DNA 
(25 µl beads to 50 µl DNA) was added to each well. This step would eliminate all larger fragments 
(~500 bp and above fragments would bind to the SPRI beads). The bead-DNA mixture was 
thoroughly but gently mixed by pipetting the solution up and down ten times, followed by placing 
the plate on a micro plate shaker set at 1800 RPM for 2 minutes. The plate was then placed onto a 
magnetic stand for 2 minutes, and visually inspected to ensure the solution had cleared. A volume 
of 50 µl supernatant was carefully collected and transferred to a new 96 well plate. 
SPRI to DNA Ratio for Runs Two to Four  
Following results obtained in the first run, the size selection ratios were altered. An additional 
fragment analysis quality control step was introduced.  
The desired average fragment size was modified to 750 bp. A review of literature resulted in the 
modification of the average library fragment size. As per Dudley et al. (2014), a fragment size of 
774 bp (range 519-1060 bp) yielded optimal sequencing read lengths. 
A single size selection was used in subsequent runs 2 to 4. A ratio of 0.5 x SPRI beads to DNA 
was used (25 µl SPRI beads to 50 µl of DNA). This would result in binding of fragments ~500 bp 
and above. The beads were washed twice with 80% (v/v) ethanol and allowed to dry as described 
in the initial bead size selection above. Once dry, the beads were re-suspended in 15 µl RBS. Ten 
microliters were transferred to a new clean 96 well plate. 
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2.3.2.4 Library Fragment Analysis  
The size selected, and indexed fragments were quantified using the Qubit dsDNA High Sensitivity 
Assay Kit as per manufacturer’s instruction (Appendix B). Fragment sizes were verified by 
fragment analysis for runs 2 to 4. Initially the fragment sizes for samples in run one was not 
determined, as it was believed the inferred sizes would be adequate, however, samples from run 
one were retrospectively fragment analysed.  
The average fragment size of the library was obtained by means of an Agilent 2100 Bioanalyzer 
utilising the High Sensitivity DNA Analysis Kits (Agilent Technologies, USA) as per the 
manufacturer’s instructions. The Agilent 2100 Bioanalyzer software, 2100 Expert (version 
B.02.08.SI648 (SR3), Agilent Technologies, USA) was utilised to obtain average fragment size 
values and visualise graphs. In the software, a sample is selected, which displays an 
electropherogram illustrating the spread of fragment DNA sizes measured in the respective sample. 
A region selecting the entire library fragment distribution, from the smallest to the largest DNA 
fragment was highlighted, and the “region table” tab is selected. Details of the region of interest is 
displayed, including sizes of the smallest and biggest DNA fragments respectively, concentration 
of the sample, and the average size of the sample. 
2.3.2.5 Library Normalisation 
All samples were quantified utilising the Qubit® 2.0 fluorometer with the Qubit® dsDNA High 
Sensitivity Assay Kit as per manufacturer’s instructions (Appendix B). Concentrations were 
obtained (in ng/µl) and converted to molarity (nmol/l). Molarity was calculated using a calculation 
provided by Illumina, by using the average fragment sizes of the library that was obtained by 
means an Agilent  2100 Bioanalyzer (Agilent Technologies, California, United States) and sample 
concentrations. Samples were diluted to a working concentration of 2 nmol/l (M). 
The following calculation was used for the molar conversion:  
𝑀𝑜𝑙𝑎𝑟𝑖𝑡𝑦 (
𝑛𝑚𝑜𝑙
𝑙
) =
(𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑖𝑛 
𝑛𝑔
µ𝑙 ) (10
6)
(660
𝑔
𝑚𝑜𝑙) (𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑙𝑖𝑏𝑟𝑎𝑟𝑦 𝑓𝑟𝑎𝑔𝑚𝑒𝑛𝑡 𝑠𝑖𝑧𝑒 𝑖𝑛 𝑏𝑝) 
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2.3.3 Library pooling and denaturing  
A series of dilutions were performed in order to obtain the correct final library concentration of 7 
pM for optimal cluster density generation. Figure 2.3 is a schematic representation of the dilution 
series that was performed: 
 
Figure 2.3: The series of library dilutions, starting at 2 nM, performed to obtain the final 
concentration of 7 pM suitable for Miseq loading and subsequent sequencing.  
 
Five microliters of each sample were added to an Eppendorf microfuge tube. The pooled samples 
were mixed by pipetting the solution up and down ten times. Five microliters of the pooled sample 
solution were taken and combined with 5 µl of 0.2 M NaOH (Sigma-Aldrich, USA). The NaOH 
was prepared by diluting 1 M NaOH with nuclease free water to a final concentration of 0.2 M. 
The solution was briefly vortexed, and incubated at room temperature for 5 min.  This resulted in 
a 1 nM pooled library solution. A volume of 990 µl of pre-chilled Hybridization Buffer (Nextera 
XT DNA sample preparation kit) was added to 10 µl of the denatured DNA solution, resulting in 
a 10 pM solution. The solution was further diluted to 7 pM by mixing 420 µl of the 10 pM DNA 
solution with 180 µl of Hybridization Buffer. 
The PhiX Sequencing Control V3 (Illumina, USA), which is a reliable adapter-ligated library 
derived from the small, well-characterized PhiX genome, was used as a sequencing control. The 
PhiX genome was used as quality control for cluster generation, sequencing, and alignment, and a 
calibration control for cross-talk matrix generation, phasing, and pre-phasing. 
Two microliters of the 10 mM PhiX solution provided in the PhiX Sequencing Control V3 kit was 
diluted with 3 µl nuclease free water. The 5 µl solution was combined with 5 µl of 0.2 M NaOH, 
vortexed and incubated for 5 minutes. The denatured PhiX solution was diluted to a final 
concentration of 20 pM by combining 10 µl of PhiX solution with 990 µl of pre-chilled 
Hybridization Buffer.  
1. Library 
Normilisation to 
2 nM
2. Denature and 
dilute with 
NaOH to 1 nM
3. Dilute with 
hybridization 
buffer  to 10 pM
4. Dilute with 
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The Nextera XT protocol advises that the final volume that is to be loaded into the reagent cartridge 
for sequencing, is 600 µl. A volume of 480 µl 7 pM library was thus combined with 120 µl 20 pM 
PhiX (20% of the final loading volume). 
2.3.4 Clustering and Sequencing  
The Illumina V3 chemistry (MiSeq Reagent Kit V3, Illumina, USA) was utilised for sequencing 
of all samples on the Illumina Miseq benchtop sequencer. The V3 chemistry was preferable in the 
context of HIV-1 sequencing, as the V3 chemistry is characterised by longer read lengths (300 bp).  
The pooled library (600 µl) was loaded into the designated well on the reagent cartridge provided 
in the MiSeq Reagent Kit V3. Instrument onscreen instructions were followed to set up the 
sequencing reaction. When prompted by the Miseq instrument, the cartridge was loaded into the 
instrument, followed by the incorporation buffer and the flow cell. Special care was taken to rinse 
the flow cell with nuclease free water followed by visually inspection to ensure no precipitates or 
residues were present, before loading it into the instrument. The sequencing reaction parameters 
of 600 cycles (300 forward cycles, and 300 reverse cycles) were specified on the instrument. The 
600 cycle parameters were selected as this is the cycle capacity of the Miseq Reagent Kit V3. The 
sample sheet, previously prepared in the Illumina Experiment Manager (Version 1.9.1), was 
uploaded into the instrument when prompted in subsequent steps. The sample sheet contains the 
unique combination of indexes assigned to each sample. A pre-check was initiated on the Miseq 
instrument, verifying that all microfluidics were operational, after which the sequencing reaction 
commenced.  
Once the sequencing run was initiated, preliminary QC criteria displaying cluster density (k/mm2), 
passing filter and Q scores were shown on the instrument’s display. Following the completion of 
a sequencing run, several sequencing reaction metrics were analysed to determine to quality of the 
run. The metrics are described below: 
• Cluster density describes the density of clusters (defined as K), for each tile, on the surface 
of the flow cell in thousands per mm2. The Illumina Nextera V3 chemistry flow-cells 
utilised for all four runs, had 38 tiles per flow cell. The final library preparation was diluted 
to obtain cluster densities within the desired range of 800 – 1200 K/mm2. Clusters below 
800 K/mm2 results in a poor under clustered run; cluster densities over 1200 K/mm2 results 
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in an over clustered flow cell in which individual base calls cannot be distinguished from 
one another resulting in poor output. 
• Clusters Passing Filter (PF) describes the number of clusters which passed the defined 
passing filter for each tile in millions. The passing filter is defined during cycles 1 – 25 of 
the first read. A chastity filter proceeds to remove the least reliable clusters from the image 
extraction results. A cluster is permitted to pass the filter if no more than one base call has 
a chastity value below a defined cut-off in the first 25 cycles. The chastity filter is the ratio 
of the brightest base intensity detected, divided by the sum of the brightest and the second 
brightest intensities (Illumina, 2015). 
• % Phasing is the average rate, in percentage per cycle, at which nucleotides in clusters are 
not incorporated and thus fall behind, and will continue to lag behind.  
• % Pre-phasing is when more than one nucleotide is incorporated in clusters per cycle, 
resulting in a sequence leading ahead. The phasing/prephasing are reported as a percentage 
per cycle (Ledergerber & Dessimoz, 2011). 
• Reads is simply the number of nucleotide reads detected in the sequencing reaction, and is 
reported in millions (M). 
• A Q score is based in the Phred scale, and indicates the probability that a nucleotide is 
called wrong by the sequencer. A Q30 score is subsequently a 1 in 1000 (0.1%) probability 
of a base being called incorrectly. A % >= Q30 value indicates the percentage of bases that 
with a quality in which the probability of a wrong base being called is less than 0.1%. 
• Yield is the amount of data that the sequencing reaction generated in GB. 
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2.4 Data Analysis 
A bioinformatics analysis pipeline was designed to effectively process raw sequence reads 
generated by the Illumina Miseq instrument for each participant sample, as seen in Figure 2.4.  
 
 
 
 
 
 
 
Figure 2.4: Bioinformatics pipeline utilised for processing raw HIV-1 pol sequence data to usable 
antiretroviral drug resistance mutation prevalence and construction of phylogenetic trees for 
phylogenetic analysis. 
 
Raw sequences containing the unique combinations of indexes for each sample were 
demultiplexed to respective participant sequences, utilising the Miseq Reporter software (version 
2.5.1.2) on the Illumina MiSeq instrument. This resulted in two .fastq files per sample, one for the 
forward read and the other for the reverse read. The .fastq files were saved and used as input 
sequences in downstream analyses.  
The .fastq files were submitted to Exatype (version 1.11.6, https://www.exatype.com, Hyrax 
Biosciences, South Africa) to identify DRMs as well as the proportions of each DRM that was 
present in each participant sample sequenced. The Exatype software aligns reads contained in each 
.fastq file to a reference HIV-1 genome (HXB2), and identifies differences relative to the reference 
genome. A coverage requirement is specified in Exatype. A minimum coverage of 330 is required 
to confidently identify mutations at 1% prevalence. At 330 times coverage a mutation may be 
identified as a true mutation, and not as a result of sequencing error. The coverage requirement is 
based on the properties of the sequencing chemistry, and the probability of incorrect base pair 
incorporation.  
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Exatype (version 1.11.6, https://www.exatype.com, Hyrax Biosciences, South Africa) was used to 
identify and annotate nucleotide mutations relative to the reference genome, and additionally 
scored to determine the functional chances the mutation would induce. Nucleotide changes in 
codons that would lead to amino acid changes, were reported and recorded. Amino acid changes 
of the sequenced samples were submitted to the Stanford Calibrated Population Resistance (CPR) 
tool and Stanford HIV-1 Drug Resistance (Stanford version 7.0) database 
(https://hivdb.stanford.edu/).  
The sequences were analysed for the presence of TDRMs, as well as persistence/reversion of those 
mutations and/or emergence of new ARV mutations over time, relative to longitudinal samples 
per participant. The “Drug resistance mutations for surveillance of transmitted HIV-1 drug-
resistance: 2009 update” paper by Bennett et al. (2009) was used for TDRMs and included the 34 
NRTI-resistance mutations at 15 RT positions, 19 NNRTI-resistance mutations at 10 RT positions, 
and 40 PI-resistance mutations at 18 protease positions.  
Mutations were identified at a 1% cut-off for the virus population that was sequenced. Prevalences 
were sorted by filtering text (.txt) files in which the prevalences were contained. MacOS (version 
10.10) terminal scripts were written and used to only keep mutations that were present at 
prevalences >1%. The filtered mutations obtained from NGS were thereafter additionally 
compared to those obtained from Sanger sequencing.  
Phylogenetic tree analysis was performed in order to confirm the genetic relatedness of each 
participant sample and to additionally confirm sample subtypes. A consensus sequence was 
obtained from each the NGS sequenced sample timepoint, for each participant in Exatype. A text 
file was created that contained a combination of the consensus sequences, the matched participant 
baseline Sanger sequences, subtype reference genomes (subtype A to K, 2016, 
https://www.hiv.lanl.gov) as well as 100 sequences randomly selected for subtypes A, B and C 
(https://www.hiv.lanl.gov) and was saved as a .fasta file. A multiple sequence alignment was 
performed using CLUSTAL X (software version 2.0; www.clustal.org), and were thereafter 
imported and visually inspected and manually edited utilising Aliview (software version 1.18; 
http://www.ormbunkar.se). The alignment file was imported into CLC Genomics Workbench 8 
(software version 8.5.1; QIAGEN, Germany) and a neighbour-joining tree, utilising the Kimura-
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80 parameter model with 1000 bootstrap replications, was constructed. The tree was exported as a 
Nexus file (.nxs) and viewed as a radial tree in FigTree (software version 1.4.2; tree.bio.ed.ac.uk). 
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CHAPTER 3: Results 
3.1 IAVI Protocol C Cohort Demographic and Clinical Data 
Demographic and clinical data of the 23 IAVI protocol C participants is shown in Table 3.1 and 
Table 1 in Appendix D. The participants were followed for an average of 26.4 months, ranging 
from 1.31 up to 65.72 months. The cohort was comprised of 17 males and 6 female participants, 
with a median age of 33 years. The majority of participants identified with TDRMs were from 
Uganda. 
Table 3.1: Demographic and clinical data of 23 participants from the IAVI Protocol C Cohort 
identified to harbour HIV-1 with TDRMs. 
Variable  
Number of participants 23 
Average age at cohort enrolment,  
(median) (min, max) (IQR) (years) 
34.78  
(33) (20, 53) (18.3) 
Average follow up period, 
(median) (min, max) (IQR) (months) 
26.4 
(22.1) (1.31, 65.72) (19.16) 
Male (%) 73.9 
Female (%) 26.1 
Average Baseline HIV-1 plasma RNA level, 
(median) (min, max) (IQR) (RNA copies/ml) 
1.11x106  
(1.48x105) (5.39x103, 9.58x106) (3.49x105) 
Average Baseline CD4 cell count, median 
(median) (min, max) (IQR) (cells/mm3) 
522.08  
(465) (189, 1079) (196,5) 
Site 
n = 7 (30.4%)   Uganda 
n = 6 (26.1%)   Kenya 
n = 5 (21.72%) Zambia 
n = 4 (17.4%)   Rwanda 
n = 1 (4.32%)   South Africa 
 
3.2 Viral RNA Extraction and RT-PCR Amplification 
Viral RNA was extracted, and the approximately 1.8 kb pol region of the samples was successfully 
RT-PCR amplified for 159 of the 160 longitudinal samples (Figure 3.1). Samples that did not 
successfully amplify in an initial extraction and amplification attempt, was re-extracted and RT-
PCR amplified. Despite several attempts, sample 57 from participant nine (baseline) failed to 
amplify. 
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Figure 3.1: RT-PCR amplification of the pol region (~1800 bp) from representative extracted 
HIV-1 viral RNA from the IAVI Protocol C cohort, electrophoresed on a 1% agarose gel 
under ultraviolet (UV) trans-illumination. Amplicon sizes were determined utilising the 
molecular weight marker (MWM, O’GeneRuler DNA Ladder Mix #SM1173, Thermo Fisher 
Scientific, Massachusetts, USA) basepairs (bp) depicted on the left lane. Participant number and 
visit dates are assigned to each respective lane. 
 
3.3 Illumina Miseq Nextera XT Library preparation 
All 159 samples that were successfully amplified were successfully sequenced on the Illumina 
Miseq platform. 
3.3.1 Amplicon Quantification 
Amplicons for all 159 samples were successfully quantified utilising the Qubit 2.0 and diluted to 
a final concentration of 0.2 ng/µl.  
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3.3.2 DNA Fragmentation and Size Selection 
Amplicons were fragmented, and adaptor sequences were added. The fragments were then subject 
to size selection. Fragment selection is one of the most crucial steps in library sample preparation 
for sequencing by synthesis next generation sequencing.  
Fragment Size Selection Results for Run One 
A double size selection was used to narrow the spectrum of fragments for run one. An average 
fragment size of ~250 bp was desired for the first run. At the time of the first library preparation, 
fragment analysis by means of the Agilent Bioanalyzer was not performed. However, the samples 
were retrospectively analysed. The graph shows the signal intensity in fluorescent units to the 
corresponding fragment size in base pairs. A representative sample was fragment analysed (sample 
five from participant one). The analysis of the sample demonstrated that the average library 
fragment size obtained from the specific double size selection bead ratios was of 280 bp. The graph 
is shown below in Figure 3.2.  
 
Figure 3.2: Electropherogram showing library fragment sizes for sample five from 
participant one. The electropherogram graphically illustrates the spread of fragments selected for 
by a double size selection using a 1x and 0.5x SPRI to DNA bead ratio, respectively. The ratios 
yielded a peak fragment size of 252 bp and an average library fragment size of 280 bp.   
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Fragment Size Selection Results for Runs two to four 
 Low quality metrics were obtained in run one. The fragment size selection was subsequently 
altered based on literature review. For runs two to four a single size selection was used. A 
representative sample (sample 47 from participant seven) was analysed. The result, shown below 
in Figure 3.3, demonstrated that the average library fragment size selected for by the single bead 
ratio selection was ~746 bp. 
 
Figure 3.3: Electropherogram showing library fragment sizes for sample 47 from participant 
seven.  The electropherogram graphically illustrates the spread of fragments selected for by a 
single size selection using a 0.5x SPRI to DNA ratio. The single selection yielded a peak fragment 
size of ~724 bp and an average library fragment size of 712 bp.   
 
 
Fragment sizes may be manipulated by using different SPRI bead rations. In run one a double size 
selection was used. The first selection step used a 1x bead to DNA ratio. This specific bead ratio 
would bind fragments ~200 bp and above. Unbound smaller fragments were eliminated by 
discarding the supernatant. A second size selection was then performed, to narrow the spectrum of 
fragments. A ratio of 0.5x SPRI beads to DNA was used. This ratio would bind fragments ~500 
bp and above. Smaller fragments less than ~500 bp would be left in the supernatant, and larger 
fragments would be bound to the beads. The larger fragments were eliminated, by keeping the 
supernatant and discarding the beads. The resulting spectrum of fragments had an average size 
distribution of 280 bp.  
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In runs 2 to 4, a single size selection was used. A single SPRI ratio of 0.5x beads to DNA was used 
to bind fragments ~500 bp and above to the beads. Smaller fragments, less than ~500 bp were 
discarded by eliminating the supernatant. A single size selection resulted in an average size 
distribution for the three library preps (runs 2 to 4) to be ~746 bp.  
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3.4 Illumina Miseq Next Generation Sequencing 
 A total of four Illumina Miseq sequencing reaction runs were performed utilising the Illumina 
Nextera XT V3 chemistry. With each run, library preparation was successively optimised to obtain 
ideal cluster densities. Miseq sequencing metrics for the four runs results are shown below in Table 
3.2. 
• K/mm2 = number of clusters per square millimetre (in thousands). 
• PF= The number of clusters passing filter for each tile (in millions).  
• Phas/Prephas percentage = The estimated percentage of molecules in a cluster for 
which sequencing falls behind (phasing) or jumps ahead (prephasing) the current cycle 
within a read. 
• Reads = Number of reads produced in the sequencing reaction (in millions). 
• Reads PF = Number of reads that passing filter (in millions). 
• % >= Q30 = The percentage of bases with a quality score of > 30.  
• Yield = Amount of data produced in sequencing reaction (in gigabytes). 
• Error Rate = The calculated error rate, as determined by the spiked in PhiX control 
sample. 
Table 3.2: Miseq sequencing metrics recorded for the sequencing runs one to four 
Run Read 
Cluster 
Density 
(K/mm2) 
Clusters 
PF (%) 
Phas/ 
Prephas 
(%) 
Reads 
(M) 
Reads PF 
(M) 
% >= 
Q30 
Yield 
(GB) 
Error 
Rate (%) 
1 
1 248 +/- 36 
98.01 +/- 
0.53 
0.171 / 
0.054 
6.22 6.09 64.57 
1.83 
4.73 +/- 
0.32 
2 248 +/- 36 
98.01 +/- 
0.53 
0.193 / 
0.026 
6.22 6.09 55.88 
7.29 +/- 
0.73 
2 
1 1408 +/- 37 
77.52 +/- 
5.20 
0.142 / 
0.042 
32.48 25.21 70.6 
7.56 
3.50 +/- 
0.42 
2 1408 +/- 37 
77.52 +/- 
5.20 
0.099 / 
0.005 
32.48 25.21 55.95 
6.10 +/- 
0.69 
3 
1 775 +/- 5 
90.69 +/- 
2.12 
0.147 / 
0.050 
19.19 17.4 91.45 
3.48 
1.16 +/- 
0.07 
2 775 +/- 5 
90.69 +/- 
2.12 
0.113 / 
0.030 
19.19 17.4 85.58 
1.30 +/- 
0.11 
4 
1 1107 +/- 25 
85.34 +/- 
2.29 
0.150 / 
0.062 
26.13 22.32 88.5 
4.46 
1.29 +/- 
0.10 
2 1107 +/- 25 
85.34 +/- 
2.29 
0.130 / 
0.060 
26.13 22.32 80.73 
1.81 +/- 
0.18 
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Overall, each run successively resulted in improved metrics each time, as library preparation was 
optimised and refined. Additionally, final dilutions were adjusted to yield ideal cluster densities. 
3.5 Exatype Results 
The Exatype software produced two diagrams per run, which served as a metric to illustrate the 
overall quality of the run.  Figure 3.4 shows sequencing reads obtained per sequencing run per 
sample. Figure 3.5 shows the average coverage of the pol gene obtained from all the samples 
sequenced per run. 
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Figure 3.4 illustrates the number of sequencing reads that were generated for each sample, for runs 1 to 4.  
A B 
C D 
 
 
Figure 3.4: Miseq sequencing reads generated in runs 1 to 4, for samples 1 to 159. The four graphs illustrate the number of 
forward and reverse sequencing reads, as well as unaligned and low-quality sequencing reads generated for each sample, per run. 
Run one to four are shown in graphs A to D, respectively.  
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The variance observed in the peaks, and thus number of reads per sample can be attributed to 
unequal amounts of sample that are added to each sequencing reaction. The library normalisation 
step, in which all samples are diluted to 2 nM and pooled, aims to normalise the amount of sample 
added per reaction such that each sample is sequenced equally; thus, theoretically that each sample 
produces the same amount of reads per reaction. The library normalisation step was optimised and 
subsequently the peak variance range decreased with each consecutive run. Figure 3.4 D illustrates 
an acceptable read variance range; however, optimisation may yet be required in the library 
normalisation step to further decrease the range. 
Overall, the quality of each successive run increased as the protocol was optimised, and the 
technique better understood. Figure 3.4 A illustrates a large number of non-aligned and poor-
quality reads per sample, indicating that the quality of the library sequenced was poor. The average 
number of paired forward and reverse reads for run one was approximately 100 000 reads per 
sample. This value increased to an average of approximately 500 000 reads per sample for run 
two, however a very large number of unpaired and poor reads were obtained in the second 
sequencing run. In run three a decrease in unaligned and poor-quality reads was observed, yet the 
average reads per sample was approximately 200 000 reads. In run four, poor and unaligned reads 
were near to the number of paired read obtained for each sample, with an approximate average of 
400 000 reads per sample. 
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Figure 3.5. was produced by the Exatype software (Hyrax Biosciences, South Africa), and is a 
graphic representation of the read coverage of the pol gene (or vertical depth; i.e. how many times 
a section of pol was sequenced) for all samples sequenced per sequencing. A minimum coverage 
of 330 (shown as a purple line in Figure 3.5) was required to identify DRMs at 1 % of the 
sequenced viral population. 
 
Figure 3.5: The average number of read coverage for the region of pol that contains prot and 
RT, for all samples (1 to 159) sequenced in the 4 sequencing runs. Coverage in number of reads, 
per run, relative to the codon position of pol obtained for all samples is shown. The reads that fall 
within the prot and RT codons are coloured in red and blue, respectively. A purple line indicates 
the minimum number of reads (330) required to identify mutations at 1% of the sequenced viral 
population. 
 
 
Overall, the read coverage obtained for all runs were more than sufficient to identify TDRM 
mutations present at equal to or greater than 1% prevalence of the sequenced viral quasispecies. 
The Exatype software had a coverage requirement of 330 reads to identify mutations < 1%.  
  
  
69 
3.6 Phylogenetic Analysis 
Phylogenetic analysis was performed in order to ensure genetic relatedness of each sample, and 
additionally to confirm the subtype of the samples. Baseline Sanger sequences and all IAVI 
baseline and follow-up consensus sequences for all 23 participants were used to draw a 
phylogenetic tree.  Each consensus sequence is generated by selecting the most common 
nucleotide observed in mapped reads at each position in the reference, including insertions 
occurring in >50% of reads. Additional subtype reference sequences and randomly selected HIV-
1 sequences from the Los Alamos HIV sequences database were used to draw the tree shown in 
Figure 3.6. 
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Figure 3.6: Neighbour-joining tree (Kimura-80 model with 1000 bootstrap) of all 23 participants. 
Participant samples are shown in blue, Subtype A-K reference genomes are shown in red, and background 
noise HIV-1 samples are shown in black. Sub-type branches, with each participant’s cluster are annotated 
on the tree. 
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3.7 Antiretroviral Drug Resistance Mutation Results 
All 159 successfully amplified samples were sequenced on the Illumina Miseq platform. The 
Exatype software produced resistance calls of mutations as per the Stanford University HIV-1 drug 
resistance database that were present at >1% of the sequenced viral quasispecies per sample. All 
mutations detected in all 23 participant’s longitudinal samples are shown in Table 2 in Appendix 
D. 
3.7.1 Conformation of Sanger Data by NGS, and Persistence and Reversion of TDRMs identified 
at baseline 
Table 3.3 below contains mutations that were detected at baseline using conventional population-
based Sanger sequencing by Price et al. 2011, and mutations identified using NGS in this study. 
Samples in this study verified the mutations that were detected by Sanger and detected additional 
minority variants that were missed by Sanger sequencing. The end point sample for each 
participant’s longitudinal sample set is shown below the baseline samples for NGS, indicating 
which mutations persisted, and which additional mutations were present at end point of the follow 
up period.  As Sanger was only performed on the initial baseline sample in which TDRMs were 
identified, there is no Sanger data for the end-point samples.  
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Table 3.3: Persistence or reversion of HIV-1 transmitted drug resistance mutations in 23 participants from the IAVI Protocol C Cohort, 
showing clinical parameters, subtype, ARV drug resistance mutations (% of amplified sequenced virus) detected by NGS, and mutations 
detected by Sanger Sequencing. 
Pct 
No 
Visit 
Days 
Viral Load 
(RNA 
copies/ml) 
CD4 
Count 
(cells/mm3) 
Sub-
Type 
Sanger 
Baseline 
Mutations 
NGS 
RT DRMs (% Prevalence) 
PR DRMs 
RT DRMs 
PR 
DRMs 
(% Prevalence) 
1 
B: 0 83400 456 
A1 
K103N L100I K103N (99.83)  
L: 152 195000 320  K103N (99.01)  
2 
B: 0 148000 496 
A1 
- M46L - M46L (99.89) 
L: 313 26500 254  - M46L (99.95) 
3 
B: 0 169000 589 
A1 
K103N, 
Y181CY 
L10I 
K103N (10.84), Y181C (71.88), 
Y188C (1.45), G190A (4.47) 
L10I (99.75) 
L: 152 350000 250  
K103N (4.46), T69N (7.11), 
Y181C (60.43), G190A (4.74), 
H221Y (5.33) 
L10I (99.89) 
4 
B: 0 66600 899 
C 
K103N - 
K103N (40.90), K103T (1.30), 
V106A (1.82), V106M (1.19), 
V108I (2.96), Y181C (5.80), 
Y188C (9.38), N348I (1.74) 
- 
L: 39 61100 698  K103N (95.91), Y188C (1.58) - 
Pct = Participant; B = Baseline sample; L = Last follow up sample; RT = Reverse transcriptase; PR = Protease; DRM = Drug resistance mutation; 
NO AMP = No amplification; - = No DRMs observed; Greyed out block = Sample was not sequenced by Sanger sequencing  
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5 
B: 0 525000 459 
D 
- I85V - I85V (98.87) 
L: 1673 90377 178   I85V (61.55) 
6 
B: 0 148069 490 
A1 
K103N L10V K103N (99.15) L10V (99.89) 
L: 313 25665 365  K103N (73.59), G190A (28.85) L10V (83.35) 
7 
B: 0 16000 975 
A1 
D67N - NO AMP NO AMP 
L: 1470 6100 653  - - 
8 
B: 0 165000 620 
A1 
K103N L10V K103N (98.96) L10V (99.67) 
L: 665 28373 465  K103N (99.27), Y188H (1.92) L10V (99.66) 
9 
B: 0 3E+06 386 
A1 
K103N L10V K103N (98.92) L10V (99.64) 
L: 671 3945 400  K103N (99.54), M184I (2.31) L10V (99.85) 
10 
B: 0 9E+06 327 
A1 
Y188C - Y188C (99.68) - 
L: 586 8445 602  Y188C (39.42) V82A (6.75) 
11 
B: 0 146000 913 
A1 
K103N, 
E138A 
- K103N (98.79), E138A (99.54) - 
L: 792 52904 758  K103N (97.99), E138A (99.75) - 
12 
B: 0 141000 303 
A1 
K103N - K103N (98.17) - 
L: 749 227879 307  K103N (97.56) - 
13 
B: 0 5390 464 
C 
- T74S - T74S (99.7) 
L: 1255 38300 204  K65R (1.35) T74S (99.61) 
14 
B: 0 392000 521 
C 
K103N T74S K103N (99.03) T74S (99.81) 
L: 1140 104773 353  K103N (98.18) T74S (99.69) 
Pct = Participant; B = Baseline sample; L = Last follow up sample; RT = Reverse transcriptase; PR = Protease; DRM = Drug resistance mutation; 
NO AMP = No amplification; - = No DRMs observed; Greyed out block = Sample was not sequenced by Sanger sequencing 
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15 
B: 0 452000 465 
C 
K103N, 
V108IV, 
M184V 
- 
K65R (1.03), K103N (98.55), 
V108I (65.64), M184V (99.17) 
- 
L: 509 30799 499  
K103N (73.81), K103S (23.84), 
G190A (1.60), K219R (1.43) 
- 
16 
B: 0 166374 189 
C 
K103N T74S K65R (1.18), K103N (98.71) T74S (99.67) 
L: 480 56569 199  K65R (1.38), K103N (98.92) T74S (99.75) 
17 
B: 0 73200 311 
A1 
K103N - K103N (99.24) - 
L: 1998 11107 308  K103N (96.52), K103S (2.78) - 
18 
B: 0 690000 1079 
A1D 
- I85V V118I (99.50) I85V (99.14) 
L: 106 134000 736  V118I (99.78) I85V (96.57) 
19 
B: 0 61000 366 
A1 
L210W - L210W (13.84) V82A (1.25) 
L: 295 12600 235  L210W (92.62) - 
20 
B: 0 333000 362 
D 
K103N - K103N (99.29) - 
L: 454 26300 384  
K70T (37.09), K103N (99.38), 
F227L (1.89) 
- 
21 
B: 0 32500 532 
D 
- M46L K219R (4.60) 
M46L (87.94), 
I47V (4.95) 
L: 512 152000 236    
22 
B: 0 121000 495 
C 
K103N - K103N (93.74), V106M (4.42)  
L: 748 40300 665  
K103N (34.36), K103S (19.55), 
V106M (33.59) 
- 
23 
B: 0 73800 621 
C 
M41L - M41L (99.67), K103R (99.46) - 
L: 828 1017 447  M41L (99.49), K103R (99.44) - 
 
Pct = Participant; B = Baseline sample; L = Last follow up sample; RT = Reverse transcriptase; PR = Protease; DRM = Drug resistance 
mutation; NO AMP = No amplification; - = No DRMs observed; Greyed out block = Sample was not sequenced by Sanger sequencing 
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The NNRTI K103N was the most prevalent mutation overall, with 60.9% (14 of 23) of participants 
presenting the mutation. Other NNRTI mutations detected were Y181C (n=1), Y188C (n=1), 
E138A (n=1), V108I (n=2). NRTIs that were detected are D67N (n=1), M184V (n=1) and L210W 
(n=1). The most prevalent PIs were T74S (n=3) and L10V (n=3); other PIs detected were M46L 
(n=2), L10I (n=1), L10V (n=3) and I85V (n=2). Additional minority quasispecies/variants were 
detected by NGS that were not detected by Sanger population sequencing. The mutations Y188C 
(n=2), K65R (n=2), G190A (n=1) and V118I (n=1) were detected at prevalences below 10% in 
baseline samples. 
 
3.7.2 Longitudinal Persistence and Reversion Analysis of TDRMs 
Figures 3.7.1, 3.7.2 and 3.8 below shows TDRM outcomes throughout the longitudinal follow-up 
period for the 23 participants. The figures are separated into participants in which full reversion 
was observed, in which a combination of persistence and reversion of TDRMs were observed, and 
in which full persistence of TDRMs identified at baseline are observed. 
Reversion of TDRMs was observed in 17% of participants (4 out of 23) (participant three, seven, 
15 and 21). A mutation is said to be reverted when the mutation was below the study cut-off of 1% 
of the sequenced viral population. Viral quasispecies from participants 7 and 21 (Figure 3.7.1) 
showed complete reversion of D67N and M46L over time, respectively. A combination TDRM 
persistence and reversion was observed in participant three and 15 (Figure 3.7.2). Participant three 
harboured HIV-1 quasispecies which showed the persistence of K103N, Y181C, G190A and L10I, 
and the reversion of Y188C. Participant 15 similarly harboured quasispecies which showed 
persistence of K103N, and reversion of V108I and M184V.  Figures 3.7.1 and 3.7.2 below 
graphically illustrate the viral load of participants relative to time in which TDRM reversion, and 
reversion and persistence respectively, was observed. 
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Figure 3.7.1: Viral load against follow up period in days for participants in which complete 
reversion was observed. Participant seven and 21 are shown in blue (A) and red (B) respectively. 
A TDRM is written in red where it was detected below 1%. Reversion of TDRMs for both 
participant seven and 21 occurred within 300 days after the baseline sample.  
A 
B 
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Figure 3.7.1 A, illiterates the longitudinal follow-up of the single TDRM D67N identified in 
participant seven, and shows the rapid reversion of the mutation.  The baseline sample in the 
longitudinal set of samples failed to amplify, and thus as the mutation was detected by means of 
population-based Sanger sequencing by Price et al. 2011, the prevalence was assumed to be >20% 
of the sequenced viral population.  In the remaining seven samples for participant seven, no DRMs 
were identified at a prevalence greater than 1% of the sequenced viral population. It was thus 
concluded that the D67N mutation reverted in participant 7. 
Figure 3.7.1 B, illustrates the persistence/reversion outcome of the TDRM M46L across the five 
samples that make up the longitudinal sample set for participant 21. A gradual decline in 
prevalence of M46L is observed in the first 3 longitudinal samples, after which the M46L mutation 
was no longer detectable above 1% of the sequenced viral population for the remaining samples. 
It was concluded that M46L reverted in participant 21. 
.
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Figure 3.7.2: Viral load against follow up period in days for participants in which both 
persistence and reversion of TDRMs was observed.  Participant 15 (A) and participant three 
(B) are shown in red and blue, respectively. TDRMs are written in red where detected below 1%. 
 
B 
A 
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Figure 3.7.2 A and B both illustrate a combination of persistence and reversion of TDRMs 
identified in participants three and 15. A ranger of mutations was detected for both participants. In 
participant 15, illustrated in Figure 3.7.2 A, V108I and M184V both were below 1% of the 
sequenced viral population by end-point follow up, whereas K103N remained a major mutation. 
The prevalence of V108I remained >50% of the sequenced viral population for the three 
longitudinal samples, and increased to >80% in the fourth. However, in the fifth a rapid decline 
was observed as the prevalence dropped to 4.04%. Soon after, in the sixth and the final seventh 
sample, the V108I mutation was no longer present at > 1% of the sequenced viral population and 
was thus noted as have reverted. The M184V mutation had a similar rapid decline. For the first 
four follow-up samples, the prevalence was well above 97% of the sequenced viral population. In 
the fifth follow-up sample, a rapid decline to 15.70% was observed. The mutation soon reverted 
as in the sixth sample the mutation prevalence further declined to 1.15% and was ultimately no 
longer detected > 1% of the sequenced viral population in the final seventh sample.    
Figure 3.7.2 B illustrates the reversion of the TDRM Y188C, and persistence of K103N, Y181C, 
G190A, and the polymorphic L10I. Y188C was identified in participant three as a minor variant, 
at only 1.45% of the sequenced viral population. The mutation was not identified by Price el al., 
2011, which used Sanger sequencing. The mutation prevalence increased to 3.38%, as a viral load 
spike occurred in the second follow-up sample, but thereafter declined and was no longer present 
> 1% of the sequenced viral population for all subsequent follow-up samples (sample three, four 
and five). Y188C was thus reported as reverted. 
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Persistence of TDRMs, with no reversion observed was seen in 78% of participants (19 of 23 
participants). Figure 3.8 (A and B) shown below, illustrates the changes in viral load of 
participants which showed persistence of TDRM, relative to time. The participants were separated 
based on follow up time. Participants followed for less than 800 days are shown in A, and a follow 
up period of more than 800 days is shown in B. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8: Viral load changes during the follow up period (in days) for participants in which 
no TDRM reversion was observed. The various participants are each shown in a different colour, 
and participants followed for less than 800 days are shown in A, and more than 800 days are shown 
in B.  
A 
B 
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Figures 3.8A and B illustrate the viral loads over time for participants in which persistence of all 
detected TDRMs are observed. Viral loads for the majority of participants appear to stabilise below 
2x105 viral copies/ml to the latter end of the longitudinal follow-ups. Despite the end-point viral 
loads, no consistent trend among the various samples presents itself, other than the progression 
from acute HIV-1 infection to the early stages clinical latency. None of the participants in this 
study initiated ART during the longitudinal follow-up. 
 
Table 3.4 below summarizes the TDRMs that were detected by Sanger and confirmed by NGS, 
and their persistence or reversion outcomes at the end of the follow-up period. TDRMs that were 
not detected by Price et al. 2011, but detected in participants in this study are noted, as well as 
persistence or reversion outcomes.  
Table 3.4: Summary table of TDRMs detected by Sanger and confirmed by NGS, and minority 
TDRMs detected by NGS only with observed outcomes 
Participant 
Mutations 
detected by 
Sanger and 
confirmed by 
NGS 
TDRM 
Observed 
Outcome 
Mutations 
detected only 
by NGS  
TDRM 
Observed 
Outcome (as minority 
variant) 
1 K103N Persists     
2 M46L Persists     
3 
K103N Persists Y188C Reverts 
L10I Persists 
G190A Persists 
Y181C Persists 
4 K103N Persists 
Y188C Persists 
V108I Reverts 
5 I85V Persists     
6 
K103N Persists 
    
L10V Persists 
7 D67N Reverts     
8 
K103N Persists 
    
L10V Persists 
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9 
K103N Persists 
    
L10V Persists 
10 Y188C Persists     
11 
K103N Persists 
    
E138A Persists 
12 K103N Persists     
13 
T74S Persists 
    
K65R Persists 
14 
K103N Persists 
    
T74S Persists 
15 
K103N Persists 
    
K65R Persists 
V108I Reverts 
M184V Reverts 
16 
K103N Persists 
K65R Persists 
T74S Persists 
17 
K103N Persists 
    
K103S Persists 
18 I85V Persists V118I Persists 
19 L210W Persists     
20 K103N Persists     
21 M46L Reverts     
22 
K103N Persists 
    
V106M Persists 
23 M41L Persists     
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CHAPTER 4: Discussion and Conclusion 
4.1 Discussion  
The use of ARV drugs has significantly reduced HIV-1 associated morbidity and mortality (Palella 
Jr et al., 1998). Global rollout of ART has allowed 17 million HIV-1 infected individuals to access 
lifesaving therapy (UNAIDS, 2016a). Unfortunately, an inevitable consequence of ART is the 
emergence of drug resistant HIV-1, ultimately resulting in ineffective treatment resulting in 
treatment failure (Deeks, Smith, Holodniy, & Kahn, 1997; McDonald & Kuritzkes, 1997). Drug 
pressure, sub-optimal treatment regimens and drug non-adherence, in combination with HIV-1’s 
high replication rate, results in the unavoidable selection of drug resistance mutations (Reviewed 
by Clavel & Hance, 2004). It is well acknowledged that ADR may be transmitted to a new host 
via sexual transmission (Conlon, Klenerman, Edwards, Larder, & Phillips, 1994; Imrie, Beveridge, 
Genn, Vizzard, & Cooper, 1997).  
In resource-rich geographical locations in which virological monitoring techniques, such as viral 
resistance genotyping, are readily performed, the transmission of viruses containing one or more 
drug resistance mutation ranges from 10 to 15% (Steinhauer et al., 1992; Walker et al., 1986). It 
is, however, important to note that ART has been available and more accessible in resource rich 
locations for a considerable period of time longer than lesser resource locations. In contrast to this, 
resource-limited geographical locations, such as Sub-Saharan Africa, see an estimated 5 to 10% 
prevalence transmission of drug resistant HIV-1 (Hamers et al., 2011; A. A. Johnson et al., 2004). 
Since the ART rollout in these resource-limited locations are generally not well monitored with 
virological genotyping, TDR HIV-1 is likely to increase, with significant clinical and public health 
consequences. Globally, there is a paucity of data on viral diversity and evolution of TDR HIV-1. 
This study describes the evolutionary mechanisms of ARV drug resistant HIV-1, after transmission 
to a new host, to provide insight into persistence and/or rates of reversion of the TDRMs to wild 
type over time. A total of 159 longitudinal samples from 23 participants from the IAVI protocol C 
cohort were studied. 
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4.1 Data Quality  
The data obtained in all four of the NGS sequencing reactions were of satisfactory quality to 
identify mutations >1% of the sequenced viral population. The average coverage obtained across 
the 1.8 kb region of pol far surpassed the minimum required coverage. All metrics, post data 
quality control, were sufficient to proceed to downstream analysis.  
The number of samples across the four sequencing reactions ranged from 38 to 45 sample per run. 
Based on the high coverage obtained from sequencing this number of samples, the sequencing 
reaction may be optimised to include a much higher number of samples that the minimum 
amplicon coverage to detect minority variants is still obtained.  On the Illumina Miseq platform, 
using dual index libraries, 384 uniquely indexed samples may be sequenced together in one 
reaction (Illumina, 2016a). Increasing the number of samples per sequencing reaction will 
significantly reduce the price per sample. As NGS is cost prohibiting, a lower per-sample 
sequencing cost could allow clinical diagnostic laboratories to provide an NGS HIV-1 
TDRM/DRM testing facility, especially in resource-limited developing countries. 
4.2 Sanger Sequencing and NGS 
Conventional Sanger sequencing has the capacity to identify HIV-1 mutations that are present at 
> 20% of the sequenced viral population (Palmer et al., 2005). Palmer et al. (2005) used single-
genome sequencing analysis (based on limiting-dilution assays) of viruses obtained from 26 
patients with prior drug exposure to at least two ARV drug classes, and were failing treatment. 
Standard population-based Sanger sequencing was initially performed, and drug resistance 
mutations were identified. In a later experiment, the extracted viral RNA obtained from the 
infected patients was reverse transcribed, and a single copy of cDNA per positive PCR was diluted 
and obtained by using a real-time PCR method. Fifteen to 23 single sequences were obtained per 
patient. The single sequences were then amplified, and Sanger sequenced. The results to this study 
revealed that HIV-1 mutations present at <10% of the viral population were never identified by 
Sanger in the initial population-based sequencing method. Moreover, mutations present between 
10% and 35% were only identified 25% of the time by Sanger sequencing (Palmer et al., 2005).  
The inability of Sanger sequencing to identify low prevalence mutations presents a problem with 
significant clinical implications; the inability to detect HIV-1 minority variants (<20% of the 
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sequenced viral population). This emphasises the importance of the findings showing that NGS, 
on the other hand, has the capacity to identify mutations well below 1%; depending on the coverage 
obtained in the sequencing run (Li & Kuritzkes, 2013; Zagordi, Klein, Däumer, & Beerenwinkel, 
2010). In the context of TDRMs, the capability to identify and study mutations at extremely low 
prevalence allows one to better understand two important factors. First, whether a mutation has 
truly reverted or persists at a low prevalence, and second, the clinical and treatment outcome 
implications a low prevalence mutation might have. 
The current limitation with the Illumina Miseq sequencing by synthesis chemistry used in this 
study, is the short 300 bp read length. In the context of HIV-1, longer read lengths are preferred as 
it allows for the identification of DRMs that occur together in a unique viral sequence (i.e. 
combination mutations). Combination mutations have been shown to have an impact on the 
resistance profile of a viral strain (Liang, Mesplède, Oliveira, Anstett, & Wainberg, 2015; Tisdale, 
Alnadaf, & Cousens, 1997; Wensing et al., 2015). Currently, it is possible to identify mutations 
that occur together, but only when limited to the shorter 300 bp read. In the context of HIV-1 drug 
resistance, a limited number of mutations occur within 300 bp of one another. It would thus not be 
possible to elucidate all mutations that occur in a single viral genome by using the sequencing by 
synthesis chemistry. Other chemistries, such as the Pacific Biosciences single molecule real time 
sequencing, produces average reads > 10,000 bp, and has the capacity to produce reads > 60,000 
bp. Using this method, the entire HIV-1 genome, which is approximately 9.2kb, could be 
sequenced, and all mutations occurring in the same genome in an individual unique strain could 
be identified. This would allow for the study of individual strains, and to better understand which 
combination of mutations lead to a survival advantage when transmitted to a drug naïve host. 
4.3 Phylogenetic Analysis 
Phylogenetic analysis served as a method to determine whether any sample contamination had 
occurred, and whether all participant longitudinal samples were genetically related. Each 
participant’s samples clustered together significantly, indicating that all samples were indeed from 
the same participant, and that no significant sequence alteration was induced by PCR bias (please 
see Figure 3.8).  
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The phylogenetic analysis proved valuable in the context of participant seven. As discussed in 4.5, 
the baseline sample failed to amplify and could not be sequenced by NGS. The D67N mutation, 
that was detected by Sanger, could not be verified by NGS in the baseline sample, and was not 
detected in any subsequent longitudinal samples. Phylogenetic analysis, however, confirmed that 
the Sanger sequence, and all other consensus NGS sequenced, clustered significantly.  
The phylogenetic analysis furthermore confirmed the HIV-1 subtypes that had previously been 
identified for each participant (Price et al., 2011).  
4.4 PCR Bias 
The PCR amplification of HIV-1 may result in the artificial inflation of mutations and the 
unwanted introduction of artefacts and errors (Hughes & Totten, 2003; Mansky & Temin, 1995; 
Perelson, Neumann, Markowitz, Leonard, & Ho, 1996). First, sequence diversity might be 
introduced by the misincorporation of nucleotides by the DNA polymerase. Second, PCR mediated 
recombination of HIV-1 viral strains may occur during the PCR amplification steps (Meyerhans, 
Vartanian, & Wain-Hobson, 1990; Yang, Wang, Dorman, & Kaplan, 1996). Third, as a large 
amount of DNA amplicons are generated from a small number of starting templates, the true 
original sampling of the populations may be obstructed. The starting templates may get resampled, 
which may lead to sequencing resampling, as opposed to the true observation of independent viral 
strains (Jabara, Jones, Roach, Anderson, & Swanstrom, 2011).  
Errors introduced by PCR bias and PCR resampling are intrinsically extremely difficult to detect 
in the final sequenced product, as there is no way distinguish between what the true viral sequenced 
and the PCR error introduced sequence is.  This is of importance when the mutations have drug 
resistance implications, and certain viral strains are resampled and amplified more than others. A 
skewed and incorrect representation of the true viral population may be obtained.  
Work performed by Dudley et al. (2012) investigated the errors introduced by PCR amplification. 
The study PCR amplified, prepared and sequenced an HXB2 HIV-1 plasmid and HIV-1 clonal 
viral stock, that was not expected to have any mutations relative to the HXB2 reference genome, 
together with patient samples. The group reported no false drug resistance mutation above a 
frequency of 0.71%. Similar work done by Zagordi et al. (2010) found that in PCR amplified HIV-
1 samples, the substitution error rate was approximately 0.25% across a 1.5 kb region of the 
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gag/pol genes, as opposed to 0.05% in non-PCR amplified samples. However, complete PCR 
resampling was observed at a lower percentage. In the case of significant resampling, one strain 
was severely inflated by PCR, which resulted in a skewed and incorrect population representation.  
A limitation of this study was the fact that PCR bias and PCR resampling was not eliminated. 
Despite this, the fact that consistent prevalences were observed in several participant samples over 
time, where the samples had been extracted and RT-PCR amplified at different time points, implies 
that PCR bias/resampling was not a major issue.   
Future research could focus on repeating the RT-PCR amplification using unique molecular 
identifier (UMI) tagging/molecular barcoding (Casbon, Osborne, Brenner, & Lichtenstein, 2011; 
Kinde, Wu, Papadopoulos, Kinzler, & Vogelstein, 2011; Van Laethem, Theys, & Vandamme, 
2015). In the library preparation steps of NGS, each original DNA fragment in a sample is tagged 
with a unique string of unique nucleotides. In the resulting sequencing product, one would have 
the capacity to statistically identify the PCR induced artefacts and errors. The PCR bias affected 
sequencing products may then be bioinformatically discarded. 
4.5 Drug Resistance Mutation Results 
This study utilised next generation sequencing techniques, with unparalleled coverage and 
capacity, and allowed TDRMs to be identified and tracked in longitudinal samples at > 1% 
prevalence of the sequenced viral population. Overall, only six of the 43 (14%) total TDRMs 
identified in the 23 participants reverted and were undetectable at levels <1% at the last time point 
tested. Complete reversion of all detected TDRMs was observed in only two participants (8.7%). 
TDRM persistence of all detected mutations was observed in 19 of 23 (82%) participants. A 
combination of persistence and reversion of TDRMs were observed in two participants (8.7%).  
The rates at which TDRMs revert, and thus become undetectable, are dependent on multiple 
factors. These include the number of required back mutations, the fitness of the mutated virus 
relative to the wild type, the rate at which the mutated virus replicated and thus viral turnover, and 
the presence of possible compensatory mutations (De Ronde et al., 2001; Goudsmit, De Ronde, 
Ho, & Perelson, 1996; Yerly et al., 1998). Due to HIV-1’s high error rate, fitter viral progeny will 
inevitably arise due to random back mutation. A virus with specific mutations, or with lack of 
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mutations but with slightly higher replicative capacity, will compete with the mutated virus and 
ultimately outcompete it.  
4.5.1 NNRTIs 
NNRTI mutations identified in this study were K103N (n=14), G190A (n=1), Y181C (n=1), 
Y188C (n=1), E138A (n=1) and V108I (n=2). Of the 20 total NNRTI mutations identified, 17 
(85%) persisted until end-point follow-up. NNRTI drugs that select for the above mutations are 
EFV (Bacheler et al., 2000; Reuman, Rhee, Holmes, & Shafer, 2010; Winslow et al., 1996), NVP 
(Gulick et al., 2004; Richman et al., 1991), RVP (Azijn et al., 2010; Rimsky et al., 2012) and ETR 
(Vingerhoets et al., 2005). Non-adherence to these drugs may lead to selection of a combination 
of the above-mentioned mutations, and transmission to a new host. A study by Nanfack et al. 
(2017) investigated the longitudinal persistence of TDRMs in 66 drug-naïve individuals by three 
different resistance testing methods. The group used Sanger sequencing, and thereafter compared 
results using an amplification-refractory mutation system (ARMS) PCR which was then sequenced 
with NGS. Results showed that NNRTIs were found to persist for over 3 years in the absence of 
drug pressure (Nanfack et al., 2017).   
The NNRTIs K103N, G190A, Y181C, and Y188C were detected at baseline in participant three 
of this study. NVP selects for the exact combination of mutations identified in this participant. The 
Y181C mutation was detected at a 71.89% of the sequenced viral population, the K103N mutation 
at 10.85% prevalence, and the Y188C and G190A mutations were detected at 1.45% and 4.47%, 
respectively.  
A study by Conway et al. (2001) identified this same mutation profile in patients who had received 
NVP, as monotherapy, or in combination with another NRTIs (AZT or DDI). Resistance mutations 
were studied by a phenotypic resistance assay, in which extracted viral genetic regions of interests 
were cloned into a pGEMT3ΔPRT plasmid and transfected into MT4 cells. The HIV-1 expressed 
by the cell culture was studied for drug susceptibility. The NVP resistant clones were subsequently 
Sanger sequenced and NVP resistance mutations identified. In one particular participant, the same 
combination of K103N, G190A, Y181C, and Y188C was identified (Conway et al., 2001). 
Due to limitations in the Sanger sequencing technology, mutations that were identified by Conway 
et al. (2001) were present at a prevalence of >20% of the sequenced viral population. The mutation 
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prevalences identified in participant three in this study ranged from 1.45% to 71.89%. Comparing 
this study’s findings with that of Conway et al. (2001) presents participant three as an interesting 
case.  
A possible explanation for the resistance mutation profile observed in participant three is as 
followed: This male participant may have been infected with the drug resistant virus by a female 
who had previously received single dose nevirapine (sdNVP) in an attempt to prevent mother-to-
child HIV-1 transmission. The sdNVP would have selected for the resistance profile observed, and 
thus transmitted to, participant three. This is a plausible explanation given that at the time of this 
study, sdNVP was readily available for use in Kigali, Rwanda (Delvaux et al., 2009).  
The transmitting individual may have also had transmitted drug resistance, and may have been 
infected with a founder virus which carried Y181C. The rate of TDRM transmission was noted to 
be 8% for the IAVI protocol C samples used in this study (Price et al., 2011); a rate very similar 
to the 7.7% rate of TDRM transmission found before 2011, as found in a review of literature done 
by Stadeli et al. (2013) (Stadeli & Richman, 2013). This data may confer some plausibility to this 
first explanation.  
If the transmitting individual did undergo sdNVP treatment, Y181C would have led to treatment 
failure (Richman et al., 1991), and furthermore selected for the additional NVP resistance 
mutations (K103N, G190A, and Y188C) (Conway et al., 2001). The initial viral reservoirs that 
were established at infection for the transmitting initial would carry the Y181C mutation, and thus 
would have supplemented the Y181C population. Upon transmission to a new host, Y181C would 
be observed as the dominant transmitted mutation, and the other NVP resistance mutations would 
be observed as minority mutations, as seen in participant three. 
The low viral fitness costs of K103N (Collins et al., 2004; Palmer et al., 2006) and Y181C (Cong, 
Heneine, & García-Lerma, 2007; Martinson et al., 2007) (Dykes et al., 2001) may explain why 
these two mutations are identified at higher prevalences than the others. It may also explain how 
K103N proceeded to increase in prevalence to 38.06% and how Y181C decreased to 57.29% in 
12 days after the baseline sample. The viral load in the 12-day period also increased over six-fold. 
Data from the transmitting individual would, however, be required to make significant conclusions 
with regard to this hypothesis.  
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4.5.1.1 K103N 
The most prevalent mutation that was identified in the 23 participants from the IAVI protocol C 
was K103N (14/23; n= 61%), which persisted throughout study duration. The high prevalence of 
K103N, and persistence in the participants as a TDRM is consistent with findings by several other 
studies. Ferrerira et al. (2017) identified K103N at 77% of TDRMs, by population-based 
sequencing in a cohort of recently infected drug naïve patients. A study by Yebra et al. (2011) 
investigated an increase of transmitted drug resistance among HIV-1 infected individuals from 
Sub-Saharan Africa as a subpopulation in Spain, relative to the native Spanish population. The 
study, once again, identified K103N as the most frequent mutation (74% of identified TDRMs), 
using conventional population based Sanger sequencing (Yebra et al., 2011). Studies by Castro et 
al. (2013) and Little et al. (2008) both identified K103N as the predominant TDRM, at 73/313 
(23%) and 11/14 (79%), respectively (Castro et al., 2013; Little et al., 2008). These studies found 
K103N to persist for up to between 3.4 and 3.7 years after infection (Castro et al., 2013; Little et 
al., 2008). As NGS has the capacity to detect mutations at a significantly lower prevalence of the 
sequenced viral population, the prevalence of K103N may have been higher if NGS was used.  
K103N confers a relatively small fitness cost. Collins et al. (2004) created K103N clones by site 
directed mutagenesis; and generated and expressed several other mutant viruses (V106A, Y181C, 
Y188C, and G190A). Competitive assays were performed, and K103N was found to have a very 
small effect on the replicative capacity and viral fitness of the mutant virus (Derdeyn et al., 2004). 
A similar methodology was followed by Gerondelis et al. (1999) who also found that K103N has 
insignificant effects the viral fitness of the virus (Gerondelis et al., 1999). 
K103N confers high-level resistance to EFV and NVP (Bacheler et al., 2000; Gulick et al., 2004; 
Margot, Lu, Cheng, & Miller, 2006). If transmitted to a treatment naïve individual, and not 
detected as a minority variant or tested for, the mutation will rapidly lead to treatment failure when 
treated with EFV or NVP regimens (Bacheler et al., 2000; Parkin, Gupta, Chappey, & Petropoulos, 
2006). The mechanism of resistance for K103N involves the selective replacement of a lysine by 
an asparagine, that does not alter the overall complexed structure of the reverse transcriptase 
enzyme and the drug (NNRTIs) if bound. The asparagine, however, creates a hydrogen bond in 
the enzyme in the unbound drug state, which subsequently leads to the entrance of the drug binding 
pocket to be smaller. The smaller entry sterically hinders the NNRTIs from entering the pocket 
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(Clavel & Hance, 2004; Maga, Radi, Gerard, Botta, & Ennifar, 2010), causing a significant 
reduction in the binding of the drug to its target site. The K103N mutation thus minimally effects 
the enzymes activity, and viral fitness, causing K103N to emerge rapidly and to persist (Craigo et 
al., 2004; Dykes et al., 2001; Nicastri et al., 2003; Palmer et al., 2006).  
Overall, K103N appears to be a very common mutation in the cohort used for this study, and 
additionally persists for a significant amount of time for all participants identified in this study. 
K103N additionally confers high level resistance to commonly used NNRTI drugs. It is thus of 
importance for any individual that is to initiate ART, to undergo an HIV-1 drug resistance test. 
Furthermore, it is important that a technique such as NGS is used, that has the capacity to detect 
K103N at both a major and minority level.  
4.5.1.2 Y181C 
Y181C was identified in participant three (1/23; n= 4.35%) and persisted until end point follow-
up. Little et al. (2008) used conventional population-based Sanger sequencing and detected Y181C 
as a TDRM in 1/14 (7.14%) of the patients in the study. The study found that Y181C, as a TDRM, 
persisted for up to 46 weeks after the estimated date of infection of the individuals (Little et al., 
2008). Another study by Castro et al. (2013) detected Y181C as a TDRM in 20 patients of a 313-
patient cohort (6.4%), using population-based Sanger sequencing. Results of the study found the 
mutation to persist for over a median of 67.8 weeks (1.3 years). From previous reports, Y181C 
does not appear to be a common mutation, with reported prevalences being the approximately the 
same as in this study. The observations in this study are thus consistent with previous literature 
reporting on the persistence of this mutation.  
Y181C has been shown not to reduce HIV-1’s replicative capacity in any significant manner in-
vitro. Work performed by De Luca et al. (2006) investigated the effect of Y181C on the replicative 
capacity of the virus by utilising a range of techniques. The group performed growth competition 
assays, replication kinetics assays, and single-cycle replication assays to determine that the fitness 
of a Y181C mutant was very similar to that of the unmutated wild type virus (De Luca, 2006). 
Growth competition assays performed by Iglesias-Ussel et al. (2002) reported that the Y181C 
mutation has near negligible effects on the replicative capacity and thus fitness of the virus 
(Iglesias-Ussel, Casado, Yuste, Olivares, & López-Galı́ndez, 2002).  
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Y181C confers high-level resistance to and selected NVP (Richman et al., 1991; Wu et al., 2012), 
and high-level resistance to EFV when used in conjunction with NVP (Winslow et al., 1996). 
Y181C is additionally selected by ETR (Vingerhoets et al., 2005) and RVP (Azijn et al., 2010). A 
50-fold reduction to NVP is observed in Y181C mutants (Rhee et al., 2004), with a fivefold, 
threefold and twofold reduction to ETR (Vingerhoets et al., 2010), RPV (Rimsky et al., 2012) and 
EFV (Rhee et al., 2004) respectively.  
The resistance mechanism of action for Y181C involves the selective substitution of a tyrosine to 
a cysteine amino acid at position 181. The NNRTI drugs, EFV and NVP, bind to the conserved 
tyrosine, which forms part of the p66 subunit of the reverse transcriptase enzyme near the 
polymerase active site. The subunit is subsequently involved in the formation of a hydrophobic 
pocket in a drug bound state. When EFV and/or NVP bind to the tyrosine residue, the hydrophobic 
pocket is created. This causes the surface area of the polymerase active site to significantly reduce, 
thus greatly hindering the polymerisation activity of the reverse transcriptase enzyme (Selmi et al., 
2003). The lack of the tyrosine in an unbound drug state does not appear to impede the activity of 
the enzyme in any significant way, and thus does not seem to significantly reduce the fitness of 
the virus (De Luca, 2006; Selmi et al., 2003).   
Overall, the persistence of Y181C over 5 months, noted in participant three, suggests that the 
mutation does not have a major impact on viral fitness; particularly evident by the high viral loads 
(Please refer to Table 2 in Appendix D). Since our study could not look at mutations that occurred 
in combination, future work could focus on the effects of Y181C on viral fitness, not only as a 
single mutation, but as part of combination mutations. In addition to this, considering the fact that 
Y181C persists and confers high level resistance, it is important to consider Y181C before 
initiating treatment.  
4.5.1.3 G190A 
G190A was also identified in participant three (1/23; n=4.35%) and persisted as a minority 
mutation (<10% of the sequenced population) throughout the follow up period of 5 months. The 
persistence of G190A, as observed in this study, has been reported in previous studies. Castro et 
al. (2013) identified G190A in 17/313 (5.43%) patients using conventional population-based 
Sanger sequencing. The study found that G190A persists as a TDRM and as a major mutation 
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(>20% of sequenced population) for over 3.6 years (Castro et al., 2013). Another study by Shet et 
al. (2006) used an allele-specific real-time PCR method to detect common TDRMs, such as 
G190A, and found the mutation in 2/112 patients (1.8%). The mutation persisted for over 3 years 
(Shet et al., 2006). The persistence of G190A can be attributed to the fact that the mutation has 
been shown to have a minimal effect on replication efficacy relative to wild type and K103N. 
Gerondelis et al. (1999) investigated viral fitness by observing the effects that induced mutations 
have on the RNase H cleavage ability of HIV-1 RT. RNase H cleavage is the process in which the 
original viral RNA strand is removed in order to complete the RNA to cDNA reverse transcription, 
prior to host genome integration (Wisniewski, Balakrishnan, Palaniappan, Fay, & Bambara, 2000). 
The rate at which RNase H cleavage occurs dictates the rate of reverse transcription. In a G190A 
mutant, a slight reduction in the rate of DNA 3′-end-directed RNase H cleavage relative to wild 
type RT was observed, which indicated a slightly less fit mutant (Gerondelis et al., 1999).   
The G190A mutation is selected by, and confers high-level resistance to, NVP and EFV (Bacheler 
et al., 2000; Reuman et al., 2010). G190A reduces NVP susceptibility by over 50-fold (Rhee et al., 
2004), and EFV susceptibility by five to ten fold (Huang, Gamarnik, Limoli, Petropoulos, & 
Whitcomb, 2003). The mechanism of action in which G190A results in resistance is caused by the 
selective replacement of a glycine by an alanine. The methyl group on the alanine, in proximity to 
the drug binding site, results in steric hinderance to the NNRTI inhibitor. In a mutated state, the 
inhibitor has a reduced binding efficiency, and the formation of the hydrophobic pocket which 
results in enzyme dysfunction is not achieved (Lyidogan & Anderson, 2014). It is important to 
note, however, that the alanine side chain in the mutated virus leads to hyper susceptibility to DLV, 
which results in a favourable interaction with the methyl group (Lyidogan & Anderson, 2014). 
Despite the selective glycine alanine substitution, it does not appear to hinder the function of RT, 
and thus does not significantly affect the fitness of the mutated virus (Gerondelis et al., 1999).  
Overall, G190A persisted in participant three without any significant effect on the viral fitness of 
the virus. This is consistent with the literature surrounding this mutation (Gerondelis et al., 1999; 
Shet et al., 2006). The lower prevalence persistence of G190A, as compared to K103N and Y181C, 
indicates that this is a less fit mutation relative to K103N and Y181C. Despite being a less fit 
variant, the fitness cost of G190A was not sufficient to lead to reversion in the follow up period. 
Future research could focus on G190A as a combination mutation, with mutations such as K103N 
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and Y181C, and explore how the viral fitness is affected. Despite G190A not appearing as a 
commonly transmitted mutation, the mutation persists for a period after infection and confers 
significant drug resistance against NVP and EFV.  
4.5.1.4 Y188C 
Y188C was identified as a TDRM in participant three, four and 10 (3/23; n=13%). Varghese et al. 
(2009) used ultra-deep pyrosequencing on the Roche 454 platform to identify TDRMs in 
individuals that were failing ART. The study identified Y188C in 1/12 (8.3%) of the study 
participants (Varghese et al., 2009). Another study by Ndembi et al. (2008) investigated the 
prevalence of TRDMs in recently infected drug naïve individuals in Cameroon, by means of 
Sanger population based sequencing, and identified the Y188C mutation in 2/79 (2.53%) 
individuals (Ndembi et al., 2008). The two studies above did not, however, study the persistence 
of reversion of Y188C. 
In participant three, Y188C was identified at 1.45%. as a minority mutation (< 20% of the 
sequenced viral population), and reverted after 12 days. Fitter viral strains, that have been shown 
to have higher viral fitness relative to Y188C (such as K103N, Y181C or G190A), may have 
outcompeted the minority variant. Research performed by Collins et al. (2004) created several 
HIV-1 strains which contained a single drug resistant by means of site directed mutagenesis, which 
were used to generate viral stocks, and used in competition assays. Results showed that Y188C 
was the weakest variant relative to other major NNRTIs, and that the fitness hierarchy was as 
follows: wild type > K103N > Y181C > G190A > Y188C (Derdeyn et al., 2004). This viral fitness 
hierarchy was confirmed by Gadhemsetty et al. (2010), and subsequently Y181C is considered an 
intermediate fit mutation relative to the other mutations identified in participant three.  
In participant four, Y188C was identified as a minority mutation, and persisted below 10% of the 
sequenced viral population until endpoint. It is important to note, however, that the follow-up 
period for participant four was short (39 days), and that the prevalence that Y188C was identified 
at in the last sample was 1.59%.  A longer follow-up period would have afforded the study an 
opportunity to observe Y181C in combination with other fitter mutations (such as K103N), and 
the persistence/reversion outcome of the mutation.  
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Y181C persisted as a solitary mutation in participant 10. The mutation was detected well over 99% 
of the sequenced viral population until 13 months post the baseline sample, and declined to 39.4% 
in the last sample five months later. As a solitary mutation, the population prevalence would be 
high for the first year. However, the weaker Y188C mutant would gradually start to decline. This 
is due to the fact that back mutations by random mutagenesis may allow for fitter/wild type strains 
to emerge. There is a possibility that PCR bias could have occurred in the last sample of participant 
10 (sample 79). The sharp decline of the Y181C prevalence is not consistent with prevalences 
observed throughout the follow-up period. This could be due to the sudden detection of V82A, as 
well as the relatively low viral load in the last sample (which would cause a limited PCR template). 
Nonetheless, the Y188C mutation persisted for the entirety of the follow up period of 586 days.  
Y188C is selected by, and confers, high-level resistance to NVP (Richman et al., 1991; Wu et al., 
2012) and EFV (Winslow et al., 1996). The mutation causes at least a 50-fold reduction in 
susceptibility to NVP (Rhee et al., 2004), and a 20-fold reduction to EFV (Vingerhoets et al., 
2010). The mechanism of resistance by which Y188C leads to resistance, is caused by the cysteine 
which replaces the wild type tyrosine. The cysteine lacks the aromatic side chain; a necessary 
component  for extensive stacking interactions between the tyrosine and the bound NNRTI 
inhibitors (J Ren et al., 2001). The wild type tyrosine at position 188 is moreover found at the top 
of the NNRTI binding site and leads to interactions between the aromatic side chain to a tryptophan 
at position 229. This then leads to a hydrophobic sub-pocket which facilitates the binding affinity 
of NNRTI inhibitors (J Ren et al., 2001).. The lack of the tyrosine chain leads to a decrease in the 
binding affinity of NNRTIs. Ren et al. (2001) found an 83-fold reduction in the affinity of NVP to 
the RT drug active site in the Y188C mutant relative to wild type (J Ren et al., 2001). The cysteine 
also, however, causes some conformational changes in the mutant enzyme, which subsequently 
results in a less efficient RT enzyme and negatively affects the efficiency and the general fitness 
of the virus (J Ren et al., 2001).  
Overall, Y188C has the potential to persist (as seen in participant 10), and additionally confer 
resistance to commonly used ARVs. Therefore, it is an important mutation to include in resistance 
screening. Although not commonly detected, the mutation may lead to treatment failure if not 
detected prior initiation of ART. 
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4.5.1.5 E138A 
The E138A mutation was detected in participant 11 (1/23; n=4.35%) at baseline at a prevalence of 
>99% of the sequenced viral population. The mutation furthermore persisted at >99%, until the 
end of the follow up period of 792 days, and additionally persisted in combination with K103N 
(which was also identified at baseline at 98.79% of the sequenced viral population). The viral strain 
identified in participant 13 appears to carry both E138A and K103N mutations in the same viral 
genome. The addition of E138A to K103N in the same virus does not appear to hamper the viral 
fitness of K103N in any significant manner, as viral loads and prevalences remained high 
throughout the follow-up period (Please refer to table 2 in appendix D). E138A is a common 
polymorphic mutation which has proven not to affect the fitness of the virus. McCullum et al. 
(2013) performed a study in which several mutations at position 138 were generated and used in 
competition assays to study relative mutant fitness. The study found that among the different 
mutations (namely, E138A, E138G, E138K, E138Q, and E138R, E138A and E138G) were the 
most fit substations (McCallum et al., 2013). Additionally, the fitness relative to wild type was 
found to be near identical (McCallum et al., 2013).  
A study by Pingen el al. (2014) used population-based Sanger sequencing to sequence virus 
isolated from newly infected, drug naïve individuals, and identified E138A as a TDRM in 1/31 
patients (3.23%). In addition to this, the mutation was observed to persist for over 10 months 
(which was the follow-up cut off for this study)(Pingen, Wensing, et al., 2014). Further research 
could contribute to a better understanding of the effects of viral fitness when in combination with 
other mutations, such as K103N observed in this study. The mutation combination does not appear 
to have a negative effect on the viral fitness. 
The selective replacement of glutamic acid to alanine in E138A leads to a slight affinity reduction 
of the NNRTI inhibitor to the drug binding hydrophobic pocket (Tambuyzer, Nijs, Daems, Picchio, 
& Vingerhoets, 2011). Limited research has been published on E183A mechanism of action, as 
the polymorphic mutation leads to low-level resistance to NNRTI drugs (Tambuyzer et al., 2011). 
The change from an acid side chain of glutamic acid to a hydrophobic side chain of aniline may 
lead to a slight conformational change. This, in turn, might alter the NNRTI the hydrophobic drug 
binding pocket and consequently slightly alter the binding affinity. E138A confers low-level 
resistance to, and is weakly selected by, ETR (Tambuyzer et al., 2011) and RPV (Haddad et al., 
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2011). The mutation leads to a twofold reduction in RPV and ETR susceptibility (Haddad, 
Stawiski, Benhamida, & Coakley, 2010). A study by Porter et al. (2016) detected the presence of 
E138A in peripheral blood mononuclear cells (PBMC) DNA at baseline in a longitudinal study. 
The study administered ART and suppressed viral replication in infected individuals. Interestingly, 
regardless of the presence of E138A, four patients who received treatment containing 
TDF/FTC/RPV did not lead to virological rebound (Porter et al., 2016).  
In line with previous findings, the high prevalence persistence of E138A does not appear to affect 
the viral fitness of the of the mutation in any significant manner (McCallum et al., 2013; Pingen, 
Wensing, et al., 2014).  The effects of combination mutations (such as E183A and K103N) seen 
in participant 11, were not investigated in this study; thus, future research could focus on how 
polymorphic mutations (such as E138A) affect the persistence/reversion of mutations such as 
K103N. E183A does confer low level resistance and appears to persist.   
4.5.1.6 Accessory mutation V108I 
V108I is considered a non-polymorphic accessory mutation  (Wu et al., 2012). This mutation was 
detected at 65.64% at baseline in participant 15, and detected as a minority variant, at 2.96%, in 
participant four (2/23; n=8.7%). At the time of this study, there was limited literature on the 
persistence of V108I as a TDRM, as it confers only low-level resistance to both EFV (Wu et al., 
2012) and NVP (Reuman et al., 2010). It appears that the reversion of V108I, in combination with 
other NNRTI mutations, was achieved in a short amount of time. Interestingly, even though the 
mutation was present at high proportions in participant 15, the mutation was lost at 56 days post 
baseline. In participant four, it was lost within 39 days. V108I does not appear to confer any 
significant survival or replicative advantage to the virus; even when in combination with other 
mutations. This is evident in the fact that the mutant was detected as a major mutation in participant 
15, and a minority mutation in participant four, and in both instances, it reverted in a short amount 
of time.   
V108I is selected by NVP and EFV, and causes low-level resistance to both (Vermeiren et al., 
2007). A twofold reduction in drug susceptibility to NVP and EFV is observed when V108I is 
present (Rhee et al., 2004).  
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It is evident that the rapid reversion of V108I observed in this study appears to hamper the 
replicative capacity and fitness of the virus. This is due to the fact that the variants, with fitness 
comparable to that of wild type (K103N), persisted and outgrew the mutation. Overall the mutation 
confers low-level resistance and does not appear to persist. 
4.5.2 NRTIs 
NRTIs that were identified in this study are K65R (n=2), D67N (n=1), M184V (n=1) and L210W 
(n=1). M184V was identified in participant 15 and K65R was detected as a minority variant in 
participants 15 and 16. NRTI TAMs detected were D67N in participant seven and L210W in 
participant 19. Of the 5 NRTI mutations identified, 2 (40%) of the mutations persisted, and 3 (60%) 
reverted below 1% of the sequenced viral population. NRTI drugs, such as 3TC (Back et al., 1996), 
FTC (Wang et al., 2004) and TDF (White et al., 2005), are commonly used as regimens in ART, 
and select for NRTI mutations identified in this study. At the time of sample collection for this 
study (2006 – 2011), the above-mentioned drugs were available for use as ART in the IAVI 
protocol C countries (Kenya; Uganda; Rwanda; Zambia; South Africa). 
4.5.2.1 M184V 
The M184V mutation was detected in one participant (1/23; n=4.35%), participant 15, at a 
prevalence of 99.2% of the total sequenced population in the first baseline sample. A study by 
Castro et al. (2007), explored a cohort of 313 recently HIV-1 infected and drug naïve patients, and 
identified M184V as a TDRM in 34 (10.86%) of these patients. The Castro study additionally used 
population-based Sanger sequencing to identify TDRMs and found M184V to revert in all 34 
patients in which the mutation was identified.  The mean time of reversion was approximately one 
year, although the study found that the minimum time M184V was found to be undetectable was 
five months. The reversion time of the mutation might have been longer, if NGS technology with 
a lower limit of detection, was used to longitudinally follow the persistence/reversion of mutations. 
A study by Little et al. (2002) identified M184V by population-based sequencing in 5 out of 258 
(1.94%) recently infected drug naïve patients – no longitudinal follow-up was performed. 
K103N was identified in combination with M184V at a prevalence of 98.6% at baseline in 
participant five. Due to the high prevalence of both M184V and K103N, it is likely that both 
mutations may have been contained and co-expressed in a single viral genome. It is evident that 
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K103N is more fit as a single mutation, as opposed to when in combination with M184V, as it’s 
prevalence remained >90% until the last sample, where only then it dropped to 73.81%. M184V’s 
prevalence, however, steadily declined over the follow up period until it was eventually 
undetectable below the cut-off of 1% in the final sample. The viral strain that co-expressed both 
mutations may have been the dominant strain in the quasispecies shortly after infection. However, 
as the viral load declined, so did the prevalence of M184V, and thus the strain which contained 
both K103N and M184V. Work performed by Cong et al. (2007) found that a strain which carried 
both K103N and M184V mutations had a 16.1 times reduction in viral fitness relative to wild type. 
The group generated recombinant virus with various single or combination mutations by 
transfecting MT-4 cells with cloned RT sequences from patients and an RT depleted proviral 
molecular clones. Fitness was then subsequently assessed in competition assays (Cong et al., 
2007). The M184V mutation is thus generally considered an unfit mutation, and its rapid reversion 
due to its high fitness cost is well reported (Cong et al., 2007; Harrison et al., 2010). The V108I 
mutation was detected at 65.6% at baseline in participant 15, when in combination with M184V 
and K103N. The accessory mutation may have been co-expressed in some of M184V-K103N dual 
mutation strains. However, as the viral load declined, and both V108I and M184V reverted, it does 
not appear that V108I had any significant effect on the persistence of M184V. 
M184V is selected by, and confers high-level resistance to, 3TC and FTC with a >100-fold reduced 
susceptibility (Grant et al., 2010; Harrigan et al., 2000; Whitcomb, Parkin, Chappey, Hellmann, & 
Petropoulos, 2003). The mutation may also be selected by, and cause low level resistance to, ABC 
and DDi (Harrigan et al., 2000; Whitcomb et al., 2003). It is important to note that M184V 
increases susceptibility to AZT, d4T and TDF, and hinders the formation of resistance to these 
drugs (B. A. Larder, Kemp, & Harrigan, 1995; Masquelier et al., 1999). The mechanism of action 
by which the M184V mutation causes resistance, involves the selective substitution of a 
methionine to a valine near the drug binding site in the RT enzyme. The smaller non-polar side-
chain of valine lacks a thiol group which would otherwise be used for the formation of disulphide 
bonds, and thus for secondary and tertiary protein structure formation (Clavel & Hance, 2004). 
The altered structure of the M184V mutant protein causes an increase in drug discrimination 
relative to the wild type protein, which ultimately leads to a greater capacity to distinguish between 
dNTPs and non-extendable nucleoside analogue monophosphate NRTI drugs. In addition to this, 
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the mutant RT is less efficient, which imposes a fitness cost on the virus (Clavel & Hance, 2004; 
Harrison et al., 2010).  
M184V is an overall unfit mutant that confers high resistance to 3TC/FTC. M184V is reported, 
and seen in participant 15, to have a reduced fitness (Harrison et al., 2010). The degree to which 
fitness is reduced appears to depend on the co-expression of other mutations. K103N, in 
combination with M184V, imposes a significant fitness cost. Further work could investigate how 
accessory mutations, such as V108I, affect the fitness and the persistence/reversion of the virus. 
Despite M184V having a high fitness cost, and low persistence potential, the mutation still confers 
high level resistance to 3TC/FTC (Harrigan et al., 2000), and appears to have the capacity to be 
transmitted and establish infection in a new host.  
4.5.2.2 K65R 
K65R was detected as a minority variant in two participants (2/23; n=8.7%); participant 15 and 
16. It persisted in both participants until endpoint at a prevalence of between 1-3% of the 
sequenced viral population. K65R was not detected in baseline in participant 13, but emerged 
approximately 2 months after the first baseline sample. Castro et al. (2013) identified K65R in 
5/313 (1.6%) of a cohort of drug naïve and newly infected HIV-1 individuals. A study by Metzner 
et al. (2011) identified K65R in 4/146 (2.7%) of recently HIV-1 infected drug naïve patients, by 
using allele-specific real-time PCR (Metzner et al., 2011). In both participants 15 and 16, K65R 
persisted at a low prevalence of between 1-3% throughout follow up. Work by Cong et al. (2007) 
used single mutation competitive assays and found the relative viral fitness of K65R relative to 
wild type to be low. More fit, or wild type virus would rapidly outcompete K65R mutants (Harrison 
et al., 2010). A study by Deval et al. (2003) moreover found pol recombinant viruses, that contain 
the K65R mutation, to have a reduced replicative capacity of up to 53%, relative to wild type. 
Generated recombinant viruses were subjected to single cycle virus growth assays in order to 
determine replicative capacity (Deval et al., 2004).   
The K65R mutation is selected by TDF, ABC, d4T and DDi (García-Lerma et al., 2003; Wainberg 
et al., 1999), and reduces the susceptibility to these 2 fold and d4T 1.5 fold (Petropoulos et al., 
2000). The mechanism of action for resistance by K65R is similar to that of M184V; K65R is a 
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mutation that occurs near the drug binding site and ultimately causes in increase in drug 
discrimination (Clavel & Hance, 2004).  
As K65R is considered an unfit mutation that confers low-level resistance, the low-level 
persistence in both participant 15 and 16 is interesting. K65R was detected with K103N in both 
participants. It would appear that the co-existence of separate strains that carry K103N and K65R 
would allow for the less fit K65R virus to replicate at a level that is sufficient to maintain a low 
prevalence. The combination of K65R and K103N, as TDRMs, have been observed and reported 
previously in literature (Metzner et al., 2011), but this study used allele-specific real-time PCR, 
and thus prevalences or persistence/reversion were not reported. Future work could investigate 
what would allow for the low-level persistence of K65R to occur with a fitter virus, such as K103N 
seen in participant 15 and 16. 
4.5.2.3 D67N 
D67N was identified and rapidly reverted in participant seven (1/23; n=4.35%). Castro et al. (2013) 
identified D67N as a TDRM in 27/313 (8.6%) of recently infected patients using population based 
Sanger sequencing (Castro et al., 2013). In contrast to this, a much lower prevalence of D67N as 
a TDRM was found, also using population based Sanger sequencing, in a larger study by Yerly et 
al. (2007); specifically, only 9/822 (1.1%) of recently HIV-1 infected individuals (Yerly et al., 
2007). In summary, Castro et al. (2013) and Yerly et al. (2007) found D67N to persist for a 
significant period after infection (> 6 years) in drug naïve individuals.  
A study by García-Lerma et al. (2004) produced recombinant virus with patient derived RT 
sequences that contained D67N as a single mutation. A RT-deleted HXB2-based proviral 
molecular clone was used for the expression of the D67N mutant recombinant virus, which was 
then used in fitness assays and growth competition assays. The study found that D67N could 
replicate efficiently in the absence of a drug pressure, and had a potential to persist for a significant 
amount of time (> 5 years) (García-Lerma, MacInnes, Bennett, Weinstock, & Heneine, 2004). A 
similar study by Cong et al., (2007) evaluated the fitness of 11 key RT mutations, of which D67N 
was one. Mutant virus was created by site-directed mutagenesis and expressed to be used in fitness 
assays. Results showed that D67N was a fit virus as a single mutation, and imposed very limited 
fitness cost (Harrison et al., 2010).  
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D67N, as a type 2 TAM, is selected for and results in low-level reduced susceptibility to AZT and 
d4T (García-Lerma, Nidtha, Blumoff, Weinstock, & Heneine, 2001). TAMs’ mechanism of 
resistance involves a process termed ‘pyrophosphorolysis’; a reaction that removes chain-
terminating NRTI drugs and reinstates an extendable primer, consequently facilitating primer 
unblocking (Clavel & Hance, 2004). 
The baseline sample, in which D67N was identified using Sanger sequencing, by Price et al. 
(2011), could not be RT-PCR amplified and subsequently sequenced by NGS. However, as the 
mutation was identified by Sanger, and not NGS, the prevalence can be assumed to be >20% of 
the sequenced viral population (Palmer et al., 2005). To confirm genetic relatedness of the samples, 
phylogenetic analysis was performed (please refer to the results displayed in Figure 3.8). All 
samples for participant seven, including the baseline sample, grouped in a cluster, thus indicating 
that all samples are from the same patient. The D67N mutation was thus concluded to have reverted 
in participant seven. This outcome of D67N has not yet been observed in previous publications 
and warrants further investigation.  
4.5.2.4 L210W 
The final NRTI and TAM that was detected was L210W, and identified in participant 19 (1/23; n 
=4.35%). The mutation was identified by NGS at a prevalence of 13.85% of the sequenced viral 
population; increasing to a prevalence of 92.62% in the end point sample. L210W was also found 
to persist throughout follow-up. Castro et al. (2013) identified L210W, as a TDRM, in 25/313 
(8%) of newly HIV-1 infected, drug naïve patients using Sanger sequencing, and found the 
mutation to persist for up to 4.8 years (Castro et al., 2013). A study by Boden et al. (1999) identified 
L210W in 1/80 (1.3%) of individuals identified to have transmitted drug resistance; however, 
longitudinal data on these participants was not explored A study by Little et al. (2008) found 
L210W in 1/14 (7%) of participants who were drug naïve and recently infected. The study found 
the mutation to persist for up to 170 weeks (3.3 years) after infection (Little et al., 2008).  
L210W is considered a very fit mutant with a low fitness cost. Work performed by Cong et al. 
(2007) used single mutant analysis between HXB2 wild type and a L210W mutant, by producing 
clones using site directed mutagenesis. The mutants were expressed and used in growth 
  
103 
competition assays. Following this, the group could not identify a significant difference in viral 
fitness between L210W and wild type virus (Harrison et al., 2010).  
L210W is considered a classical, type 1 TAM. It is selected by ABC, TDF and ZDV; conferring 
low level resistance to only AZT (Centers for Disease Control and Prevention, 2016; World Health 
Organization, 2016a). The mechanism of action includes the process of ‘pyrophosphorolysis’, as 
described in D67N’s mechanism of action. 
L210W does not appear to have any significant effect on viral fitness, as viral loads remained high 
throughout follow-up in participant 19. Although L210W does not confect great resistance to ARV 
drugs, the mutation has potential to persist for a significant amount of time after infection (Little 
et al., 2008). L210W in combination with other mutations warrant more work, to perhaps better 
understand how L210W as a TAM in combination with other NRTIs/NNRTIs may affect mutation 
persistence/reversion. 
4.5.3 PIs 
The PI mutations identified were M46L (n=2), and the accessory mutations identified were: T74S 
(n=3), I85V (n=2), L10V (n=3), and L10I (n=1). PI based regimens are not commonly 
administered, and are used only in individuals that are failing commonly used first line regimens 
(World Health Organization, 2015). The combination of TDF, 3TC/FTC and EFV, on the other 
hand, are commonly administered; they require less frequent administration, have fewer adverse 
side effects, and have better virological treatment response (World Health Organization, 2015). 
Despite this, the PI based treatments may have better outcomes because of the increase of drug 
resistance.  
4.5.3.1 M46L 
M46L was identified in two participants (2/23; n=8.7%); as a single mutation in participant two, 
and as a combination mutation in participant 21. The mutation persisted in participant two, but 
reverted to wild type in participant 21. Little et al. (2008) used Sanger sequencing to identify M46L 
as a single mutation in 2/14 (14.3%) of recently HIV-1 infected, drug naïve patients, and found 
the mutation to persist for up to 170 weeks (3.3 years) post infection (Little et al., 2008).  Castro 
et al. (2013) identified M46L as a TDRM (both as single and in combination) in 16/313 (5.0%) of 
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newly HIV-1 infected individuals, and found the mutation as a single mutation to persist for up to 
3.1 years (Castro et al., 2013).  
M46L, as a lone mutation, does not appear to significantly affect the replicative capacity and viral 
fitness of transmitted viruses. M46L, when in combination with other common mutations such as 
K103N, G190A, and Y181C, does not persist and reverts within a short period of time (<1 year) 
(Harrigan et al., 2000). The reversion of M46L, as a combination mutation, was observed in 
participant 21 in this study. A study by Pingen et al. (2014) produced mutant HIV-1 by means of 
site directed mutagenesis contained M46L as a single mutation, as well as a combination strain 
that consisted of several strains of different common mutations. The study found that M46L had a 
significant decrease in replicative capacity and viral fitness when in combination with such as 
K103N, G190A, and Y181C; ultimately  leading to the reversion of the mutation within 1 year 
(Harrigan et al., 2000).  
M46L is considered a non-polymorphic PI selected mutation; it is primarily selected by IDV, NFV, 
FPV, ATV and LPV, and leads to potential low-level resistance to ATV and LPV (Cann & Karn, 
1989; Garriga et al., 2007; Little et al., 2002).   
Overall, M46L is a mutation that confers low level resistance, and may persist or revert, depending 
on its combinations with other mutations. In participant 21, there was no consistent combination 
mutation with which M46L was identified. Low prevalence mutations (<20% of the sequenced 
viral population), such as K219R, K103N and G190A, were identified at various time points 
throughout the follow up. The prevalence of M46L, however, steadily declined until no longer 
detected (>1% of the sequenced viral population) 1.4 years after the first sample. The time frame 
of the reversion of M46L, as a combination mutation, in participant 21, is consistent with the 
findings of Castro et al. (2013). The follow-up for participant two was, however, shorter (0.85 
years), and based on previous reports, would persist as a solitary mutation (Harrigan et al., 2000). 
Additional work may be required to further investigate the effects of M46L in combination with 
other PIs, NNRTI, and NRTI mutations.   
4.5.3.2 Accessory PI mutations T74S, I85V and L10I/V 
T74S, I85V and L10I/V are polymorphic accessory mutations. T74S was identified in participant 
13, 14 and 16 (3/23; n=13%) and persisted in all 3 participants. T74S confers no resistance to any 
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PI drugs currently in use. The persistence and low effect on the viral fitness of T74S as a TDRM, 
has been previously reported and consistent with literature (Gonzalez et al., 2008; Price et al., 
2011).  
I85V was identified in participants 5 and 18 (2/23; n=8.7%) and persisted until endpoint in both. 
I85V is a non-polymorphic PI-selected mutation that does not, in any manner, affect PI 
susceptibility (Rhee et al., 2004). In addition, I85V does not reduce the viral fitness of the viral 
strain (Robinson, Myers, Snowden, Tisdale, & Blair, 2000). The polymorphic accessory NRTI 
V118I mutation was detected with I85V in participant 18; both persisting well above 99% 
prevalence of the sequenced viral population until end point. The virus fitness does not appear to 
be affected by this combination of mutations. Persistence observed is consistent with literature 
reports (Robinson, Myers, Snowden, Tisdale, & Blair, 2000).  
L10I/V were commonly detected in participants 3, 6, 8, and 9 (4/23; n=17.4%) at very high 
prevalences (>90% of sequenced viral population) and persisted in all participants. L10I/V 
mutations are PI selected, polymorphic accessory mutations, that may increase the replicative 
capacity of the virus when in combination with other PI selected resistance (Tzoupis, Leonis, 
Mavromoustakos, & Papadopoulos, 2013).  
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4.2 Conclusion 
This study describes the population dynamics of transmitted drug resistant HIV-1, and the 
persistence/reversion of the transmitted drug resistant mutations, to treatment naïve individuals.  
The use of NGS technology provided unprecedented coverage and capacity to observe the 
dynamics of TDRMs confidently at low prevalence’s (< 1% of the sequenced viral population). 
The use of NGS technologies enable the detection of minority drug resistance variants, otherwise 
missed by conventional population-based Sanger sequencing. Moreover, NGS technologies allow 
for a higher number of samples per resistance testing sequencing reaction; effectively reducing the 
price per sample per HIV-1 resistance test.  
Findings confirmed that a range of ARV drug resistance mutations, previously known to have 
negative consequences for viral replication, do not appear to affect the transmission efficiency of 
the virus. These include M184 and K65R. However, mutations that impose a significant fitness 
cost revert in the absence of ARV drug pressure, followed by outgrowth of fitter viral strains or 
wild type quasispecies.  
 
Below presents a summary of mutations that were explored in this study: 
The reversion of Y188C in participant three was due to its fitness cost, relative to the other 
mutations with which the mutation was transmitted. Fitter mutations, such as K103N, Y181C and 
G190A, followed the previously reported and well established NNRTI fitness hierarchy, and out-
competed the Y188C virus until it was below the limit of detection of this study.  
M184V, identified in participant 15, also reverted due to the mutation’s significant fitness cost; 
consistent with previous reports (Harrigan et al., 2000). M46L was found to persist in participant 
two as a single mutation and reverted in participant 21 as a combination mutation. The 
persistence/reversion of M46L is therefore dependent upon whether the mutation is transmitted as 
a single, or as a combination mutation. The reversion of V108I and D67N has not been reported 
extensively in previously literature. Further work may be performed to investigate the effects that 
the accessory mutation V108I may have on the persistence/reversion when in combination with 
other mutations. Future research could also explore how the mutation may influence the viral 
fitness and the persistence of the combination strain, and of the V108I mutation itself. D67N has 
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been reported to persist and not affect replicative capacity (García-Lerma et al., 2004; Harrison et 
al., 2010). Future studies may investigate the replicative capacity of the viruses from participant 
seven.  
Overall, six of the 43 (14%) total TDRMs identified in the 23 participants reverted (below 1% of 
the sequenced viral population). Of the 43 TDRMs identified, six were not identified by 
conventional population-based Sanger sequencing, and four of the six persisted until end follow-
up. These findings highlight the importance of detecting minority variants that are missed by 
conventional population-based Sanger sequencing, as missed mutations may have significant 
clinical consequences, such as treatment failure.  
In 21 of the 23 (91%) participants studied, at least one TDRM mutation persisted throughout the 
follow up period. Findings confirming observations from previous studies that TDRMs, 
particularly NNRTI mutations such as K103N, generally persist after transmission to a new host 
(Geretti et al., 2009; Nishizawa et al., 2015). 
A rise in transmitted HIV-1 drug resistance is currently observed in developing Sub-Saharan 
countries; namely, Kenya, Uganda, Rwanda, Zambia and South Africa (Hofstra, Schmit, & 
Wensing, 2017). These countries constitute the participant cohort of this study (Price et al., 2011). 
The increase in the rate of DRM transmission may be attributed to increased ART rollout, the lack 
of treatment adherence, and the absence of resistance testing facilities and sub-optimal treatment 
strategies (Hofstra et al., 2017). Rates of transmission can be classified into three main categories, 
according to the WHO. These include the following:  low rate (<5%), intermediate rate (5-15%), 
and high rate (>15%). The WHO recommends that surveillance studies are performed on a regular 
basis in order to assess the rate of DRM transmission. The most recent reports show that the 
prevalence of transmitted HIV-1 drug resistance for the countries explored in this study are as 
follows: Kenya: 14% (intermediate) (Eneyew, Seifu, Amogne, & Menon, 2016); Uganda: 10.8% 
(intermediate) (Hamers et al., 2011); Rwanda: 7.7% (intermediate) (Bennett et al., 2009); Zambia: 
4.4% (low) (Bennett et al., 2009; V. A. Johnson et al., 2009); and South Africa: 9% (intermediate) 
(Steegen et al., 2016).  Recent studies have, however, reported that countries that have made ART 
available to HIV-1 infected individuals for >5 years are significantly more likely to observe an 
increase in drug resistance transmission (Stadeli & Richman, 2013). In addition to this, countries 
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observed in the IAVI protocol C are expected to soon increase to high rates of resistance 
transmission (Price et al., 2011). 
Results from this study highlight the importance of understanding the population dynamics of TDR 
HIV-1 in the absence of drug pressure for clinical management. The intermediate rates of drug 
resistance transmission for countries of the IAVI protocol C cohort, used in this study, are soon to 
increase drastically. Due to the multitude of factors that play a role in exacerbating transmission 
rates, it is critical importance that drug resistance transmission are well understood, and effective 
and insightful public health strategies are successfully implemented such that. The results from 
this study could be used to modify ART regimens so as to include more affordable  drugs, with 
much higher barriers to resistance such as dolutegravir (DTG). 
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6. Appendices  
Appendix A: Ethics Clearance 
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Appendix B: DNA Work 
1. GeneJet DNA (Thermo Fisher Scientific, Massachusetts, USA) purification kit protocol 
 
1. Add a 1:1 volume of Binding Buffer to completed PCR mixture (e.g. for every 100 µL of 
reaction mixture, add 100 µL of Binding Buffer). Mix thoroughly. Check the color of the solution. 
A yellow color indicates an optimal pH for DNA binding. If the color of the solution is orange or 
violet, add 10 µL of 3 M sodium acetate, pH 5.2 solution and mix. The color of the mix will 
become yellow. 
2. Optional: if the DNA fragment is ≤ 500 bp, add a 1:2 volume of 100% isopropanol (e.g., 
100 µL of isopropanol should be added to 100 µL of PCR mixture combined with 100 µL of 
Binding Buffer). Mix thoroughly. 
Note. If PCR mixture contains primer-dimers, purification without isopropanol is recommended. 
However, the yield of the target DNA fragment will be lower 
3. Transfer up to 800 µL of the solution from step 1 (or optional step 2) to the GeneJET 
purification column. Centrifuge for 30-60 s. Discard the flow-through. 
Notes. If the total volume exceeds 800 µL, the solution can be added to the column in stages. After 
the addition of 800 µL of solution, centrifuge the column for 30-60 s and discard flowthrough. 
Repeat until the entire solution has been added to the column membrane. Close the bag with 
GeneJET Purification Columns tightly after each use! 
4. Add 700 µL of Wash Buffer (diluted with the ethanol as described on p. 3) to the GeneJET 
purification column. Centrifuge for 30-60 s. Discard the flow-through and place the purification 
column back into the collection tube. 
5. Centrifuge the empty GeneJET purification column for an additional 1 min to completely 
remove any residual wash buffer. 
Note. This step is essential as the presence of residual ethanol in the DNA sample may inhibit 
subsequent reactions. 
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6. Transfer the GeneJET purification column to a clean 1.5 mL microcentrifuge tube (not 
included). Add 50 µL of Elution Buffer to the center of the GeneJET purification column 
membrane and centrifuge for 1 min. Note 
• For low DNA amounts the elution volumes can be reduced to increase DNA concentration. An 
elution volume between 20-50 µL does not significantly reduce the DNA yield. However, elution 
volumes less than 10 µL are not recommended. 
• If DNA fragment is >10 kb, prewarm Elution Buffer to 65 °C before applying to column. • If the 
elution volume is 10 µL and DNA amount is ≥5 µg, incubate column for 1 min at room temperature 
before centrifugation. 
7. Discard the GeneJET purification column and store the purified DNA at -20 °C 
 
2. Agarose Gel Preparation  
• 1% Agarose gel (200 ml) Add 2 g of agarose to 200 ml of 1 × TAE buffer. 
 
• 50×TAE buffer (1 L) Weigh out 242 g tris base. Add 57.1 mL glacial acetic acid and 100 
mL 0.5 EDTA. Add 800 mL of distilled water. Adjust pH to 8.0 with HCl. Top up to 1L 
with dH2O. Store at room temperature. 
 
 
3. Qubit 2.0 Fluorometer High Sensitivity Assay  
1.1 Set up the required number of 0.5-mL tubes for standards and samples. The Qubit dsDNA HS 
Assay requires 2 standards. 
Note: Use only thin-wall, clear, 0.5-mL PCR tubes. Acceptable tubes include Qubit assay tubes (Cat. 
no. Q32856) or Axygen® PCR-05-C tubes (part no. 10011-830). 
 
1.2 Label the tube lids. 
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Note: Do not label the side of the tube as this could interfere with the sample read. Label the lid of each 
standard tube correctly. Calibration of the Qubit® Fluorometer requires the standards to be inserted into 
the instrument in the right order. 
1.3 Prepare the Qubit® working solution by diluting the Qubit dsDNA HS Reagent 1:200 in Qubit 
dsDNA HS Buffer. Use a clean plastic tube each time you prepare Qubit working solution. Do 
not mix the working solution in a glass container. 
Note: The final volume in each tube must be 200 µL. Each standard tube requires 190 µL of Qubit working 
solution, and each sample tube requires anywhere from 180–199 µL. Prepare sufficient Qubit working 
solution to accommodate all standards and samples. 
1.4 Add 190 µL of Qubit working solution to each of the tubes used for standards. 
1.5 Add 10 µL of each Qubit standard to the appropriate tube, then mix by vortexing 2–3 seconds. 
Be careful not to create bubbles. 
Note: Careful pipetting is critical to ensure that exactly 10 µL of each Qubit® standard is added to 190 µL 
of Qubit® working solution. 
1.6 Add Qubit® working solution to individual assay tubes so that the final volume in each tube 
after adding sample is 200 µL. 
Note: Your sample can be anywhere from 1–20 µL. Add a corresponding volume of Qubit® working 
solution to each assay tube: anywhere from 180–199 µL. 
1.7 Add each sample to the assay tubes containing the correct volume of Qubit working solution, 
then mix by vortexing 2–3 seconds. The final volume in each tube should be 200 µL. 
 
1.8 Allow all tubes to incubate at room temperature for 2 minutes. 
Proceed to reading standards and samples 
2. On the Home screen of the Qubit 3.0 Fluorometer, press DNA, then select dsDNA High 
Sensitivity as the assay type. The “Read standards” screen is displayed. Press Read 
Standards to proceed. 
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Note: If you have already performed a calibration for the selected assay, the instrument prompts you to 
choose between reading new standards and running samples using the previous calibration. If you want to 
use the previous calibration, skip to step 2.4. Otherwise, continue with step 2.2. 
2.1 Insert the tube containing Standard #1 into the sample chamber, close the lid, then press 
Read standard. When the reading is complete (~3 seconds), remove Standard #1. 
 
2.2 Insert the tube containing Standard #2 into the sample chamber, close the lid, then press. 
Read standard. When the reading is complete, remove Standard #2. The instrument 
displays the results on the Read standard screen.  
 
2.3 Press Run samples. 
 
2.4 On the assay screen, select the sample volume and units: 
a. Press the + or – buttons on the wheel to select the sample volume added to the assay tube 
(from 1–20 μL). 
b. From the dropdown menu, select the units for the output sample concentration. 
2.5 Insert a sample tube into the sample chamber, close the lid, then press Read tube. When 
the reading is complete (~3 seconds), remove the sample tube. The instrument displays the 
results on the assay screen. The top value (in large font) is the concentration of the original 
sample. The bottom value is the dilution concentration. 
 
2.6 Repeat step 2.6 until all samples have been read. 
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Appendix C: Nextera XT library preparation guide 
1. Fragmentation of Input DNA 
During this step, input DNA is tagmented (tagged and fragmented) by the Nextera XT 
transposome. The Nextera XT transposome simultaneously fragments the input DNA and 
adds adapter sequences to the ends, allowing amplification by PCR in subsequent steps. 
 
Consumables: 
 
Item Quantity Storage Supplied 
ATM (Amplicon Tagment Mix) 1 tube -25°C to -15°C Illumina 
TD (Tagment DNA Buffer) 1 tube -25°C to -15°C Illumina 
NT (Neutralize Tagment Buffer) 1 tube Room Temperature Illumina 
Input DNA (0.2 ng/μl) - -25°C to -15°C User 
96-well hard shell TCY plate 1 plate Room Temperature User 
Microseal 'B' adhesive film - Room Temperature User 
 
 
Preparation 
 
1. Remove the ATM, TD, and input DNA from -25°C to -15°C storage and thaw on ice. 
2. Visually inspect NT to make sure that there is no precipitate. If there is precipitate, 
vortex until all particulates are re-suspended. 
3. After thawing, mix reagents by gently inverting the tubes 3–5 times, followed by a brief 
spin in a micro centrifuge. 
Make NTA 
Make sure that the reaction is assembled in the order described for optimal kit performance. You 
do not need to assemble the reaction on ice. 
1. Label a new 96-well TCY plate NTA (Nextera XT Tagment Amplicon Plate). 
2. Add 10 μl TD Buffer to each well to be used in this assay. Change tips between samples. 
 
Calculate the total volume of TD for all reactions, and divide the volume equally among the wells 
of a PCR eight-tube strip. Use a multichannel pipette to dispense into the NTA plate. 
3. Add 5 μl input DNA at 0.2 ng/μl (1 ng total) to each sample well of the NTA plate. 
It is critical to use the full amount of input DNA. 
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4. Using a multichannel pipette, gently pipette up and down 5 times to mix. Change tips 
between samples. 
5. Add 5 μl ATM to the wells containing input DNA and TD Buffer. Change tips between 
samples. 
Calculate the total volume of ATM for all reactions, and divide the volume equally among the wells 
of a PCR eight-tube strip. Use a multichannel pipette to dispense into the NTA plate. 
6. Using a multichannel pipette, gently pipette up and down 5 times to mix. Change tips 
between samples. 
7. Seal the NTA plate with a Microseal 'B' adhesive seal. 
8. Centrifuge at 280 × g at 20°C for 1 minute. 
9. Place the NTA plate in a thermal cycler and run the following program: 
Make sure that the thermal cycler lid is heated during the incubation. 
• 55°C for 5 minutes 
• Hold at 10°C 
10. When the sample reaches 10°C, proceed immediately to Neutralize NTA as the 
transposome is still active. 
 
_______________________________________ 
 
Neutralize NTA 
Calculate the total volume of NT for all reactions, and divide the volume equally among the 
wells of a PCR eight-tube strip. Use a multichannel pipette to dispense into the NTA plate. 
1. Carefully remove the Microseal 'B' seal and add 5 μl NT Buffer to each well of the NTA 
plate. Change tips between samples. 
2. Using a multichannel pipette, gently pipette up and down 5 times to mix. Change tips 
between samples. 
3. Seal the NTA plate with a Microseal 'B' adhesive seal. 
4. Centrifuge at 280 × g at 20°C for 1 minute. 
5. Place the NTA plate at room temperature for 5 minutes. 
 
2. Indexing (PCR Amplification) 
In this step, the tagmented DNA is amplified via a limited-cycle PCR program. The PCR 
step also adds index 1 (i7) and index 2 (i5) and sequences required for cluster formation. 
It is critical to use the full amount of recommended input DNA and not add extra cycles of 
PCR cycles to ensure libraries that produce high-quality sequencing results. 
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Consumables: 
 
Item Quantity Storage Supplied 
NPM (Nextera PCR Master Mix) 1 tube -25°C to -15°C Illumina 
Index 1 primers (N7XX) 1 tube each -25°C to -15°C Illumina 
Index 2 primers (S5XX) 1 tube each Room Temperature Illumina 
Microseal 'A' film - Room Temperature User 
 
Preparation 
Utilising the samples sheet prepared in Illumina Experiment Manager, index primers will be added 
to each sample. One N7X and one S5X primer. The Illumina Experiment Manager will verify 
whether the combination of primers will result in a unique and usable set of primers. 
Remove NPM and the index primers (i5 and i7) from -25°C to -15°C storage and thaw on a bench 
at room temperature. Allow approximately 20 minutes to thaw NPM and index primers. After all 
reagents are thawed, gently invert each tube 3–5 times to mix and briefly centrifuge the tubes in a 
microcentrifuge. Use 1.7 ml Eppendorf tubes as adapters for the microcentrifuge. 
Amplify NTA 
1. Add 15 μl NPM to each well of the NTA plate containing index primers. Change tips 
between samples. 
Calculate the total volume of NPM for all reactions, and divide the volume equally among the 
wells of a PCR eight-tube strip. Use a multichannel pipette to dispense into the NTA plate. 
2. Add 5 µl index primer 2 primers (white caps) to each well. 
 
3. Add 5 µl index primer 1 primers (orange caps) to each well. 
Each primer added as per the sample sheet. 
4. Using a multichannel pipette, gently pipette up and down 5 times to mix. Change tips 
between samples to avoid index and sample cross-contamination. 
5. Cover the NTA plate with Microseal 'A' film and seal with a rubber roller. 
6. Centrifuge the NTA plate at 280 × g at 20°C for 1 minute. 
7. Perform PCR using the following program on a thermal cycler: 
Make sure that the thermal cycler lid is heated during the incubation. 
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• 72°C for 3 minutes 
• 95°C for 30 seconds 
• 12 cycles of: 
— 95°C for 10 seconds 
— 55°C for 30 seconds 
— 72°C for 30 seconds 
• 72°C for 5 minutes 
• Hold at 10°C 
 
SAFE STOPPING POINT 
If you do not plan to proceed immediately to PCR Clean-Up, there are two options for 
storage. The NTA plate can remain on the thermal cycler overnight or you can store it at 
2°C to 8°C for up to two days. 
 
 
3. Size Selection 
This step uses AMPure XP beads to purify the library DNA, and provides a size selection 
step that removes short library fragments from the population. 
A double size selection protocol is followed in order to omit fragment sizes that are either too 
small or too large. 
Consumables 
Item Quantity Storage Supplied 
RSB (Resuspension Buffer) 1 tube -25°C to -15°C Illumina 
AMPure XP beads User Determined 2°C to 8°C Illumina 
Freshly prepared 80% ethanol (EtOH) - 
Room 
Temperature 
Illumina 
96-well MIDI plates - 
Room 
Temperature 
User 
 
Preparation 
1. Bring the AMPure XP beads to room temperature. 
2. Prepare fresh 80% ethanol from absolute ethanol. 
Always prepare fresh 80% ethanol for wash steps. Ethanol can absorb water from the air 
impacting your results. 
__________________________________________________ 
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Make CAN 
1. Centrifuge the NTA plate at 280 × g for 1 min (20˚C) to collect condensation. 
2. Label a new MIDI plate CAA (Clean Amplified Plate). 
3. Using a multichannel pipette set to 40 μl, transfer the PCR product from the NTA plate to the 
CAA plate. Change tips between samples. 
4. Vortex the AMPure XP beads for 30 seconds to make sure that the beads are evenly dispersed. 
Add an appropriate volume of beads to a trough. 
5. Using a multichannel pipette, add 23 μl AMPure XP beads to each well of the CAA plate. (Note 
this is a 0.575 ration specific to this protocol) 
6. Gently pipette mix up and down 10 times. 
Alternatively the solution can be mixed by shaking the CAA plate on a microplate shaker at 1800 
rpm for 2 minutes. 
7. Incubate at room temperature without shaking for 5 minutes. 
8. Place the plate on a magnetic stand for 2 minutes or until the supernatant has cleared. 
9. With the CAA plate on the magnetic stand, use a multichannel pipette to remove and discard 
the supernatant carefully. Change tips between samples. 
10. With the CAA plate on the magnetic stand, wash the beads with freshly prepared 80% ethanol 
as follows: 
a) Using a multichannel pipette, add 200 μl freshly prepared 80% ethanol to each sample well. 
Do not resuspend the beads yet. 
b) Incubate the plate on the magnetic stand for 30 seconds. 
c) Carefully remove and discard the supernatant. 
 
11. With the CAA plate still on the magnetic stand, allow the beads to air-dry for 15 minutes. 
12. Elute in 55 µl RBS. 
13. Transfer 50 µl of DNA to new plate (CAA2). 
14. Add 37.5 µl AMPure XP beads (Note this is a 0.75 ratio specific to this protocol) 
15. Gently pipette mix up and down 10 times. 
Alternatively the solution can be mixed by shaking the CAA plate on a microplate shaker at 1800 
rpm for 2 minutes. 
16. Incubate at room temperature without shaking for 5 minutes. 
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17. Place the plate on a magnetic stand for 2 minutes or until the supernatant has cleared. 
18. With the CAA plate on the magnetic stand, use a multichannel pipette to remove and discard 
the supernatant carefully. Change tips between samples. 
19. With the CAA plate on the magnetic stand, wash the beads with freshly prepared 80% ethanol 
as follows: 
a) Using a multichannel pipette, add 200 μl freshly prepared 80% ethanol to each sample well. Do 
not resuspend the beads yet. 
b) Incubate the plate on the magnetic stand for 30 seconds. 
c) Carefully remove and discard the supernatant. 
 
20. With the CAA plate still on the magnetic stand, allow the beads to air-dry for 15 minutes. 
21. Elute in 15 µl RBS, and transfer 10 µl for Quantification. 
 
Safe Stopping point 
The CAN plate can be sealed and stored at -20°C for up to a week. 
 
 
4. Library Normalisation 
A non-bead based normalisation will be used for library normalisation. 
Quantify ALL eluted DNA samples, and dilute to 2 nM – Utilising Qubit HS DNA assay. 
It is important to note however that the base pair length of the DNA molecule will ultimately affect 
the molarity of the final DNA solution. Thus, in order to obtain a final concertation of 2nM, the 
following calculations must be performed: 
• Obtain concentration via Qubit of DNA in ng/µl. 
• With assumption that fragments sizes are 770 bp (0.75 ratio of beads), calculate molecular 
weight of DNA. 
• Calculate molarity based on length of fragments 
 
1) [(𝑁𝑜 𝑜𝑓 𝐵𝑎𝑠𝑒𝑃𝑎𝑖𝑟𝑠) × (607,4
𝑔
𝑚𝑜𝑙
)] + 158
𝑔
𝑚𝑜𝑙
= 𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑎𝑟 𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝐷𝑁𝐴 𝑓𝑟𝑎𝑔𝑚𝑒𝑛𝑡 
 
2) 
𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛(
𝑛𝑔
µ𝑙
)
𝑀𝑊 𝑜𝑓 𝐷𝑁𝐴 
 × 106 = 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑖𝑛 𝑛𝑀 
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Preparation 
Prepare 0.2 N NaOH fresh. In this instance, 0.2 N = 0.2 M (For a monoprotic base such as NaOH 
molar and normal is the same) 
Pooling of samples and making Library 
1. Once all samples are at an appropriate concentration, all the samples are pooled at 
equimolar concentrations. 5 µl of each sample is added to the pool. This is now 
referred to as the Library. 
2. Combine 5 µl of the library with 5 µl of 0.2 N NaOH. (This step denatures the 
dsDNA to ssDNA. Some alternative Illumina protocols may suggest heating the 
DNA followed by immediate cooling to prevent re-annealing; in this protocol 
however, NaOH denaturation is sufficient). 
3. Vortex briefly to mix the sample solution, then use benchtop centrifuge to collect 
sample. 
4. Incubate for 5 min at room temperature. 
 
5. Add the following volume of pre-chilled HT1 to the tube containing denatured 
DNA: 
• Denatured DNA – 10 µl 
• Pre-chilled HT1 – 990 µl 
This results in a 10 pM denatured library in 2 mM NaOH. 
6. Place on ice until ready to continue to final dilution. 
For this protocol, the DNA will be further diluted down to 7 pM. Thus to obtain this concentration 
combine the following: 
• 420 µl DNA 
• 180 µl HT1 
Invert the tube several times to mix, and pulse centrifuge the solution. 
 
 
5. PhiX preparation 
PHIX is a control that is used. 
 
In this protocol, PhiX will be used at 20%, at a concentration of 20 pM. 
1. Combine 2 µl of 10 mM PhiX with 3 µl 10 mM Tris-Cl, pH 8.5 with 0.1% Tween/Sabax water. 
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2. Combine 5 µl diluted PhiX library with 5 µl 0.2 N NaOH. 
3. Vortex to mix & use benchtop centrifuge to collect sample. 
4. Incubate at room temperature for 5 minutes to allow the library to denature into single strands 
5. Add the following volume of pre-chilled HT1 to the tube containing denatured Phix library to 
result in a 20 pM Phix library: 
• 10 µl Phix Library 
• 990 µl pre-chilled 
This 20 pM Phix library is stable for up to 3 weeks at -15°C to -25°C 
6. Mixing library and PhiX library & Loading Sample onto Cartridge 
1. PhiX will be added to the library at a 20% concentration. Thus, for a total volume of 600 µl 
combine 120 µl of Phix and 480 µl of the 7 pM pooled DNA Library. 
2. Make sure that the MiSeq reagent cartridge is fully thawed and prepared. When the reagent 
cartridge is ready for use, load the prepared libraries onto the cartridge. 
3. Using a separate, clean, and empty 1 ml pipette tip, pierce the foil seal over the reservoir labelled 
Load Samples. 
Do not pierce any other reagent positions. Other reagent positions are pierced automatically 
during the sequencing run4. Pipette 600 µl of prepared libraries into the Load Samples reservoir. 
Avoid touching the foil seal as you dispense the sample. 
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Appendix D: IAVI Protocol C Demographics and DRM Data  
1. Demographic and clinical data of the 23 IAVI protocol C participants 
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2. Drug resistance mutations detected by next generation sequencing for all 23-participant baseline and all follow up samples 
Table 2: IAVI Protocol C Drug Resistant Mutation Results Detected for All Samples 
Participant 
Number 
Sample 
Number 
Visit Date RT DRMs - NGS PR DRMs -NGS 
Viral Load 
(RNA 
copies/ml) 
CD4 Count 
cells/mm3 
1 
1 2007/11/17 K103N (99.84) - 83400 456 
2 2007/11/27 K103N (99.72) - 121000 524 
3 2007/12/19 K103N (99.56) - 238000 360 
4 2008/01/24 K103N (99.68) - 295000 458 
5 2008/04/17 K103N (99.02) - 195000 320 
2 
6 2008/04/02 - M46L (99.89) 148000 496 
7 2008/04/08 - M46L (99.92) 37600 242 
8 2008/05/05 - M46L (99.58) 60300 317 
9 2008/06/02 - M46L (99.13) 73000 334 
10 2008/08/25 - M46L (99.85) 51100 305 
11 2008/11/18 - 
K20I (1.96),  
M46L (99.94) 
35200 296 
12 2009/02/09 - M46L (99.95) 26500 254 
136 
 
3 
13 2008/05/22 
K103N (10.85), Y181C (71.89), Y188C (1.45), G190A 
(4.47) 
L10I (99.75) 169 000 589 
14 2008/06/03 
K103N (38.06), Y181C (57.29), Y188C (3.38), G190A 
(4.40), H221Y (1.47) 
L10I (99.89) 1020000 479 
15 2008/07/03 K103N (20.49), Y181C (73.59), G190A (4.63) L10I (99.84) 78100 522 
16 2008/07/28 
K103N (17.93), Y181C (74.48), G190A (7.72), H221Y 
(4.26) 
L10I (99.74) 440000 363 
17 2008/10/21 
T69N (7.11), K103N (4.46), Y181C (60.43), 
G190A (4.74), H221Y (5.33) 
L10I (99.89) 350000 250 
4 
18 2008/06/27 
K103N (40.90), K103T (1.31), V106A (1.83), 
V106M (1.19), V108I (2.96), Y188C (9.38), N348I (1.75) 
- 66600 899 
19 2008/07/10 K103N (49.68), V108I (1.44), Y188C (6.15) - 17600 390 
20 2008/08/05 K103N (95.91), Y188C (1.59) - 61100 698 
5 
21 2006/08/22 - I85V (98.87) 525000 459 
22 2006/11/07 - I85V (90.44) 125000 514 
23 2007/01/30 - I85V (81.40) 289000 456 
24 2008/01/03 - I85V (96.10) 78400 466 
25 2008/06/16 - 
M46L (1.29),  
I85V (97.51) 
1160000 443 
137 
 
26 2008/12/01 - I85V (90.48) 388000 469 
27 2009/05/19 - I85V (91.72) 228000 399 
28 2009/11/03 - I85V (89.72) 330000 406 
29 2010/04/14 - I85V (87.53) 87400 447 
30 2010/10/05 K103R (1.04) I85V (72.63) 156000 208 
31 2011/03/22  I85V (61.55) 90377 178 
6 
32 2011/08/26 K103N (99.15) L10V (99.89) 148069 490 
33 2011/09/02 K103N (98.31) L10V (99.57) 127336 537 
34 2011/10/24 K103N (98.39) L10V (99.51) 15729 524 
35 2012/01/18 K103N (96.78), V118I (1.65) L10V (99.72) 34220 454 
36 2012/04/11 K103N (98.18), V179T (1.14) L10V (99.33) 19803 424 
37 2012/07/04 K103N (73.59), G190A (28.85) L10V (83.35) 25665 365 
38 2013/09/24 K103N (99.42) L10V (99.80) - - 
7 
39 2006/08/11 NO AMP NO AMP 16000 975 
40 2006/10/02 D67N (0.020) - 10500 1010 
41 2006/12/15 D67N (0.019) - 39500 688 
42 2007/11/26 D67N (0.017) - 1770 324 
43 2008/05/02 D67N (0.017) - 5430 980 
138 
 
44 2009/09/14 D67N (0.026) - 2980 1020 
45 2010/03/03 D67N (0.030) - 2800 490 
46 2010/08/20 D67N (0.029) - 6100 653 
8 
47 2010/05/25 K103N (98.97) L10V (99.67) 165000 620 
48 2010/06/02 K103N (95.94), G190A (1.61) L10V (99.66) 100000 552 
49 2010/06/14 K103N (99.39), Y188H (21.99) L10V (95.22) 45700 551 
50 2010/06/28 K103N (99.42) L10V (99.77) 104000 534 
51 2010/07/09 K103N (99.20), M230I (1.32) L10V (99.66) 19400 506 
52 2010/08/16 K103N (75.45), G190A (19.69) L10V (69.16) 10200 596 
53 2010/11/01 K103N (98.90) 
I84V (1.96),  
L10V (57.50) 
9760 580 
54 2011/01/24 K103N (96.89), K103S (2.44), K219R (3.90) L10V (99.66) 21859 - 
55 2011/07/11 K103N (99.15), P225H (1.04) 
M46L (2.03),  
L10V (99.05) 
48734 297 
56 2012/01/05 K103N (98.21) 
N83D (1.73),  
L10V (99.71) 
319345 424 
57 2012/03/20 K103N (99.27), Y188H (1.92) L10V (99.66) 28373 465 
9 
58 2010/11/17 K103N (98.92) L10V (99.63) 2640000 386 
59 2010/11/24 K103N (98.96) L10V (99.62) 353714 645 
139 
 
60 2010/12/03 K103N (99.09) L10V (99.83) 400178 553 
61 2010/12/15 K103N (98.99) L10V (99.62) 76663 504 
62 2011/01/12 K103N (99.13) L10V (99.67) 78795 772 
63 2011/02/09 K103N (98.44) L10V (99.68) 98128 624 
64 2011/03/23 K103N (97.59) L10V (84.53) 272579 704 
65 2011/05/05 K103N (86.58), G190A (6.50) L10V (99.67) 102952 427 
66 2011/07/27 K103N (97.73) L10V (99.62) 6769 685 
67 2011/10/19 K103N (99.38), H221Y (2.47) L10V (99.61) 7047 489 
68 2012/01/13 K103N (99.54), M184I (2.31) L10V (99.85) 3945 400 
10 
69 2011/01/06 Y188C (99.68) - 9377185 327 
70 2011/01/12 Y188C (99.66) - 7176879 218 
71 2011/01/20 Y188C (99.79) - 289930 - 
72 2011/02/03 Y188C (99.51) - 794402 521 
73 2011/02/17 Y188C (99.69) - 20551 - 
74 2011/03/11 Y188C (99.78) I50V (1.84) 7348 - 
75 2011/03/31 Y188C (99.73) - 5820 759 
76 2011/05/13 Y188C (99.78) - 363549 612 
77 2011/12/09 Y188C (99.67) - 4405 546 
78 2012/03/06 Y188C (99.71) - 57085 540 
140 
 
79 2012/08/14 Y188C (39.42) V82A (6.75) 8445 602 
11 
80 2010/03/15 K103N (98.79), E138A (99.54) - 146000 913 
81 2010/04/06 K103N (99.37), E138A (99.74) - 259000 882 
82 2011/07/28 K103N (82.44), E138A (99.83) - 25636 696 
83 2012/03/12 K103N (97.08), K103S (1.30), E138A (99.52) - 176680 654 
84 2012/05/15 K103N (97.99), E138A (99.76) - 52904 758 
12 
85 2010/02/02 K103N (98.17) - 141000 303 
86 2010/05/03 K103N (97.55) - 169000 253 
87 2011/03/29 K103N (98.16) - 46473 247 
88 2012/02/21 K103N (97.56) - 227879 307 
13 
89 2007/05/03 - T74S (99.69) 5390 464 
90 2007/07/26 K65R (1.17) 
I50V (1.02),  
T74S (99.67) 
1590 664 
91 2008/01/11 K65R (1.01) T74S (99.68) 3360 654 
92 2009/05/30 K65R (1.23) T74S (99.61) 45900 265 
93 2010/04/29 K65R (1.18) T74S (99.63) 2990 179 
94 2010/10/09 K65R (1.35) T74S (99.61) 38300 204 
14 
95 2009/05/02 K103N (99.03) T74S (99.81) 392000 521 
96 2009/05/23 K103N (98.52) T74S (99.48) 433000 386 
141 
 
97 2009/06/23 K103N (98.34) T74S (99.50) 534000 503 
98 2009/09/12 K103N (98.23) T74S (99.37) 670312 354 
99 2009/12/11 K103N (98.72) T74S (98.41) 521836 469 
100 2010/02/23 K103N (98.23) T74S (99.52) 362000 291 
101 2011/05/03 K103N (98.34) T74S (99.65) 205223 310 
102 2011/07/20 K103N (97.65) T74S (99.53) 250336 336 
103 2011/12/15 K103N (98.30) T74S (99.37) 252678 447 
104 2012/06/15 K103N (98.18) T74S (99.69) 104773 353 
15 
105 2009/07/25 
K65R (1.03), K103N (98.55), V108I (65.64), M184V 
(99.17) 
- 452000 465 
106 2009/08/01 
K103N (97.59), V108I (53.92), M184V (97.01), K65R 
(1.02) 
- 217000 463 
107 2009/08/08 
K65R (1.08), K103N (97.92), V108I (52.27), 
M184V (96.63) 
- 95473 637 
108 2009/08/15 
K103N (98.52), V108I (83.50), M184V (99.34), K65R 
(1.12) 
- 95473 558 
109 2009/08/22 
K103N (93.48), V108I (48.71), M184V (76.52), G190A 
(3.71), K65R (1.02) 
- 94172 567 
110 2009/09/05 K103N (96.54), V108I (38.83), M184V (61.98), - 75619 601 
142 
 
K65R (1.01) 
111 2009/09/19 
K65R (1.42), K103N (98.17), V108I (4.04), M184V 
(15.70) 
- 57876 445 
112 2009/10/17 
K103N (91.42), K103S (6.96), M184V (1.14), K65R 
(3.24) 
- 20411 205 
113 2009/11/28 
K103N (73.81), K103S (23.84), G190A (1.60), K65R 
(1.43) 
- 30799 499 
16 
114 2011/01/25 K65R (1.18), K103N (98.72) T74S (99.66) 166374 189 
115 2011/02/08 K65R (2.23), K103N (98.65) T74S (99.82) 52219 156 
116 2011/05/31 K65R (1.18), K103N (98.73) 
V11I (1.89), 
T74S (99.67) 
117650 162 
117 2011/10/04 K65R (1.12), K103N (98.63) 
V11I (5.77),  
T74S (99.14) 
60370 166 
118 2012/05/19 K65R (1.38), K103N (98.92) T74S (99.75) 56569 199 
17 
119 2006/10/10 K103N (99.24) - 73200 311 
120 2006/11/16 K103N (99.11) - 29800 381 
121 2007/02/08 K103N (98.85) - 682000 391 
122 2007/05/03 K103N (99.11) V82A (1.45) 40100 314 
123 2007/07/27 K103N (99.10), V118I (6.29) - 6620 362 
143 
 
124 2008/01/10 K103N (99.02) - 24300 200 
125 2008/06/26 K103N (99.34) - 31600 416 
126 2008/12/10 K103N (87.16), K103S (12.21) M46I (9.78) 4260 409 
127 2009/06/02 K103N (98.27), K103S (1.01) - 13300 295 
128 2010/04/29 D67G (3.11), K103N (97.88) - 29200 327 
129 2010/10/14 K103N (95.56), K103S (3.69), G190E (1.18) - 89500 358 
130 2012/03/30 K103N (96.52), K103S (2.78) - 11107 308 
18 
131 2006/12/06 V118I (99.50) I85V (99.13) 690000 1079 
132 2006/12/14 V118I (99.53) I85V (99.51) 153000 1098 
133 2007/03/22 V118I (99.78) I85V (96.57) 134000 736 
19 
134 2007/03/26 L210W (13.84) V82A (1.25) 61000 366 
135 2007/05/08 D67G (2.30), L210W (28.90) - 73600 432 
136 2007/10/23 D67G (1.51), L210W (27.65) - 10600 298 
137 2008/01/15 L210W (92.62) - 12600 235 
20 
138 2007/10/16 K103N (99.29) - 333000 362 
139 2007/11/05 K103N (99.21) - 242000 287 
140 2007/12/03 K103N (95.70), T215A (14.07) - 135000 264 
141 2008/02/25 K103N (91.3), K103S (8.23) - 141000 274 
142 2008/05/08 K103N (47.06), K103S (23.64), V118I (30.48) - 65900 307 
144 
 
143 2008/08/12 K103N (91.19), K103S (8.44) - 121000 248 
144 2009/01/12 K70T (37.09), K103N (99.38), F227L (1.88) - 26300 384 
21 
145 2008/08/04 K219R (4.60) 
M46L (87.93), 
I47V (4.94) 
32500 532 
146 2008/08/28 K103N (13.86) M46L (69.02) 60200 605 
147 2008/11/20 G190A (16.56), F227L (2.15) M46L (32.74) 13800 473 
148 2009/07/24 - V82A (1.23) 90700 249 
149 2010/01/07   152000 236 
22 
150 2007/10/18 K103N (0.01) M46L (1.42) 14400 865 
151 2008/01/08 K103N (93.74), V106M (4.42) - 182000 692 
152 2008/04/10 K103N (60.266), V106M (36.75) - 87600 675 
153 2008/09/16 K103N (33.55), K103S (2.09), V106M (16.73) - 134000 471 
154 2009/03/19 K103N (10.03), V106M (2.93), V118I (11.00) - 42800 554 
155 2009/09/03 
K103N (34.36), K103S (19.55), 
V106M (33.59) 
- 40300 665 
23 
156 2009/08/12 M41L (99.67), K103R (99.46) - 73800 621 
157 2009/08/26 M41L (99.62), K103R (99.41) - 6520 593 
158 2011/06/01 M41L (99.77), K65R (1.08), K103R (99.37) L90M (1.73) 3097 468 
159 2011/07/01 M41L (99.49), K103R (99.29) - 2436 - 
145 
 
160 2011/11/18 M41L (99.49), K103R (99.44) - 1017 447 
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